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Abstract
Abstract
The second extracellular loop (E2) of the Mi muscarinic acetylcholine receptor 
(mAChR) links transmembrane (TM) helices 4 and 5 and is predicted to play a role in 
the acetylcholine (ACh) binding pocket. Potential ligand contact residues were selected 
using a rhodopsin homology model of the Mi mAChR and mutated to alanine. Cys98, 
postulated to form a disulphide (S-S) anchor to Cysl78, Asp99, possibly part of a ligand 
access channel, and Phel97 and Trp378, predicted to complete the floor of the binding 
pocket, were also mutated. The double cysteine mutant was also generated. Radioligand 
binding assays showed that COS-7 cells expressed mutants at near to wild-type (WT) 
levels except for Cys 98 Ala, Cysl78Ala and Asp99Ala (10-20% of WT). The affinity 
of the antagonist (-)-N-methylscopolamine (NMS) was reduced by Cys98Ala (40-fold), 
Asp99Ala (22-fold), and Cysl78Ala (16 fold). ACh affinity was reduced by Asp99Ala 
(11-fold), Cys98Ala (12-fold), Argl71Ala (7-fold), Cysl78Ala (70-fold) and Ilel80Ala 
(5-fold). The TM domain mutants Phel97Ala and Trp378Ala reduced NMS affinity 90 
and 400-fold respectively but reduced ACh affinity only 2-fold and 13-fold. The 
mutants, supplemented with six E2 loop mutants from a previous study were able to 
activate the Gq-linked phosphoinositide signalling pathway. Cysteine mutations 
produced greater than 2500-fold reductions in ACh potency resulting in a 10-20-fold 
loss of signalling efficacy. Effects were also observed for other E2 loop mutants, most 
notably a 9-fold loss of efficacy for Serl84Ala. Dissociation rate constants for NMS 
and 3-Quinuclidinyl Benzilate (QNB) were increased by the majority of mutations, 
Argl71Ala, Cysl78Ala and Trp378Ala being the most significant. The results imply 
that the E2 loop plays a more important role in the binding of ACh than NMS while 
NMS may bind deeper within the TM domain than ACh. Maintenance of the S-S bond 
was essential for receptor activation. Studies with additional ligands showed that 
pilocarpine, oxotremorine-M and oxotremorine followed an ACh-like binding pattern, 
whereas the atypical agonists McN-A-343 and AC-42 may bind outside the ACh 
binding pocket.
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Chapter 1.
Chapter 1.
Introduction
1.1. G-protein Coupled Receptors; Classification
Communication between cells in biological systems is a fundamental necessity for the 
growth and survival of organisms. Cell to cell communication is mediated by cell 
surface receptors that essentially act as sensors and interpreters of extracellular activity. 
Receptors co-ordinate the various communicative signals from chemical messengers 
received by a cell and initiate a signalling pathway within the cell that can have various 
outcomes on cellular processes such as gene transcription and/or alterations of calcium 
concentration for example. Neurotransmitter molecules such as acetylcholine, metal 
ions such as potassium or hormones such as epinephrine are the major entities of cell­
cell chemical communications. Muscarinic acetylcholine receptors (mAChRs) belong to 
a super-family of receptors known as the G-protein coupled receptors (GPCRs). GPCRs 
are a vast and diverse set of membrane bound signalling molecules. Ubiquitous 
throughout the body, GPCRs perform essential roles as mediators of communication 
between the extra-cellular environment and the intra-cellular space and are important 
for many physiological processes including, regulation of neuronal excitability, 
cognition, metabolism, behaviour, reproduction and development. It is therefore no 
surprise that approximately half of all modem pharmaceuticals are directed at G-protein 
coupled receptors, the top selling ones treat diseases such as asthma, migraines hyper­
tension schizophrenia, peptic ulcers and numerous allergies (Wise et al., 2002). 
However, the number of drugs that are available target only a tiny minority of GPCRs 
and successfully treat only a fraction of GPCR-related diseases. It is evident therefore 
that there is still huge potential for the development of GPCR-targeted pharmaceuticals, 
although identifying which GPCRs require modulation for treatment requires an 
enormous and multi-disciplined effort.
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A recent and comprehensive reverse transcription-polymerase chain reaction study 
(Vassilatis et al., 2003) reported that a total of 750 GPCRs are expressed in human 
tissues. Of these 367 bind endogenous ligands (endoGPCRs); endoGPCR ligands 
include peptides, amino acids, small neurotransmitter molecules and nucleotides the 
remainder (283 human) are olfactory chemosensory receptors, binding ligands from the 
external environment such as pheromones and tastes. Another study of 2003 
(Fredriksson et al., 2003) using a phylogenetic approach put the total of human GPCRs 
at closer to 800, of which 342 were functional non-olfactory receptors and 458 olfactory 
receptors, and account for -2% of the human genome. Classification of such a large and 
important family of proteins is complex and the existence of pseudogenes and repeats in 
the naming of GPCRs only adds to the complexity. Thus, for the purposes of this study I 
will refer to the classification system described by Fredriksson et al (Fredriksson et al., 
2003) known as the GRAFS system. Here GPCRs are classed phylogenetically into five 
main families: Glutamate (15 members), Rhodopsin, (701 members the largest group), 
Adhesion (24 members), Frizzled/taste (24 members) and Secretin (15 members). The 
families are further sub-divided according to the type of ligand that they bind. There is 
practically no sequence homology between the major family groups. However, this 
large super-family of proteins shares the same basic structural architecture. They all 
contain 7-Transmembrane (7-TM) helical domains that span the cell membrane and are 
connected by 3 intra and 3 extra-cellular loops with the N-terminus positioned 
extracellularly and the C-terminus in the cytoplasm. Variability among GPCR structures 
occurs in all areas of the sequence. Sequence variation is least in the transmembrane 
domains and greatest at the N & C-Termini. For a full and current review of GPCR 
structure (Stenkamp et al., 2005)
A short synopsis of each of the main groups in the GRAFs system will be given. Figure
1.1 illustrates the GRAFS classification system as described by Fredriksson. The
12
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Secretin family (named after the first receptor cloned in this class) bind large 
polypeptides that share well-conserved amino acid sequences that act in a paracrine 
fashion. In the classical A-F classification system secretin and adhesion receptors were 
grouped in the same category (Class B) but recent genomic analysis of the adhesion 
receptors by Bjamadottir et al place adhesion and secretin receptors in two distinct 
families of receptor (Bjamadottir et al., 2004) The secretin receptors share a typical 7- 
TM structure but are distinguished by a 60-80 amino acid N-terminus, containing a 
sequence rich in cysteine residues that form conserved disulphide bonds which are 
particularly important for the binding of peptide ligands. This group consists of the 
hormone binding receptors such as the parathyroid hormone receptors (PTHR), the 
corticotrophin-releasing hormone receptors (CRHRs) and the secretin receptor itself 
(SCTR). Also belonging to this group are the calcitonin family of receptors and the 
calcitonin-like receptor, CGRP (calcitonin gene related peptide). CGRP is an unusual 
receptor because it requires the co-expression of RAMPs (receptor activity modifying 
proteins) in order for cell trafficking and ligand interaction to occur (Conner et al., 
2006). RAMPs have three biological functions they transport co-expressed calcitonin 
like receptors to the cell surface, define its pharmacology and dictate its state of 
glycosylation (Foord and Marshall, 1999).
All members of this family have been shown to regulate intracellular cyclic AMP via 
adenylyl cyclase coupling upon stimulation of the Gs class of G-proteins and some of 
the members of this class can also activate phospholipase C (PLC) (Harmar, 2001) The 
adhesion receptors are a relatively new but unique category of GPCRs (Fredriksson et 
al., 2003). These receptors have been previously termed LNB-7TM receptors (Long N- 
Terminal class B -7TMs) and have large and complex functional domains in their N- 
Terminal regions. These include multiple epidermal growth factor-like (EGF) domains, 
conserved cysteine motifs. As the name might suggest these receptors are thought to
13
Chapter 1.
Figure  l .l .T h e  GRAFS Svtem of G P C R  Classification
Adhesion
Receptors
Immune system cell 
receptors
Cell-cell, cell-ECM
binding
CELSRs
BAIs
LECs
Glutamate
Receptors
Modulators of 
synaptic excitation 
mGlul-8 (GRM) 
GABA a & b 
CASR 
TAS1 (taste 
receptors)
Secretin Receptors
Hormones/polypeptides
PTHR
SCTR
CRHRs
Frizzled/Taste Receptors
Cell proliferation and tissue 
development/sensing taste 
FDZ1-10 TAS2
Rhodopsin-Like Receptors
The a-group-Prostaglandins, amine, melatonin and MECA 
receptors. Muscarinic receptors. The P-group-peptide 
binders. The y-group-, MCH, chemokine. The 8-group- 
MAS-related, glycoprotein, purine and olfactory recepotors.
Overview of the classification of G-protein Coupled Receptors based on the GRAFS 
system as described by Fredriksson et al 2003. Blue cylinders represent TM-helices, 
orange ovals ligand binding domains, yellow circles conserved disulphide bonded 
cysteine residues, green triangles EGF-like motifs and green semicircles N-terminal 
lobes of the Glutamate receptor class. The Mi mAChR belongs to the Rhodopsin-Like 
Receptors. Developed from (Fredriksson et al., 2003) and (Bockaert and Pin 1999).
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participate in cell adhesion and are highly expressed in the immune system, specifically 
in leukocytes e.g the F4/80 molecule but EMR1 and CD97 for example have been found 
to be expressed in granulocytes, monocytes and resting T and B-cells. The adhesion 
properties of these receptors derive from glycosylated asparagine residues in the large 
N-terminus (200 -  2800 amino acids) that form mucin-like stalks. This is a diverse 
group of receptors with many isoforms that contain distinct functional domains. The 
variety of isoforms produced in this family of receptors is provided by mRNA splicing 
of large clusters of exons expressed in cells of the immune system. According to 
Freidriksson the adhesion family can be sub-divided into 3 or 4 sub types, the EGF- 
LAG seven pass G-type receptors, the brain-specific angiogenesis-inhibitory receptors 
(BAIs) the lectomedin receptors (LECs) and the EGF-like module containing receptors 
(EMRs), of which CD97 and F4/80 are members. As a group the adhesion receptors 
function to aid immune cell migration, anchor cells to the extracellular matrix, induce or 
amplify localised inflammatory responses and guide neuronal development (Stacey et 
al., 2000)
The Glutamate receptor family is divided into four sub-groups, most importantly the 
eight metabotropic glutamate receptors (mGluR), mGlul-8 and two y-aminobutyric acid 
(GABA) receptors, which include non- GPCR ionotropic receptors (GABAa) that act as 
ion channels which increase permeability of chloride ions causing hyperpolarization or 
inhibition of neurons; and metabotropic GPCRs (GABAb) which are involved in K+ 
efflux from neurons. The principal effect of GABAb agonism is muscle relaxation. 
There is also the single calcium-sensing receptor and five receptors proposed as taste 
receptors. The ligand binding sites for these receptors reside within the large 
extracellular domains that characterize this group of receptors. The metabotropic 
glutamate receptors are divided into three groups dependant upon their G-protein 
coupling, binding of selective ligands and effector activation. mGlul and 5 couple to Gq
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and activate PLC, whereas mGlu 4, 6, 7 and 8 couple to G* and G0 and inhibit adenylyl 
cyclase. mGlu2 couples to Gi and Go and also inhibits adenylyl cyclase but binds a 
different set of selective agonists and antagonists. Sharing the typical 7-TM spanning 
helical domains of the GPCR super-family the glutamate receptors are distinguished by 
their characteristic N-terminal domain. The N-terminal domain consists of two lobes 
that form a glutamate-binding cavity, which is often referred to, as the “venus fly trap” 
domain due to the closure of the two lobes around the bound glutamate molecule, 
leading to the activation of the receptor. Glutamate is an important neurotransmitter and 
glutamate receptors are widely distributed at pre and post-synaptic locations throughout 
the central nervous system where, in general they modulate mechanisms of neuronal 
excitability. Glutamate receptors are implicated in many psychiatric and neurological 
disorders of the central nervous system, prompting a sustained effort to regulate 
glutamate receptor activity via pharmacological means. Glutamate is the major neuro- 
excitatory transmitter molecule of the mammalian nervous system. GABAb acting via 
GABAa ionotropic receptors is the major inhibitors of synaptic transmission. Knockout 
mice studies have shown that the metabotropic glutamate receptors play key roles in 
motor learning and spatial memory (mGlul), retention of spatial learning and fear 
contextualisation (mGlu5), motor function and seizure states (mGlu4), processing of 
visual stimulation (mGlu6) and amygdala dependent learning and epilepsy etiology 
(mGlu7) (Schoepp, 2001). Both mGlu and GAB A receptors have ionotropic receptor 
counterparts that are less closely related to each other than their 7-TM namesakes and 
function as transmitters of excitatory or inhibitory action potentials. Thus the roles of 
the GABAb and mGlu receptors are more modulatory in the control of synaptic 
inhibition/excitation, monitoring excess or a deficit of neurotransmitter in the synaptic 
cleft.
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The Frizzled/Taste2 receptors cluster together in the same group due to a few consensus 
sequences in TM2 (IFL), TM5 (SFLL) and TM7 (SxKTL) (Fredriksson et al., 2003). 
The N-terminal of the Tas2 receptors is very short (unlike Tasl of the glutamate family) 
and unlikely to contain a ligand binding domain whereas the Frizzled receptors have a 
200 amino acid N-terminal with a conserved set of cysteine residues that harbours a 
Wnt binding domain, known as the fz motif. The fz motif is found in many other non- 
GPCR proteins, for example it is found in the collagen W H Ial protein and in some 
receptor tyrosine kinases (Rehn et al., 1998). In the body these two classes of receptor 
perform entirely different functions. Surprisingly, the Tas2 receptors are dissimilar 
enough from the Tasl receptors found in the Glutamate group to warrant placing them 
in a group of their own. Expressed in the tongue and palate epithelium taste receptors 
provide valuable information about the quality of food. Tasl R2 receptors have been 
indicated to form heteromeric complexes with Tasl R1 and Tasl R3 receptors of the 
Glutamate group that can bind various taste related amino acids. For example a Tasl R2 
and a Tasl R1 complex can detect the artificial sweetness of aspartate (Nelson et al.). 
However, as a homomeric complex Tas2 receptors have been shown, by expressing 
Tas2 genes in “sweet cells” in the mouse, to detect only bitter tastes. Many of the 
natural ligand/taste molecules that bind to taste receptors are unidentified but candidates 
for the Tas2R16 in humans include salicin and related compounds (Mueller et al., 
2005).
The Wnts are a group of 20 or more, vertebrate genes that express secreted 
glycoproteins that act as the ligands for members of the Frizzled group of GPCR’s, of 
which there are 10 members so far described (FZD1-10). These ligands and the Frizzled 
receptors are essential for the early development of mammalian cells and tissues, 
regulating cell proliferation, apoptosis and cellular polarity. Frizzled receptors were 
shown to trigger a G-protein induced phosphatidylinositol response by Slusarski et al
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(Slusarski et al., 1997) leading to the expression of an extensive array of gene products 
essential for embryonic development including for example, transcription factors, Ras 
related proteins, chaperone related proteins, kinases, apoptotic proteins and proteins 
important for chromosomal separation (Li et al., 2004)
The rhodopsin family of receptors, comprising 241 non-olfactory out of 701 receptors, 
are the largest group in the 7-TM family. However, the number of reported receptors in 
this group seems to vary quite considerably throughout the literature and many 
receptors of this group remain “orphans” with no known ligand that can be assigned to 
them. Using the GRAFS system of classification the rhodopsin family of GPCRs can be 
sub-divided into four separate groups, the a-group, includes the prostaglandins (15 
members), the amine receptors (40 members), the melatonin receptors (3 members). The 
p-group has no branches and comprises 35 peptide binding receptors. The y-group 
includes, the melanin-concentrating hormone (MCH) (2 members) and the chemokine 
(42 members) cluster of receptors. The 8-group has four main clusters, the MAS-related 
receptors (8 members), the glycoprotein receptors (8 members) the purine receptors (42 
members) and the olfactory receptors (-460 members). Due to the huge and diverse 
nature of the rhodopsin group of receptors detailed descriptions of all the members is 
beyond the scope of this chapter. Instead focus will be given to two members of the 
amine group of receptors, the dopamine and serotonin receptors which are of direct 
relevance to this study, since the muscarinic acetylcholine receptors, the focus of this 
study, belong to this group and share similar structural and activity characteristics. 
Rhodopsin itself will be covered in more detail in a following section when a more 
detailed description of the 7-TM receptor structure will be given.
Included in the rhodopsin family of receptors is the peptide binding neurokinin 
receptors 1, 2 and 3 (NK-1 NK-2 and NK-3) which bind the mammalian tackykinins,
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substance P, neurokinin A and B respectively. Although these receptors are homologous 
they display a different pharmacology (Gether, 2000). This is due to multiple epitopes 
found throughout these receptors which contribute to the sub-type selectivity of 
tackykinin peptides. Substitution of the extracellular loops of NK-1 and NK-3 for 
example suggested that the first extracellular loop and two residues of the second 
extracellular loop were involved in the binding of tackykinin peptides (Fong et al., 
1992). Other studies involving chimeric receptors (Gether et al., 1993) suggested that 
neurokinin A may partially enter the transmembrane binding crevice. This indicates that 
there are differences in the binding modes of homologous peptides. Other rhodopsin- 
like peptide binding receptors such as the V2 vasopressin receptor are also likely to 
have this ligand binding selectivity determined by key residues in the extracellular loop 
regions and residues at the top of the transmembrane domains (Cotte et al., 1998). There 
is evidence that that the extracellular loops are also involved in the binding of peptide 
ligands for the angiotensin (Hjorth et al., 1994), somatostatin (Liapakis et al., 1996) and 
opioid (Wang et al., 1995) receptors.
The biogenic amine receptors all share similar structural architecture of the classic 
GPCRs with seven membrane spanning helical regions linked by 3 intra and 3 extra 
cellular loop regions with the N-terminus on the extracellular side and the C-terminal on 
the intra cellular side of the plasma membrane. A conserved disulphide bond linking the 
top of TM 3 to the second extra cellular loop is a conserved feature of all the amine 
receptor sub-types although in general overall sequence homology is variable among the 
different classes. Dopamine receptors, serotonin or 5-HT (5-hydroxytryptamine) 
receptors, histamine receptors, adrenergic receptors, trace amine receptors and 
muscarinic receptors all bind structurally related small biogenic amines that act as 
neurotransmitter molecules in the central and peripheral nervous system and perform a 
vast array of functions and are implicated in the etiology of many disease states. It is
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therefore of little surprise to know that the pharmacological control of these receptors
potentially offers enormous therapeutic benefits and as such discovery of selective
ligands is currently of paramount importance to both the academic and pharmaceutical
industries.
Dopamine, the major catecholamine of the brain and the endogenous agonist of 
dopamine receptors serves to regulate a plethora of functions in the mammalian brain 
and is implicated in such diseases as Parkinsons, schizophrenia and Tourettes syndrome. 
Dopamine receptors fall into five distinctive sub-types (D1-D5). The Di and D5 receptors 
positively stimulate adenyly cyclase generating a signal transduction cascade via the 
cAMP second messenger system, differentiating them from D2, D3 and D4 which inhibit 
adenylyl cyclase activity. The Di and D5 receptors share a high degree of conservation 
in their transmembrane regions as do D2, D3 and D4 and therefore not surprisingly a 
similar pharmacological distinction is made between the sub-types, so that Di and D2 
like receptors bind agonists such as apomorphine and antagonists such as 
chlorpromazine with variable shifts in affinity. The Di receptor is the most widespread 
of the dopamine receptors in both the central and peripheral nervous systems. 
Activation of Di, D2 and D3 receptors in the ventral striatum for example controls 
forward locomotion, whereas in the nucleus accumbens agonist binding to D3 receptors 
inhibits locomotor activity (Diaz et al., 1995). For full reviews of dopamine receptor 
functions see (Jackson and Westlind-Danielsson, 1994). Another important role for 
dopamine receptors is their role in reinforcing properties of drug (especially cocaine) 
self administration, where D2 receptors stimulate drug reinforcement and stimulate 
cocaine seeking behaviour (Self et al., 1996). Other functions of dopamine receptors in 
the brain include cognition and emotive responses. In the peripheral nervous system 
dopamine receptors are located in blood vessels, adrenal glands, kidneys, and the heart 
and are responsible for inhibition of norepinephrine and vasodilation, inhibition of
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aldosterone secretion, increase of renal filtration rates and stimulation of rennin
secretion, respectively. For a comprehensive review of dopamine receptors and a full set
of references see (Missale et al., 1998).
Serotonin or 5-HT receptors are perhaps the most complex group of neurotransmitters 
found in the central and peripheral nervous system. They comprise of at least 14 
members (5-HT 1-7), including multiple splice variants and 3 sub-types belonging to the 
ligand-gated ion channel group of receptors. Expressed from an intron-less gene 
(Chanda et al., 1993) 5-HT-receptors bind the endogenous and intrinsically fluorescent 
neurotransmitter serotonin, which is secreted at numerous sites throughout the central 
and peripheral nervous system. The primary function of 5-HT receptors upon activation 
by serotonin is to inhibit adenylyl cyclase reducing intra-cellular levels of cAMP. This 
action is mediated predominantly via the G(Xi/0 class of G-proteins, although studies 
have shown that 5-HT receptors can interact with a range of G-protein a-sub-units with 
differing affinities, in mammalian cells the heirachy is Gaj3 > Ga^ >Gan »  Ga0 »  
Gct2 » G a z. (Gamovskaya et al., 1997) and (Raymond et al.). Messenger RNA for 5- 
HT receptors has been found in the gut, muscle, kidneys and lymphatic tissue, but is 
predominant in the limbic forebrain, i.e. hippocampus, raphe nuclei, amygdala, 
hypothalamus and the cortex. Here they are involved in maintaining circadian rhythms, 
thermoregulation, mood, pain, addictions, libido, and locomotor activity. Other 
evidence has shown 5-HT receptor involvement in obsessive compulsive disorder, 
asthma and heart conditions. For detailed reviews of 5-HT receptors see (Pucadyil et al., 
2005) and (Hoyer et al., 2002).
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1.2. Structure of 7-TM Receptors Based on the Rhodopsin X-Ray 
Crystallographic Structure.
The first attempts by Hibert et al (Hibert et al., 1991) in 1991 to reveal the general 
structure of GPCRs using computer generated three dimensional homology models 
based on the structure of bacteriorhodopsin, gave clear insight to the existence of seven 
transmembrane spanning helices. These authors also tried to define the ligand binding 
sites for the dopamine D2, 5 HT2, cli and P2 adrenergic receptors and the M2 mAChR. 
Although their details were a little inaccurate, they did provide a good working model 
upon which further experiments could be designed to further refine those missing 
details. An alpha carbon template for the 7-TM helices in the rhodopsin family of 
GPCRs was created by Baldwin et al (Baldwin et al., 1997). Taking sequence 
information from -500 GPCR sequences and using frog rhodopsin as a template they 
generated data that provided more precise information on the structures orientations, 
locations and lengths of the TM helices. The authors also suggested the possible 
orientation of the chromophore binding site although they could not describe it in detail. 
This provides a basis for further experiments including for example, site directed 
mutagenesis (Han et al., 1996a; Han et al., 1996b), substituted cysteine accessibility 
methods (SCAM) (Javitch et al., 1994., Javitch et al., 1995.), creation of metal binding 
sites (Elling et al.,1995 Thirstrup et al., 1996) and site-directed spin labelling studies 
(Farahbakhsh et al., 1993; Farahbakhsh et al., 1995.) Although Baldwin et al. created a 
template for GPCR structure compatible with the combined data, the over simplification 
of using straight helical segments meant that helix axes parameters needed more 
refining. The race to create a true atomic high resolution X-ray crystallographic 
structure was on.
Finally, in 2000 the X-ray crystallographic structure of the photoreceptor rhodopsin was 
solved at 2.8 Angstroms resolution. To date, Rhodopsin is the only GPCR for which a
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high-resolution structure has been determined (Palczewski et al., 2000; Teller et al., 
2001). Consequently, the structure solved by Palczewski and colleagues has been 
widely employed as a model for other GPCRs and has superseded earlier models based 
on electron crystallography (Baldwin et al., 1997). Palczewski’s structure has remained 
the basis for the interpretation of structure-activity relationships for a wealth of 
mutagenesis and affinity labelling studies for related 7-TM receptors, see (Hulme and 
Lu, 1998; Hulme et al., 2003; Lu et al., 2001; Savarese et al., 1992). The general 
secondary (see figure 1.2) and tertiary structure (figure 1.3) of 7-TM receptors comprises 
a typical extracellular glycosylated N-terminal domain leading to seven membrane 
spanning a-helices (TM domains), connected by 3 alternating extracellular loop regions 
and 3 intracellular loop regions terminating in a shorter eighth a-helix anchored parallel 
to the lipid membrane via palmitoylated cysteines at the C-terminal region. Two highly 
conserved cysteine residues form a disulphide bond connecting the top of TM3 and the 
second extracellular loop (E2 Loop) in all but a small minority of GPCRs. This 
disulphide bond appears to be crucial for correct expression and maintenance of the 
structural stability of the receptor and is a general feature with the cysteine pair 
conserved in virtually all GPCRs (Davidson et al., 1994; Savarese et al., 1992).
The transmembrane a-helices vary from between 20-30 amino acids in length, 
somewhat longer than predicted by hydrophobicity plots (Trumpp-Kallmeyer et al., 
1992). This was due to the complex dielectric nature of the membrane and the failure of 
the hydrophobicity plot method to identify helices that contained polar residues on both 
sides of that helix. Surprisingly nearly 40% of the transmembrane domain interacts with 
the phospholipid head groups (Ballesteros et al., 2001) rather than the hydrophobic core 
as may be expected. For amine receptors, residues at the cytoplasmic boundaries are 
rich in basic amino acids, such as lysine and arginine and provide an overall positive 
charge complementing the negative charge of the phospholipids head groups. This
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allows the correct orientation of the receptor into the membrane and is referred to as the
“positive inside rule”. The cytoplasmic ends of the TM helices can be determined by the
presence of regions rich in basic residues.
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Figure  1.2. Secondary S truc tu re  of 7-TM  R eceptors
Extracellular
S-S bond
Glycosylation
COOH
Intracellular GRKSite
The general secondary structure of 7-TM receptors is represented here in the form of a 
snake diagram of the Mi mAChR based on Baldwin et al. structure (Baldwin et al., 
1997). The residues of the Mi mAChR are shown in circles. Blue circles indicate 
residues that have been mutated to alanine in this study. Helical domains coloured pink 
have been previously mutated by this laboratory. Counting from the N-terminus there 
are seven transmembrane helices connected by 3 extracellular loops and 3 intracellular 
loops. An eighth helix lies parallel to the membrane anchored by a palmitoylated 
cysteine residue at its C-Terminus. Also shown are the two highly conserved cysteine 
residues that form a disulphide link between the top of TM3 and the E2 loop. At the N- 
Terminal end there are two asparagine residues that allow glycosylation of the receptor. 
The large third intracellular loop incorporates a G-protein receptor kinase (GRK) 
binding domain and in this model some residues have been omitted from the 13 loop and 
the C-terminus for the sake of clarity.
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1.2.1. The Transmembrane Helices
High resolution structural data revealed that the TM helices contains numerous kinks 
twists and bends at various positions. A -26° kink in the helices is produced by proline 
residues. The steric clash of the pyrrolidine ring with the backbone and the loss of a 
hydrogen bond between the amide and the carbonyl at position i-4 result in the kinking 
of the TM helix (Barlow and Thornton, 1988; Sansom and Weinstein, 2000). Kinks can 
also be produced by glycine residues that can impart flexible hinge-like regions (Kumar 
and Bansal, 1998).Twists and bends in the TM helices can be caused by serine, 
threonine and asparagine residues which retain the ability to hydrogen bond with the 
carbonyl of the protein backbone from the preceding a-helical turn (Ballesteros et al., 
2000). The residues that face outward into the membrane are predominantly 
hydrophobic (Trumpp-Kallmeyer et al., 1992), as may be expected for residues that are 
in contact with the lipid bilayer. Residues at the cytoplasmic end of the TM helices are 
involved in the coupling of the heterotrimeric G-proteins (see sections 1.3 and 1.5). 
Since rhodopsin is still the only GPCR whose structure has been solved the following 
descriptions of the TM helices all relate to the rhodopsin template and similar structures 
are assumed for other GPCRs in the rhodopsin class and differences are indicated where 
evidence exists. The following will refer to residues according to the nomenclature of 
Ballesteros and Weinstein (Ballesteros, 1995), whereby the helix number is followed by 
a number indicating its relative position to the most conserved residue of the helix, 
which is assigned the number .50. Eg 3.50 refers to the most conserved residue 
(Arginine) in helix three and 3.49 indicates the residue that precedes it. The following 
structural information can be found in more detail in refs (Ballesteros et al., 2001b; 
Teller etal., 2001)
TM1 is 44 A long and contains 30 residues starting at Trp 1.30 and ending with Gin 
1.59. It has an angle to the membrane normal of 25° and the helix itself has a slight 12°
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of bend due to a proline at position 1.49. Although proline is conserved in the opsin 
group of receptors most amine receptors have a glycine-asparagine sequence that 
generates a similar kink angle. In fact Gly 1.49 is highly conserved in the amine 
receptors.
TM2 also has 30 residues and in rhodopsin the N-terminal of the helix is kinked at an 
angle of 24° to the membrane normal and the C-terminal of the helix at a 33° angle to the 
membrane normal. The TM2 helix starts at Pro2.38 at the cytoplasmic end and ends at 
His 2.67 at the extracellular end. In bovine rhodopsin the kink occurs at the Gly-Gly-X- 
Thr-Thr sequence. Although this sequence is not fully conserved in the Mi mAChR 
there are two threonine residues at an analogous position. As in rhodopsin these 
threonine residues may cause the kink by the formation of hydrogen bonds with the 
carbonyl oxygen of the proceeding helical turn, thus stabilising the bend. The D2 
Dopamine receptor, another cationic receptor which does retain proline residues at 
similar locations (Pro-X-Thr) may also have a similar bend. It is likely that differently 
located proline residues may be feature in the structural diversity of GPCRs. An 
example occurs in TM2 of the chemokine CCR5 receptor where a Thr-X-Pro motif has 
been identified (Govaerts et al., 2001).
TM3, the longest helix (48 A) with 33 residues from Pro 3.22 at the top end to Val 3.54 
at the cytoplasmic end has a tilt angle of 33° to the membrane normal. This 33° tilt 
positions this helix so that it bisects the helical bundle bringing it into contact with 
TM2, TM4, TM5 and TM7. This has important implications for the maintenance of 
ground state and activated state interactions between residues of these helices. The 
cytoplasmic end of TM3 contains the particularly well conserved E(D)RY motif 
important for G-protein interaction. In rhodopsin there are a number of subtle bends 
creating a - 1 2 ° kink, caused by a series of serine, threonine and cysteine residues that
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are -50% conserved in other GPCRs, but essentially this helix is nearly straight. In the 
Mi mAChR 4 serine residues could potentially produce the same subtle kink and it is 
likely that it is a feature of most 7-TM receptors. To support this it has been shown that 
if the D2 receptor TM3 domain is modelled as an ideal a-helix then it clashes sterically 
with TM4 (Ballesteros et al., 2001).
TM4 is the shortest helix at only 23 amino acids in length from Asn 4.46 to Val 4.62. 
Apart from the 24° kink at the very end of the helix provided by two proline residues 
4.59 and 4.60, the helix is straight. Only one proline is found at this position in Mi 
mAChRs and D2 dopamine receptors. A similar kink as that found in rhodopsin was 
discovered in the D2 receptor by Javitch et al. (Javitch et al., 2000) by the use of the 
substituted cysteine accessibility method. TM4 it has been hypothesised, serves as a 
stabilising support for the inactive ground state of the receptor, or it may be involved in 
receptor dimerisation involving an outward facing Trp 4.50 residue.
TM5 at 26 residues in length runs from Asn 5.35 to Gin 5.60. At 35A long it has two 
internal kinks of 25° and 15°. The actual helix domain of TM5 extends for just 3 helical 
turns (12-residues) and is possibly a dynamic structure. The kink at the highly 
conserved proline 5.50 results in an unusual bulge at His 5.46 suggested to be caused by 
it hydrogen bonding with Glu 3.37 of TM3. However, this hydrogen bond does not 
appear to be conserved in other 7-TM receptors, although other sequences may provide 
a similar distortion, a series of threonine residues in Mi mAChR for example. In the D2 
receptor it was predicted that the serine residue 5.42 made direct contact with the ligand 
in the binding pocket, but when a standard proline link was modelled, this residue faced 
away from the binding site. Thus it was concluded that the unusual kink and distortion 
may be necessary for a proper ligand contact to be made and that the helix may need to 
rotate to achieve this (Allman et al., 2000; Liapakis et al., 2000).
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TM6  is the second longest of the helical bundle at 31 amino acids and the most kinked, 
with a bend of 36°. Proposed to be critically involved in the activation mechanism of the 
7-TM receptors it is unlikely that the structure of TM6  shows too much variability 
between the different classes of receptors. It is the highly conserved proline 6.50 that 
provides the universal kink predicted in this helix in nearly all GPCRs. TM6  forms van- 
der Waals interactions and a water mediated hydrogen bonding network with TM2, 
TM3 TM5 and TM7. The highly conserved tryptophan 265 in rhodopsin (Trp 378 Mi 
mAChR) is a key residue in this h-bond netwok because it is involved in both the 
binding of ligand and the activational state of the receptor.
TM7 is the shortest helix with only 21 residues spanning from Ile7.33 to Tyr 7.53. TM7 
is elongated and distorted around the retinal attachment residue Lys 269 where the helix 
differs from an a-helical structure to a tighter 3io- helix (Riek et al., 2001). This has the 
effect of constricting the binding cleft in which the retinal is attached. Rhodopsin is the 
only TM receptor that has its ligand covalently bound. It therefore seems unlikely that a 
similar unusual structural architecture exists in other GPCRs. A kink at this position 
was discredited by double revertant mutagenesis study conducted on the 5 HT2 receptors 
(Sealfon et al., 1995). However, SCAM studies of the D2 receptor did predicted a large 
degree of twisting at position Ser 7.46 similar to that seen for rhodopsin (Fu et al., 
1996). Since methylsulfonate reagents could not bind to a cysteine at this position it was 
deemed unlikely that a normal proline kink was present. This evidence suggests that a 
similar twisting effect occurs in most 7-TM receptors at this point. The tighter 310-Helix 
is continues until Val 7.45/Ala 7.46 where an acute 41° bend is produced (Riek et al., 
2001) tilting the helix away from the central cleft. Beyond this point the helix reverts to 
an a-helical formation for one turn before a conserved proline 7.50 kinks the helix 
again. This proline is part of the conserved NPXXY motif a signature sequence found in
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nearly all GPCRs. At the cytoplasmic end of TM7 there is a short four residue linker
region that connects the cytoplasmic helix to the main TM helical bundle.
Helix 8  of rhodopsin is 10 residues in length and starts at Lys 311. Helix 8  is anchored, 
perpendicular to the plane of the membrane aqueous interface, by buried side chain 
contact residues at the cytoplasmic end of TM1 eg Phe 58 and Val 61 and TM7 Phe 313 
and Met 317. These contacts are required for proper folding of rhodopsin receptor. In 
bovine rhodopsin helix 8  is further secured to the lipid membrane via two 
palmitoylation sites at a conserved cysteine residue, Cys 322 and at Cys 323 (Langen, 
1999). A single cysteine at position 457 was shown using alanine scanining mutagenesis 
to be the palmitoylation site of the M2 mAChR (Hayashi, 1997), analogous to Cys 435 
in the Mi mAChR. Helix 8  may be responsible for the correct orientation of the receptor 
in the membrane as well as being involved with Gt a-sub-unit interactions. The C- 
terminal region preceding helix 8  is just 4 residues long from residue 334 to 338 and is 
likely to be a flexible and mobile entity with no apparent conformation.
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Figure 1.3. 3D-Homology M odel of the 1VL m A C hR  R eceptor: L a tera l 
View
The figure shows the rhodopsin homology model of the Mi mAChRs seen from the 
lateral, membrane spanning view. The model shows the various twists, kinks and bends 
that are a feature of the seven transmembrane helices due to proline, serine or threonine 
residues (see text for details). To produce the homology model, 20 models created by 
threading the Mi amino acid sequence on to the rhodopsin model were energy 
minimised using molecular dynamics software (Lu, 2001). The arrangement of the 
transmembrane helices and their conformational kinks are easily distinguished in this 
view. The binding pocket for exogenous ligands such as acetylcholine is indicated by 
the inclusion of an ACh molecule at the approximate position of the central binding site. 
The binding site lies approximately one third of the way down the inner surface of the 
transmembrane helices.
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1.2.2. The Intra and Extra Cellular Domains
It is very likely that the cytoplasmic (intracellular) loops are flexible and mobile and 
this is reflected in their poor resolution in the X-ray crystallographic structure of 
rhodopsin (Palczewski et al., 2000; Teller et al., 2001). Thus their structures are not well 
defined due to several different conformations observed especially for the 13 loop. 
Nevertheless, a general outward projection of the intracellular loops into the cytoplasm 
is consistent with a canopy structure that enables interaction with all three G-protein 
sub-units in the membrane. In a later study of rhodopsin structure (Li et al 2004.) using 
a molecular replacement strategy from the 2.8A model, the details of the extracellular 
loop domains become clearer. The II loop is short in length, just 5 residues in 
rhodopsin and comprises mainly basic and hydrophobic residues that are 97% 
conserved in the opsin family. Two residues, Leu 6 8  and Arg 69 are inwardly facing 
and make van der Waals and H-bonding interactions with TM1, TM2 and Helix 8 . The 
importance of the first intracellular loop to receptor activation is still a matter for debate 
with few studies providing direct evidence of its critical involvement. Nevertheless, the 
length of the II loop is conserved among GPCRs, suggesting a structural role. Studies 
by Moro et al. on the Mi receptor (Moro et al., 1994) and Amatruda et al. on Formyl 
peptide receptors (Amatruda et al., 1995) have shown that maintenance of the II loop 
structure is necessary for efficient ligand dependent G-protein coupling. The debate is 
whether or not residues of the II loop make direct contact with the G-protein or whether 
loss of function in mutagenesis studies is due to structural perturbations.
The 12 loop contains, at its N-terminus region, the highly conserved Asp-Arg-Tyr motif 
and the middle Arg residue occurs in 99% of all GPCRs in the rhodopsin class of 
receptors (Baldwin et al., 1997). In fact the N-terminus of 12 forms a cytoplasmic 3-tum 
helical extension of TM3. The Asp-Arg-Tyr (DRY) motif has been the focus of many 
reports that show that the mutation of the Arg residue in the middle of the motif causes
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drastic reductions in the efficiency of G-protein coupling. (Jones et al., 1995; Prossnitz 
et al., 1995; Scheer et al., 1995) and so has been proposed as the switch that enables G- 
protein interactions (Burstein et al., 1998). In fact these authors also suggested that it is 
the entire 12 loop that acts as the switch responsible for G-protein activation. The Jones 
et al study (Jones et al., 1995) also showed that the charge preserving Arg-Lys mutation 
retained the ability for the Mi receptor to couple to the G-protein. Li et al (Li et al. 
2004) report that the 12 loop is L-shaped and lies parallel to the membrane. In the 
conserved E(D)RY motif Glu 134 (E instead of D in rhodopsin) is negatively charged 
and forms a salt bridge with Arg 135. Arg 135 also forms van der Waals contacts with 
hydrophobic residues of TM6 . The protonation of Glu 134 is required for the activation 
of transducin (Gt), possibly emphasising the importance of the motif in the GPCR 
signalling processes. However, there is an argument that the DRY sequence is not 
required for G-protein activation. A study by Rosenkilde et al. (Rosenkilde et al., 2005) 
showed that the conversion of the DRY sequence to DTW in open reading frame 7 of a 
rhodopsin-like 7-TM receptor encoded by the equine herpervirus signalled as effectively 
as wild type. The tyrosine residue of the motif is less well conserved and a different 
amino acid occurs at this position in -20% of GPCRs in the rhodopsin class (Baldwin et 
al., 1997). Though not essential for G-protein coupling this residue when mutated, often 
leads to large reductions in expression (Lu et al., 1997), indicative of a role in 
stabilising the functional conformation.
The 13 loop is a less well conserved structure in the rhodopsin class of GPCRs, showing 
considerable variability in sequence length. In rhodopsin itself the 13 loop contains just 
35 residues, whereas in the Mi receptor the 13 loop extends for more than 150 residues. 
Furthermore, deletion of 129 amino acids from the middle of the 13 loop sequence 
produces some loss of function and decreased efficacy yet G-protein coupling is still 
viable (Lu et al, 1997). This shows that it is the N-terminal and C-terminal domains of
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the 13 loop that are critical for activation of the G-protein, although selectivity is 
conferred by the specific residues of different classes of GPCRs. In the muscarinic 
receptors M1-M5, mutagenesis studies (Hill-Eubanks et al., 1996) identified a limited 
number of uncharged hydrophobic residues in the N-terminus that can determine G- 
protein selectivity. In a site directed spin labelling study these residues mapped to an 
amphiphilic a-helix in rhodopsin that are believed to form a surface conducive to G- 
protein coupling (Altenbach et al., 1996). Similarly, 4 hydrophobic residues at the C- 
terminus of the 13 loop in M3 receptors (Ala488, Ala489, Leu492 and Ser493) are also 
involved in the recognition of G-proteins. These residues are conserved in Mi but are 
different in M2 and M4. Residues of this region have been studied extensively in 
mutagenesis studies and are reviewed by Wess et al (Wess, 1996). An overview of the 
intracellular loops is illustrated in figure 1.4 below.
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Figure  1.4. 3D-Homology M odel o f the Mi_ m A C hR  R eceptor: 
C ytoplasm ic View
C-Terminus
The figure shows the view of the Mi homology model from the cytoplasmic surface. 
Residues at the cytoplasmic surface provide contacts for activation of G-proteins. The 
highly conserved DRY sequence occurs at the N-terminus of the 12 loop at the 
cytoplasmic end of TM3 and may be a key motif involved in the binding of G-protein. 
Selectivity for G-protein interaction is determined by sequence variation in the N- 
terminus and C-terminus of the 13 loop domain (se below for further details)
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The N-terminal domain varies enormously between GPCR families. The glutamate, 
frizzled, taste and the peptide-binding rhodopsin-like receptors for example have large 
N-terminal domains involved in the binding of larger peptide ligands, although perhaps 
not exclusively so. The N-terminal domain of the Via Vassopressin receptor, for 
example, has been shown to bind only peptide agonists but not peptide or non-peptide 
antagonists (Hawtin et al., 2000) and this also seems to be true of other 
neurohypophysical hormone receptors, such as the oxytocin receptor (OTR) (Postina et 
al., 1996), although it was shown that the extracellular loops of the OTR were also 
involved in agonist binding. In rhodopsin the N-terminus has a globular structure 
comprising 33 amino acids and is glycosylated at Asn 2 and at Asn 15 with a 
Man3GlcNAc3 carbohydrate moiety (Teller et al., 2001). The N-terminus and the E2 
loop are cross-linked by water mediated H-bonds between the p i-02 hairpin and the 03- 
0-4 hairpin and the whole structure has been described a s forming a ‘plug’ over the 
retinal binding pocket
Relatively little is known about the function of the El loop in the rhodopsin class of 
receptors, but it has been shown to be important for the binding of peptide ligand in the 
mouse Corticotrophin Realeasing Factor receptor 2p (Grace et al 2004) and a conserved 
aspartate is important for the binding of vasoactive intestinal peptide (VIP) to to the VIP 
receptor as shown by mutagenesis studies (Du et al. 1997). In the Matsui study of the 
Mi mAChR (Matsui et al., 1995) the Trp 91 to Ala mutation reduced ACh affinity by 
-40-fold and affected the affinity of several antagonists and Trp 91 was proposed to be 
one of the residues that line the ligand access channel. The El loop is presumed to have 
a more structural and stabilising role in the rhodopsin class of receptors and may be 
critical to the correct folding of the nascent peptide. It may also be important for the 
binding of allosteric and selective ligands as proposed by Spalding et al. and Matsui et 
al. (Matsui et al., 1995; Spalding et al., 2002).
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The E2 loop of the Mi mAChR is the focus of this study and is discussed extensively 
throughout the study. See below for a description of the E2 loop.
The E3 loop is a short sequence of just nine (rhodopsin) or seven (mAChRs) amino 
acids and there is no sequence homology between the GPCRs in the rhodopsin class. 
Although there has been little interest in the E3 loop in terms of endogenous ligand 
activation it has been shown in the M2 receptor that it is important for allosteric ligand 
interactions. The authors of a recent study using mAChR E3 loop chimeras (Jakubik et 
al., 2005) showed the importance of a three amino acid sequence (Asn-Val-Thr) in 
positive co-operativity of strychnine-like allosteric modulators. Another mutagenesis 
study (Huang et al., 1999) showed that gallamine and W84 (allosteric modulators) share 
a binding epitope on the E2 loop and near the junction of the E3 loop and TM7 on the 
M2 mAChR. The extracellular loops of a version of the Mi mAChR homology model 
are depicted in figure 1.5 below.
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Figure  1.5. 3D-Homology M odel o f the Mi m AChR: E x trace llu la r 
View
TM1
The extracellular view shows the anti-clockwise order of the seven transmembrane 
helices as viewed from the extracellular surface. The position of the Cys-Cys disulphide 
bond that links the top of TM3 with the E2 loop is highlighted as yellow sticks The E2 
loop (shown in green) doubles back on itself and the residues flanking the S-S bond 
protrude towards the ligand-binding pocket. The central binding pocket is indicated by 
the inclusion of an ACh molecule in the core of the molecule. Whether or not residues 
of the E2 loop are directly involved in ligand contact is one of the issues to be 
investigated in this study. NB. The full N-terminal domain is not shown in this model.
N-Tenninus
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1.3. General Principles of G-protein Coupled Receptor Activation.
GPCRs exist in multiple states, minimally an inactive state (R) stabilised by antagonists 
and an active conformation (R*) stabilised by agonists. The binding of agonists at the 
exofacial side activates a selection of specific hetero-trimeric G-proteins on the 
cytoplasmic side of the receptor catalysing GDP release from the a-sub-unit of the G- 
protein heterotrimer and its replacement by GTP. The major, larger component of 
heterotrimeric G-proteins the a-domain (-39-45 KDa) is tightly bound to both the p- 
sub-unit (35-39 KDa) and the y-sub-unit (6 -8 KDa) to form a complete and functional 
complex. To date there have been 28 distinct a-sub-units described divided into 4 
families as determined by their sequence homology, Gs, Gj, Gq and G12 and these 
interact with the p and y sub-units of which there are 5 and 12 different variants 
respectively (Cabrera-Vera et al., 2003). Although not all combinations are favoured, 
the diversity of sub-unit interactions provides the specificity required for the subtleties 
of GPCR signal transduction. Even so, the py sub-units always remain associated.
The mechanisms for heterotrimeric G-protein coupling are common to all membrane
bound GPCRs. The binding of G-protein transfers a reversible and specific signal into
the cell. The binding of the nucleotide GDP to the a-sub-unit allows the Py sub-units to
bind also, this greatly increases the association of the Ga sub-unit with the receptor.
Although the a  sub-unit of the G-protein can bind to the receptor in the absence of the
py sub-units, their binding to the GDP associated a-sub-unit significantly enhances
receptor binding. The binding of an agonist in the central binding pocket activates the
receptor by causing a conformational change which favours the binding of a
heterotrimeric G-protein complex. On binding to the receptor the a  sub-unit rapidly
replaces the bound GDP with GTP. The binding of GTP destabilises the tight
interaction between the a  and Py sub-units of the G-protein and the complex is
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predicted to dissociate, although this is a matter of debate. Bunemann et al. have shown 
using a FRET approach that YFP labelled Gaj and CFP labelled G(3y sub-units did not 
dissociate upon noradrenaline activation of <X2a adrenergic receptors in living cells 
(Bunemann et al., 2003). Assuming dissociation of the sub-units does occur then the 
a  and py sub-units can then activate numerous membrane associated effector proteins 
depending on the sub-type specificity of the G-protein sub-units, which in turn initiate 
further downstream signalling cascades. Examples of downstream effectors are, 
adenylyl cyclase, phospolipase Cpi-4 , phospholipase A2, tyrosine kinases, ion channels 
and mitogen activated protein kinases. For example activation of the Mi mAChR 
inhibits the M-current potassium channel leading to an increase in neuronal firing rates. 
Some of these effectors could be activated or indeed be inhibited by G-protein sub­
units, or could be activated/inhibited via second messenger molecules further down the 
signalling pathway. Initially, signal cascades may result in alteration of intra-cellular 
calcium ion or cAMP levels. As a further consequence of GPCR activation, a multitude 
of intermediary signal transduction pathways can be initiated, potentially leading to 
gene transcription. The signal is terminated by the intrinsic GTPase activity of the a- 
sub-unit that hydrolyses GTP to GDP and the cycle can begin again. See figure 1.6 for 
the heterotrimeric G-protein structure and figure 1.7 for an overview of the G-protein 
activation cycle.
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Figure  1.6. S tru c tu re  of H etero trim eric  G -protein  Com plex
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Ref darwin.bio.uci.edu/~bardwell/231 B_2004_Sigl .ppt
Basic tertiary structure of a heterotrimeric G-protein complex. The a  sub-unit is shown 
in green, in yellow the p sub-unit is shown and in red the smaller y  sub-unit. GTP 
displaces GDP and binds to the a  sub-unit upon activation of the receptor, resulting in 
the release of the a  and py sub-units from the receptor-G-protein complex to initiate a 
signal transduction cascade via downstream effector proteins. The a  sub-unit, which has 
intrinsic GTPase cap-ability, hydrolyses GTP into GDP and the cycle of activation can 
begin again.
41
Chapter 1.
In most signal transduction systems G-proteins are present in the cell in 10-100 molar 
excess compared to receptors at - 1 0 0 , 0 0 0  copies per cell, with one receptor having the 
potential to activate up to 100 G-proteins before desentisation events remove the 
receptor from the cell surface (Alousi et al., 1991). Recent evidence suggests that the 
coupling of G-proteins to receptors may not always occur by the classic diffusion and 
collision model, but rather that homodimers of receptors are pre-coupled to the G- 
protein trimer creating a pentameric complex poised to initiate a signal cascade (Nobles 
et al., 2005). Evidence of this has also been provided by Baneres et al (Baneres and 
Parello, 2003). Using a MALDI-TOF mass spectrometry cross-linking strategy and 
neutron scattering in solution, they showed, in-vitro, that the human leukotriene B4 
receptor exists as homodimer pre-coupled to a single heterotrimeric G-protein complex, 
with the agonist having a significantly (> 1 0 -fold) higher affinity for the pentameric 
complex than for the monomeric or dimeric receptor alone. Evidence contradicting pre­
coupling is provided by Hein et al. (Hein Peter, 2005). Using another FRET based study 
these authors could not find any evidence of receptor G-protein pre-coupling but that 
coupling of the a la adrenergic receptor to Gai and py sub-units occurred via the 
classical collision model. It would appear that both mechanisms are possible depending 
upon the nature of the signal to be transmitted. If the signal is required to be transduced 
at high speed, then pre-coupling of receptor and G-protein complexes would be 
favoured. However if amplification of the signal is required then it may be more 
favourable to for collision coupling to occur.
The coupling of receptors to G-proteins and their subsequent activation is described by 
the ternary complex model. The model (figure 1.7b) shows that the binding of an 
agonist is distinct from the binding of G-protein to the receptor. It is assumed that the 
association of receptor and a GDP ligated G-protein complex is reversible and has an 
affinity constant described by the term Kg. The second assumption is that it is the
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receptor-G-protein complex (RG) that is responsible for the activation process to occur. 
The activation of the G-protein is realised upon the catalysis of GDP dissociation and 
the rapid association of GTP from the cytosol. This process is described by the catalytic 
rate constant kc*. An agonist, when bound to the receptor, can affect the rate of this 
catalytic exchange because agonist binding can change the aK parameter, the fraction 
of receptors in the activated state. The effect of ligand binding can be expressed in terms 
of a cooperativity factor a , which for agonists is greater than 1 and for antagonists and 
inverse agonists is less than 1. The same cooperativity factor applies to the affinity of 
the ligand for free receptor relative to the G-protein-receptor complex. This means that 
the binding of an agonist can enhance G-protein coupling and that agonist can bind with 
a higher affinity to receptors that are precoupled to G-protein complexes than they can 
to free receptor. Conversely, the binding of inverse agonists or antagonists reduces the 
likelihood of a receptor G-protein complex being formed and may bind with lower 
affinity to pre-coupled RG complex.
Hydrolysis of bound GTP via the GTPase activity of the G-protein inactivates the G- 
protein and is governed by the rate constant kh. The rate at which inactivation of the G- 
protein occurs can be increased by accessory RGS proteins (regulators of G-protein 
signalling). RGS proteins are best described as GTPase activating protein (GAPs) which 
bind to the activated form of Ga accelerating GTPase activity, thus promoting a rapid 
termination of G-protein signalling. For the Mi mAChR, RGS2 is responsible for 
termination of signalling and was found to bind directly to the third intracellular loop to 
effect G q /n  a  signalling (Bernstein et al., 2004). It is the conformation of the 13 loop 
that determines the selectivity of RGS proteins and not the class of the Ga sub-unit. 
Phospholipase C pi is also believed to interact with the RG complex and modulate 
activation (Biddlecome et al., 1996).
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T Figure  1.7. An Overview  of the G -protein  A ctivation Cycle.
G -protein  activation  c y c le
agonist
receptorPY subunit subunit
Effector proteins
KG
R  ---- » RG
m w11I11 K!
AR ARG
ctKG
GDP
Knt
V
GTP
GDP
Kc#
V
GTP
Kh
Binding of an agonist to the exofacial side of a G-protein coupled receptor causes a 
conformational change that opens a G-protein binding pocket on the cytoplasmic side of 
the receptor. Binding of the G-protein to the activated receptor catalyses the release of 
GDP and the binding of GTP to the a-sub-unit of the G-protein complex. Bound GTP 
then allows the partial or complete dissociation of the a-sub-unit from the Py sub-unit. 
The mobilised sub-units are then free to initiate multiple downstream signalling 
cascades via interaction with effector proteins such as phospholipase C (PLC). The 
process is terminated by the inherent GTPase activity of the a  sub-unit which may be 
accelerated by G-protein activating proteins (GAPs) such as RGS proteins. The release 
of inorganic phosphate allows re-coupling of the a  and Py sub-units.
NB. Kbin = Ach affinity constant. KG = G-protein affinity constant.
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Although the simple ternary complex model successfully describes the binding of 
agonist and the consequent activation of the receptor, it provides no insight into the 
mechanistic origin of the cooperativity factor a. By incorporating the cooperativity 
factor into the two-state model of receptor activation some progress can be made. The 
so-called extended ternary complex model (below) shows that it is the activated state of 
the receptor which must bind and activate the G-protein. This model shows that there is 
a background or basal concentration of activated receptor (R*) which can activate the 
G-protein independently of agonist binding. This basal level of signalling is governed 
by the conformational constant K. The effect of ligand binding can be seen by the 
degree to which the conformational constant changes and becomes aK in the ligated 
state of the receptor and the ligand binding constant K a  becomes <xKa. Experimentally 
measured binding constants can now be determined by a combination of parameters. 
Kbin =  K a (1 + c x K ) / (1+K). Basal signalling and ligand induced signalling efficacy are (K 
/ 1+K) KG and aK / (1+aK) KG. Variations in the fraction of receptors in the activated 
state when fully occupied lead to differences in ligand efficacy. Variations in receptor 
signalling such as those induced by mutations can effect any of the parameters of the 
system and so lead to characteristic phenotypes.
The Extended Ternary Complex Model
R
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1.3.1 Desensitisation of GPCRs
Activation of G-protein signalling pathways is not a constant process and steps must be 
taken by the cell to guard against over stimulation. High activation of a receptor can 
lead to a reduced ability to signal in the future. This is known as desensitisation and is 
the opposite of sensitisation where under stimulation can lead to an increased ability for 
the receptor to be stimulated. Receptors can become desensitized in two ways. Firstly 
by controlling the number of receptors on the cell surface and secondly by regulating 
the signalling efficacy of cell surface receptors. Receptors are in equilibrium between 
cell surface activity and synthesis and endosomal degradation. Agonist dependent 
stimulation of the same receptor often leads to internalisation of the receptor into 
endosomes where upon they are either re-cycled (sensitisation) or degraded in 
endosomes. A major mechanism for controlling the activity of GPCRs is the activation- 
dependent regulation of receptors, known as homologous desensitisation. This 
mechanism of desensitisation is based on the fact that the activated state of the GPCR 
acts as a substrate for protein phosphorylation by a family of GPCR kinases (GRKs). 
GRKs can distinguish between the activated and the ground state of receptors as they 
are catalytically activated by stimulated receptors. There have been 7 GRKs described 
(Willets et al., 2003). The GRK 1 & 7 family is found predominantly in visual systems 
GRK4 is found primarily in the testes, meaning that GRKs3,5 and 6  are responsible for 
the regulation of the majority of GPCRs. GRKs share a N-terminal domain structure 
similar to RGS proteins a central kinase domain and a variable C-terminal (Pitcher et 
al., 1998).
In order for GRKs to participate in homologous desensitisation they must be able to 
phosphorylate the target receptor and be localised to the membrane in the vicinity of the 
activated receptor. GRKs are located to the membrane via their carboxyl terminal 
domains which are modified with a famesyl or geranylgeranyl group. Unprenylated
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GRKs are unlikely to associate with membranes and thus are rendered inactive. Once an 
activated receptor is phosphorylated by a GRK another family of proteins, the arrestins, 
bind to the receptor. Recognising both the GRK phophorylated site and the activated 
receptor bound arrestins prevent further activation of the receptor by prevention of 
GDP-GTP exchange (Perry and Lefkowitz, 2002). Arrestins are bi-lobed proteins with a 
mainly p-sheet structure, containing a large phosphoprotein binding pocket. The GRK 
and arrestin desensitisation mechanism is also involved in the internalisation of 
inactivated receptors and the recycling of receptors back to the cell surface.
GRKs involvement in the internalisation process is simply due to their recruitment of 
arrestins to the activated receptor. Once localised at the activated receptor the arrestin 
proteins bind to both AP2, a clathrin adaptor protein, and to clatharin itself. The binding 
of clathrin then facilitates the entry of the desensitised receptors into clatharin coated 
pits which are subsequently internalised by endocytosis. Clathrin-mediated endocytosis 
of receptors depends on motifs that have been described as being on the C-terminal 
domains of receptors. However, a common endocytic motif has yet to be identified. 
GRKs and arrestins can recruit a variety of other proteins that can further regulate or 
transduce downstream signalling. For example GRKs have been reported to bind PI3- 
kinases which are involved in receptor trafficking and initiating further receptor 
dependent signalling. Arrestins also serve as adaptor molecules that can ferry a range of 
signalling proteins to activated receptors.
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1.4 Oligomerisation of GPCRs
Until the early 1980s it was presumed that GPCRs functioned as monomeric entities 
forming complexes with G-proteins upon ligand activation. It was Agnati et al. (Agnati 
LF, 1982) who proposed that GPCRs may actually form oligomeric complexes in a 
manner analogous to other membrane receptors, such as tyrosine kinase receptors. 
Evidence that GPCRs could actually form homodimeric or higher oligomeric complexes 
was first gained over a decade later by the use of coimmunoprecipitation techniques. 
Hebert et al (Hebert et al., 1996) using differential epitope tagging (HA and Myc) of the 
p2 Adrenergic receptor showed that the p2 AR homodimer was resistant to SDS 
treatment and that the homodimer stabilised the active state. They also showed that 
inverse agonists favoured the monomeric state and that this had implications for the 
biological activity of the receptor. Similar studies also revealed the existence of 
homodimerisation of the D2 dopamine receptor (Ng et al., 1996), the metabotropic 
glutamate receptor 5 (Romano et al., 1996) and the M3 mAChR (Zeng and Wess, 1999). 
One of the problems of interpreting such data is the possibility that the over expression 
of hydrophobic receptors in in-vitro systems may cause artifactual aggregations of 
receptors due to misfolding or incomplete solubilisation of the receptors. Despite 
methods used to improve solubility and stabilise dimers other methods were needed to 
demonstrate conclusively that GPCR dimerisation occurred in living cells.
The development of fluorescence resonance energy transfer techniques enabled 
researchers to observe receptor/receptor interactions in living cells without disturbing 
the cellular environment. The principle of resonance energy transfer is based on the 
transfer of nonradiative energy between the electromagnetic dipoles of an energy donor 
and an acceptor. Overlap of the emission and excitation spectra for the donor and the 
acceptor allows the energy transfer between fluorophores attached to two molecules to 
be measured and this provides an indication of the relative closeness of one molecule to
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another. There are two types of experiment, bioluminescence resonance energy transfer 
(BRET) and fluorescent resonance energy transfer (FRET). The difference is that for 
FRET assays both the donor and the acceptor are fluorescent, whereas with the BRET 
system the donor has an intrinsic bioluminescence as a result of catalytic enzyme 
activity (Hovius et al., 2000). By genetically linking either green fluorescent protein 
(GFP) or Renilla luciferasec to the C-terminus of the human 02 adrenergic receptor and 
co-expressing them in the same cells, Angers et al (Angers et al., 2000) were able to 
show colocalisation consistent with the formation of constitutive homodimers in living 
cells for the first time. Stimulating these cells with the selective p2 AR agonist 
isoproterenol increased the BRET signal and suggests that activation of the receptor 
either increases dimerisation or that conformational changes induced by activation bring 
the GFP and the luciferase moieties into even closer proximity.
A more recent study by Liang et al. (Liang et al., 2003) provided visual evidence, using 
atomic force microscopy (AFM), of the higher order organisation of rhodopsin and 
opsin receptors in their native environment. These authors revealed that rhodopsin and 
opsin form structural dimers spatially arranged in paracrystalline arrays in rod outer 
segment (ROS) disk membranes from Rpe65-/- mutant mice (retinal pigment epithelium 
deficient mice) (see figure 1.8). The specialized nature of ROS cells and the high 
density of photoreceptors in their membranes is unusual for GPCRs. The sheer number 
of receptors expressed in the membrane may force the formation of oligomeric 
complexes. As a caveat, this problem may also arise when over-expressing receptors in 
cell based systems. Over-expression of receptors may lead to aggregations of receptors, 
through hydrophobic interactions and thus may be falsely interpreted as receptor 
oligomerisation. One of the interesting debates about receptor oligomerisation is 
whether or not dimers are pre-formed during biosynthesis and export through the ER 
and Golgi apparatus or whether ligand induced activation causes monomeric receptors
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to couple to proximal receptors. One study on a non-GPCR, has shown that the 
erythropoitin receptor is preformed as a dimer and that hormone activation promotes a 
conformational change of the dimer rather than forming a dimeric complex (Livnah et 
al., 1999; Remy et al., 1999). The use of coimmunoprecipitation, western blot analysis 
and energy transfer techniques have all revealed three basic scenarios for GPCR 
dimerisation: i) the amount of stable preformed dimers is not altered upon treatment 
with ligand, eg the 8 -opioid receptor (McVey et al., 2001); ii) addition of ligand can 
alter the amount of dimers eg. p2 adrenergic receptors (Hebert et al., 1996); iii) 
dimerisation is only possible by pre-treatment with ligand eg. the somatostatin 5 
receptor (Rocheville et al., 2000).
Is dimerisation necessary for activation? Hebert et al. (Hebert et al., 1996) also showed 
in their study that perturbation of p2 adrenergic receptor dimers with an inhibitory 
peptide derived from TM6  reduced signalling activity by ~10-fold. Recent evidence 
from Guo et al. (Guo et al., 2005) has shown, using crosslinking of substituted 
cysteines, the extensive and dynamic contribution of TM4 in forming dimers of the D2 
dopamine receptor and that conformational changes at the TM4 and TM5 interfaces are 
important for receptor activation. Differences in conformation were observed, by 
changes in cross-linking of substituted cysteine residues in the dimeric complexes when 
receptors were induced by either an inverse agonist or an agonist. This suggested that 
the structure of the two protomers (each receptor in a dimer is termed the protomer) at 
the interface was related to the conformation of the binding site. Mesnier et al. (Mesnier 
and Baneres, 2004) provided evidence for the idea that the binding of ligand to just one 
binding site in the dimer was sufficient to promote the active conformation in the other 
protomer. Using purified leukotriene B4 receptor heterodimers where one protomer has 
a lower affinity for the agonist LTB4 they showed using FRET and GTPyS binding 
assays that agonist induced activation of one of the monomers in the dimeric complex
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specifically altered the conformation of the unliganded monomer. This strengthened the 
observations of Percherancier et al. (Percherancier et al., 2005) who, using a sensitive 
BRET methodology, also found that conformational changes were induced in both 
protomers of the CXCR4 and CCR2 Chemokine receptor homo and hetero dimers upon 
agonist binding to just one of the protomers.
As well as being able to form dimers and perhaps higher order oligomeric complexes 
with a receptor of the same species (homodimers) growing evidence has revealed that 
receptors are also able to form alternative functioning oligomers with other types of 
receptor (heterodimers) that are able to activate a variety of signalling pathways. The 
list of GPCR heterodimers is growing and is of immense clinical significance. For a full 
review of GPCRs that have been found to heterodimerize see Prinster et al. (Prinster et 
al., 2005). To give just one relevant example, Maggio et al (Maggio et al., 1999) 
demonstrated, using tripitramine and pirenzepine competition binding experiments with 
chimeric constructs from M2 and M3 mACh receptors, that interaction or ‘crosstalk’ 
between the two sub-types was possible. Co-transfection of an M2 mutant (N404S) that 
was unable to bind antagonist, with the WT M3 receptor showed that two entire 
receptors were able to interact to form a small subpopulation that can bind the M2 
selective antagonist tripitramine. These pharmacologically based experiments 
demonstrated that heterodimerization of muscarinic receptors is possible, but these 
authors could offer no insight to the clinical significance of their findings. If it is 
validated that heterodimerization of GPCRs is a common phenomenon that occurs in 
vivo, then the challenge facing drug discovery programs and the implications for GPCR 
regulation are enormous and mind boggling. The identification of dimer interfaces by 
studies such as Guo et al. (Guo et al., 2005) and assessing their stability and ligand 
induced or constitutive activation properties may lead to the development of novel 
compounds to regulate GPCR functions.
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Image taken from Liang et al. JBC vol 278 No. 24 pp 21655-21662
The figure shows rows of rhodopsin and opsin dimers in disk membranes taken from 
Rpe65-/- mutant mice and visualised using atomic force microscopy. The dimers are 
spatially arranged in a paracystalline lattice. An occasional monomer is indicated by an 
arrowhead. The scale bar represents 15nm and the vertical brightness is 2.0nm.
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1.5 Muscarinic Acetylcholine Receptors Sub-Types (M1-M5)
Sir Henry Dale first described two distinct acetylcholine receptors in 1914. One was 
activated by nicotine (the nicotinic receptors) and the other was activated by muscarine 
(Dale, 1914). Muscarine is the pharmacologically active ingredient derivative of the fly 
agaric mushroom, Amanita muscaria. As members of the Rhodopsin class of receptors 
they are amongst the most studied receptors of the GPCR superfamily of membrane 
proteins. Muscarinic receptors mediate the metabotropic effects of acetylcholine in the 
central and peripheral nervous systems. Pharmacological studies initially suggested the 
existence of more than one muscarinic receptor sub-type (Hammer RBC et al., 1980). 
Numa and colleagues (Kubo et al, 1986) and Peralta and colleagues (Peralta EG et al., 
1987) revealed the genetic identification of the Mi and M2 sub-types. A further 3 types, 
M3, M4 and M5 were discovered a year later by Bonner, Buckley and co-workers. 
(Bonner TI et al., 1987; Hulme et al., 1990). The chromosomal locations of the five sub- 
types are based on further work by Bonner et al. are reported to be: - Mi-1 lql2-13, M2 - 
7q35-36, M3 -lq43-44, M4 -llpl2-11.2 and Ms -15q26 (Caulfield and Birdsall, 1998). 
A line up of their individual sequences is shown below (table 1.1). The five muscarinic 
acetylcholine receptor sub-types are highly homologous in the transmembrane helical 
domains, but the N & C terminals and the loop domains show greater variability. As in 
other members of the rhodopsin-like family, highly conserved residues Asp-Arg-Tyr 
(DRY) are found at the cytoplasmic end of Transmembrane 3 (TM 3) (Jones et al., 
1995; Lu et al., 1997a) and two conserved cysteine residues form a stabilising 
disulphide bond between the 1st and the 2nd extracellular loops (Kurtenbach, 1990; 
Kurtenbach et al., 1990; Savarese et al., 1992). Careful sequence analysis has revealed 
differences in the five subtypes that are related to the ability of the sub-types to bind a 
different class of G-protein (see previous section).
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T able 1.1 A m ino Acid Sequence A lignm ent of the Five R a t m A C hR  
Subtypes
The sequence below compares the amino acid sequences of all five rat muscarinic 
acetylcholine receptor sub-types. Highlighted in green are the transmembrane domains 1- 
7 for the M \  mAChR and in yellow the location and sequence of the Mi mAChR E2 loop.
1 50
ACM1_RAT ............................................ M NTSVPPA.VS
ACM2_RAT  MNNS T. . . .NSSNN
ACM4_RAT ......................................... MXNF TPVNGSSANQ
ACM3_RAT MTLHSNSTTS PLFPNISSSW VHSPSEAGLP LGTVTQLGSY NISQETGNFS
ACM5 RAT  ME GESYNESTVN
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
51
PNITVLAP..
GL AITS
SVRLVTAAHN
SNDTSSDPLG
GTPVNHQALE
GKGPWQVAFI GITTGLLSLA TVTGNLLVLI
PYKTFEWFI VLVAGSLSLV TIIGNILVMV 
HLETVEMVFI ATVTGSLSLV TWGNILVML 
GHTIWQWFI AFLTGFLALV TIIGNILVIV 
RHGLWEVITI A W T A W S L M  TIVGNVLVMI
100
SFKVNTELKT
SIKVSRHLQT
SIKVNRQLQT
AFKVNKQLKT
SFKVNSQLKT
101 150
ACM1_RAT VNNjTFLLSLA CADLIIGTFS MNLYTTYLLM GHWALGTLAC DLWLALDYVA
ACM2_RAT VNNYFLFSLA CADLIIGVFS MNLYTLYTVI GYWPLGPWC DLWLALDYW
ACM4_RAT VNNYFLFSLG CADLIIGAFS MNLYTLYIIK GYWPLGAWC DLWLALDYW
ACM3_RAT VNNYFLLSLA CADLIIGVIS MNLFTTYIIM NRWALGNLAC DLWLSIDYVA
ACM5 RAT VNNYYLLSLA CADLIIGIFS MNLYTTYILM GRWVLGSLAC DLWLALDYVA
151
ACM1_RAT SNASVMNLLL ISFDRYFSVT
ACM2_RAT SNASVMNLLI ISFDRYFCVT 
ACM4_RAT SNASVMNLLI ISFDRYFCVT 
ACM3_RAT SNASVMNLLV ISFDRYFSIT 
ACM5 RAT SNASVMNLLV ISFDRYFSIT
RPLSYRAKRT
KPLTYPVKRT
KPLTYPARRT
RPLTYRAKRT
RPLTYRAKRT
TKMAGMMIAA
TKMAGLMIAA
TKRAGVMIGL
PKRAGIMIGL
AWVLSFILWA 
AWVLS FVLWA 
AWVISFVLWA 
AWLVSFILWA
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
2 0 1
^ ■ W Q Y L V
PAILFWQFIV
PAILFWQFW
PAILFWQYFV
PAILCWQYLV
250
GERTVLAGQC YIQFLSQPII TFGTAMAAFY LPVTVMCTLY
GVRTVEDGEC YIQFFSNAAV TFGTAIAAFY LPVIIMTVLY 
GKRTVPDNQC FIQFLSNPAV TFGTAIAAFY LPWIMTVLY 
GKRTVPPGEC FIQFLSEPTI TFGTAIAAFY MPVTIMTILY 
GKRTVPPDEC QIQFLSEPTI TFGTAIAAFY IPVSVMTILY
251 300
ACM1_RAT MfclfRETENR ARELAALQGS ET PGKGGGSSS SSERSQPGAE
ACM2_RAT WHISRASKSR IK............... KEKK EPVANQDPVS PSLVQGRIVK
ACM4_RAT IHISLASRSR VH............... KHRP EGPKEKKAKT LAFLKSPLMK
ACM3_RAT WRIYKETEKR TKELAGLQAS GTEAEAENFV HPTGSSRSCS SYELQQQGVK
ACM5 RAT CRIYRETEKR TKDLADLQGS DSVAEAKK.R EPAQRTLLRS FFSCPRPSLA
301 350
ACM1_RAT GSPESPPGRC CRC CRAPRLLQAY SWKE..EEEE DEGSMESLTS
ACM2_RAT PNNNNMPGGD GGLEHNKIQN GK. . .APRDG VTETCVQGEE KESSNDSTSS
ACM4_RAT PSIKKPPPGG ASREE..LRN GKLEEAPPPA LPPPPRPVPD KDTSNESSSG
ACM3_RAT RSSRRKYGRC HFWFTTKSWK PSAEQMDQDH SSSDSWNNND AAASLENSAS
ACM5 RAT QRERNQASWS SSRRST.... STTGKTTQAT DLSADWEKAE QVTTCSSYPS
351 400
ACM1_RAT SEGEEPGSE W I K M  P .............................MVDS
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ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
ACM1_RAT 
ACM2_RAT 
ACM4_RAT 
ACM3_RAT 
ACM5 RAT
AAV.............................AS NMRDDEITQD ENTVSTSLDH
SATQNTKERP  PT ELSTAEATTP ALPAPTLQPR
SDEEDIGSET RAIYSIVLKL PGHSSILNST KLPSSDNLQV SNEDLGTVDV
SEDEAK. PTT DPVFQMVYK......... SEA KESPGKESNT QETKETWNT
401 450
EAQAPTKQPP KS SPN TVKRPTK K GRDRGGKGQK
SRDDNSKQTC IKIVTKAQKG DVYTPTSTTV ELVGSSGQSG DEKQNWARK 
TLNPASKWSK IQIVTKQTGN ECVTA.... I EIVPATPAGM RPAAN.VARK 
ERNAHKLQAQ KSM..GDGDN CQKDFTKLPI QLESAVDTGK TSDTNSSADK 
RTENSDYDTP KYFLSPAAAH RLKSQKCVAY KFRLWKADG TQETNNGCRK
451 500
P  RGKEQLAKR KTFSLVKEKK AARTLSAXXiL
I ......................VKMPKQPAKK KPP.PSREKK VTRTILAILL
F .................... ASIARNQVRK KRQMAARERK VTRTIFAILL
TTATL.PLSF KEATLAKRFA LKTRSQITKR KRMSLIKEKK AAQTLSAILL 
VKIMPCSFPV SKDPSTKGPD PNLSHQMTKR KRMVLVKERK AAQTLSAILL
501 550
AFILTWTPYN IMVLVSTFCK DCVPETLWEL GYWLCYVNST VNPMCYALCN
AFIITWAPYN VMVLINTFCA PCIPNTVWTI GYWLCYINST INPACYALCN 
AFILTWTPYN VMVLVNTFCQ SCIPERVWSI GYWLCYVNST INPACYALCN 
AFIITWTPYN IMVLVNTFCD SCIPKTYWNL GYWLCYINST VNPVCYALCN 
AFIITWTPYN IMVLVSTFCD KCVPVTLWHL GYWLCYVNST INPICYALCN
551
KAFRDTFRLL LLCRWDKRRW 
ATFKKTFKHL LMCHYKNIGA 
ATFKKTFRHL LLCQYRNIGT 
KTFRTTFKTL LLCQCDKRKR 
RTFRKTFKLL LLCRWKKKKV
592
RK...IPKRP GSVHRTPSRQ C.
TR......................
AR......................
RKQQYQQRQS VIFHKRVPEQ AL 
EEKLYWQGNS KLP.........
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The location and biochemistry of each sub-type determines its physiology and its 
function (Bymaster et al., 2003b). Mi mAChRs are found predominantly and are the 
most abundantly expressed muscarinic receptors in all the major regions of the 
forebrain, particularly the cerebral cortex, hippocampus and the striatum (Levey, 1993). 
At these locations the Mi mAChRs are involved in higher cognitive processes such as 
learning and memory. Mi receptors mediate most of the Ach-stimulated PIP2 
breakdown and MAP kinase activation in the hippocampus and cerebral cortex 
(Hamilton and Nathanson, 2001) and activate ion channels underlying prolonged 
oscillations in the hippocampus (Fisahn et al., 2002). Muscarinic acetylcholine receptors 
also have the ability to stimulate shedding of cell surface growth factors and amyloid 
precursor proteins, which has important implications for the progress of Alzheimers 
disease. The first mAChR gene to be knocked out in mice was the Mi sub-type. 
Hamiliton and coworkers (Hamilton et al., 1997) found that Mi KO mice did not exhibit 
epileptic seizures when treated with pilocarpine, unlike the WT controls or the other 
four sub -type knockouts (Bymaster et al., 2003b). Therefore, Mi is strongly implicated 
in the pathophysiology of some forms of epilepsy. Behavioural studies of Mi knockout 
mice (Gerber et al., 2001; Miyakawa et al., 2001) showed that although Mi KO did not 
produce phenotypes deficient in motor co-ordination, nocioception or anxiety-related 
behaviour, they did show increased locomotor activity. The authors attributed this to 
increases in dopamine release and proposed that the Mi mAChR have some regulatory 
effect on the release of dopamine in the neurons of the substantia nigra. If this is the 
case, then selective Mi agonists may help alleviate symptoms of Parkinsons disease, 
which is associated with reduced striatal dopamine release. The discovery of selective 
Mi ligands may also impact on the treatment of schizophrenia, another disease where 
inappropriate Mi regulation of dopamine release in the forebrain is suspected (Gerber et 
al., 2001). Hamiliton and Nathanson (Hamilton and Nathanson, 2001) demonstrated the 
lack of a MAPK signalling pathway in primary cortical cultures of Mi-deficient mice
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and a later study, by Berkley et al. (Berkeley et al., 2001) confirmed this by showing 
that the MAPK pathway remained intact in the CA1 hippocampal neurons of M2-M5 
KO mice. Since the MAPK signalling pathway is implicit in neuronal plasticity and 
neuronal cell differentiation it is possible that deficiencies in Mi mAChR expression or 
function could be behind specific developmental, physiological or behavioural 
abnormalities.
M2 and M4 receptors both selectively couple to the Gi/o class of G-proteins and have 
very similar ligand binding profiles. M2 receptors are expressed throughout the central 
nervous system and in the periphery, especially in smooth muscle and tissues of the 
heart, whereas M4 receptors are found predominantly in the CNS, particularly the 
regions of the forebrain. In the heart M2 receptors are involved in the regulation of heart 
beat. Stimulation of the parasympathetic nervous system releases ACh from vagal nerve 
endings, which binds to (predominantly) M2 mAChRs in the sinotrial node reducing 
heart beat frequency. M2 mAChRs appear to be solely responsible for the regulatory 
effect despite the presence of the other mAChR sub-types in heart cardiac muscle 
(Caulfield and Birdsall, 1998). M2 may be involved in shivering responses as 
oxotremorine-induced tremors were ablated in M2 KO mice and furthermore, M2 
receptors found in the hypothalamus have also been implicated in the regulation of body 
temperature (Gomeza et al., 1999). Evidence of another role for M2 receptors found at 
nocioceptors in skin tissues has been demonstrated by Bemardini et al (Bemardini et al.,
2001). These authors also showed M2 KO mice had reduced sensitivity to intrathecal 
and intra cerebral ventricular oxotremorine. In hot plate tests M2 deficient mice did not 
show muscarine induced desentisization of pain impulses as opposed to M4 deficient 
mice (Bemardini et al.). Stimulation of autoreceptors at cholinergic nerve endings 
allows acetylcholine to control its own release. Zhang et al (Zhang et al., 2002a) showed 
that M2 receptors were responsible for the auto-inhibition of ACh in the mouse
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hippocampus and cerebral cortex regions of the brain. Regulation of ACh release is
fundamental to processes such as cognition and locomotor control and as such this
information is of great clinical importance and has relevance to Alzheimers and
Parkinsons disease.
M3 receptors are also located in various regions of the brain and peripheral organs and 
tissues that are innervated by the parasympathetic nervous system. They perform 
actions associated with glandular function and regulation of smooth muscle contraction, 
particularly in the gut. A striking feature of M3-deficient mice, observed by Yamada et 
al (Yamada et al., 2001b) was their significant loss of body mass accompanied by 
reductions in serum leptin and insulin levels as a result of reduced food intake. 
Expressed at relatively high levels in the hypothalamus, M3 receptors may be 
responsible, in part, for the regulation of appetite. Regulation of salivary secretion has 
also been attributed to M3 receptors found in the salivary glands. Although Yamada et 
al. (Yamada et al., 2001b) found that pilocarpine induced salivation was only 
significantly (50%) reduced at the middle concentration of three different dose 
strengths. Other studies have implicated Mi, M4 (Bymaster et al., 2003a) and M5 
(Takeuchi et al., 2002) as contributing to mAChR mediated salivation.
M4 receptors are preferentially expressed in the CNS forebrain (Levey, 1993) and are 
believed to regulate striatal dopamine release through action on the cell bodies of 
striatal GABAergic projection neurons (Zhang et al., 2002b). Mt-deficient mice show 
statistically significant increases in basal locomotor activity and suggest a regulatory 
role of M4 receptors on Dopamine Di receptor locomotor activity. This highlights the 
fact that functional interactions of the cholinergic and dopaminergic pathways are 
important for striatal function and as such its control is relevant to the treatment of 
Parkinsons disease.
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M5 receptors the last mAChR to be cloned is found in both neuronal and non-neuronal 
cells are expressed at low levels and until recently little was known about their 
physiological functions. The discovery of M5 receptors in peripheral and cerebral blood 
vessel endothelium, has implicated M5 receptors as being able to mediate ACh -induced 
dilation of arteries and arterioles. The vaso-relaxing affect of ACh effects only cerebral 
blood vessels and not the carotoid or coronary arteries via M5 mediated dilation, as 
shown by Yamada et al. (Yamada et al., 2001a). The implications for cerebrovascular 
disorders are many and as such M5 receptors are an attractive target for novel 
therapeutic strategies. M5 Knockout mice have been shown to change drug seeking 
behaviours. The conditioned place preference test showed that effects of morphine and 
opioids were significantly reduced in Ms-deficient mice (Basile et al., 2002). The 
expression of M5 receptors in the substantia nigra and the nucleus accumbens is 
consistent with their role as modulators of dopamine release in the mid-brain and their 
involvement in the rewarding effects of drug abuse. However the complex neuronal 
pathways that are involved these modulatory effects remain to be discovered.
In the greater scheme of behavioural mechanisms mAChRs are important biochemically 
active modulators of synaptic plasticity, cognition, potentiation, pathogenesis and 
psychosis and further discoveries of their physiological roles in the CNS and peripheral 
nervous system are likely. For a brief summary of mAChR sub-type localisation and 
function see table 1.2. The muscarinic receptors are clinically important targets for 
treatment of schizophrenia (M4), Alzheimers (Mi and M2) and Parkinsons (M4) disease 
as well as chronic obstructive pulmonary disease (COPD) (Mi, M2 and M3), glaucoma 
(M3), urinary incontinence and gastrointestinal mobility (M2 and M3) and have also 
been implicated as being involved in the control of appetite (M3)
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T able 1.2. Sum m ary  of M uscarinic R eceptor Sub-Types
M A C hR
Sub-Type M i m 2 M 3 m 4 M s
Predominant
Localisation
B R A IN :
cortex
hippocampus
striatum
hypothalamus
dentate
gyrus.
P E R IP H E R Y :
sympathetic
ganglion
salivary
glands
B R A I N :
Brain stem 
cerebellum 
forebrain 
olfactory bulb 
amygdala
P E R IP H E R Y :
heart,
smooth and 
cardiac muscle
B R A IN -.
cortex
hippocampus
P E R IP H E R Y :
Exocrine and
endocrine
glands,
smooth
muscle
B R A I N :
basal
forebrain
striatum
hippocampus
P E R IP H E R Y :
smooth
muscle,
vascular
endothelia
B R A I N :
substantia
nigra.
striatum.
P E R IP H E R Y :
peripheral 
blood vessels
G-protein
coupling G q /1 1 Gi/o G q /1 1 Gi/o G q /1 1
Functional
Response
M-current 
inhibition 
Stimulation of 
sympathetic 
ganglia 
Activation of 
MAP kinase 
Mediation of 
hippocampal 
oscillations
Activates 
K+ channels 
Inhibition of 
Ca2+ channels 
reduces 
cytosolic 
cAMP 
decreased 
heart rate, 
decrease 
neuro­
transmitter 
release (pre- 
synaptic)
Smooth 
muscle 
contraction. 
Glandular 
secretion. 
Decrease 
neuro­
transmitter 
release 
(pre and post 
synaptic).
Activation of 
K+ channels 
Inhibition of 
Ca channels 
Reduction of 
cytosolic 
cAMP 
Inhibition of 
neurotrans­
mitter 
release.
Facilitating
dopamine
release.
Reduction of
addictive
effect of
morphine.
Mediates
ACh-induced
dilation
of cerebral
arteries
Effectors 
& Second 
Messengers
PLC
IP3 DAG
Ca2+ / PKC
Adenylyl
Cyclase
cAMP(-)
Ion Channels 
K+ Channels
PLC 
IP3 DAG
Ca2+ / PKC 
Ion Channels
Adenylyl
Cyclase
cAMP(-)
PLC
IP3 DAG
Ca2+ / PKC
Chromosomal
Localisation llql2-13 7q35-36 lq43-44 1 lp l 2 -l 1 . 2 15q26
No. Amino 
Acids in 
Protein 
Humans/Rat
460/460 466/466 590/589 479/478 532/531
Legend: P L C  (Phospholipase C), IP 3 (Inositol 1, 4, 5 triphosphate) D A G  (Diacyl glycerol), P K C  
(Protein Kinase C)
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1.6 Muscarinic Acetylcholine Receotor Activation
Mi, M3 and M5 mAChR subtypes activate the Gq/Gn, class of G-proteins stimulating 
phospholipase Cp isoforms to break down inositol 4,5 bisphosphate (PIP2). Breakdown 
of PIP2 liberates inositol triphosphate (IP3) that mobilises intracellular calcium and 
diacylglycerol that in turn stimulates protein kinase C, leading to effects including 
modulating slow potassium and calcium conductances. Depletion of PIP2 inhibits the 
KCNQ/M (Kv7) potassium channel that modulates the M-current leading to increases in 
repetitive action potential discharges. M2 and M4 mAChRs couple primarily to G- 
proteins of the Gj and G0 class distinguishing the even numbered mAChRs from the odd 
numbered sub-types. The activation of aGi inhibits adenylyl cyclase (Nasman et al.,
2002). The p and y sub-units activate fast inward rectifier potassium channels and 
inhibit voltage sensitive calcium channels. Active mAChRs are phosphorylated by 
specific kinases, promoting the binding of arrestins, thus nucleating complexes which 
themselves can activate multiple kinase cascades (Hamilton et al., 1997). Some of the 
effector proteins and the inositol phosphate signalling cascade can be seen in figure 1.9.
Current theory suggests that the inactive ground state of mAChRs is dependent upon
specific interhelical interactions. The residues LI 16 (TM3), F374 (TM6 ) and N414
(TM7) supported by SI20 (TM3) and Y418 (TM7) have been proposed as providing a
network of Van der Waals and hydrogen bond interactions that help to selectively
stabilise the ground state of the Mi mAChR. The mutation to alanine of these residues
decreases receptor stability, increases agonist affinity and induces agonist-independent
basal signalling activity especially for the L116A mutant. (Lu and Hulme, 2000).
Mutations that produce constitutively active mAChRs have also been reported by
Spalding (Spalding and Burstein, 2001) and Schmidt (Schmidt et al.2003). The binding
of the agonist is predicted to disrupt these interhelical interactions creating a new set of
interactions that stabilize the activated conformation of the receptor. It is believed that it
is the closure of a series of binding site aromatic residues (see below figure 1 .1 1 )
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around the tetramethylammonium head group of acetylcholine that transduces binding 
energy into the energy required to rearrange the ground state network of H-bonds. 
Closure of the aromatic cage around the ACh head group is predicted to precipitate the 
re-alignment of TM6  and TM7 relative to TM3 into the active conformation (Hulme et 
al., 2003). The disruption to ground state interactions caused by closure of aromatic 
residues around ACh is likely to result in the movement of TM6  and TM3. This 
mobilisation may precipitate outward movements of the surrounding helices leading to 
the appearance of buried residues that are able to associate with a G-protein 
heterotrimer. This is a possible mechanism to describe the conformational switch that 
converts the inactive receptor into an activated state with increased affinity for G- 
protein (Hulme et al., 2001).
Structural studies of rhodopsin (Li et al., 2004 ; Okada et al., 2002) have highlighted the 
importance of a water mediated hydrogen bonding network connecting TM2, TM3, 
TM6  and TM7 that is re-organised to produce the active conformation of the receptor. It 
has also been shown using alanine scanning mutagenesis (Hulme et al., 2003; Lu et al., 
2001) that central to the activation of muscarinic receptors is the rearrangement of a H- 
bond network involving Asp71 that links TM2 to TM1 via Asn 43. Although these 
residues are important for stabilisation of the ground state they appear to have a dual 
role because they are also important for activation of the receptor. It is probable that the 
highly conserved NSXXNPXXY motif in TM7 is centrally involved in the 
conformational change that allows for a rearrangement of contacts to stabilise the 
activated state. The re-orientation of Tyr 418 may transmit the activated conformation 
of the receptor to helix 8  which lies perpendicular to the lipid bi-layer and is involved in 
the coupling of the activated receptor to a G-protein. Another residue critical for 
receptor signalling is Arg 123, again a highly conserved residue in the ‘DRY’ sequence 
in the 1 2  loop of the rhodopsin family of receptors, forms a charge-stabilised hydrogen
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bond with Glu360 (conserved in monoamine receptors and rhodopsin). Mutation of the
Glu360 residue produces constitutively active receptors, highlighting the constraining
nature of this interaction in the native receptor (Hogger et al., 1995).
Using electron paramagnetic resonance measurements, Farahbakhsh and Klein- 
Seetharaman and co-workers (Farahbakhsh et al., 1995; Klein-Seetharaman et al., 1999) 
studied the spin-spin interactions of nitroxide spin labels that were attached to the 
cytoplasmic loops and helix termini of rhodopsin. Their studies revealed that activation 
of the receptor causes a clockwise rotation of TM6 , relative to the cytoplasmic end of 
the receptor and an outward movement relative to TM3. Dunham and Farrens (Dunham 
and Farrens, 1999), using a fluorescence spectroscopic approach in conjunction with 
PyMPO-maleimide cysteine mutant reactivity experiments, provided further evidence 
that a conformational change at TM6  is characteristic of rhodopsin activation. A 
fluorescence spectroscopy study by Jensen et al on the P2 Adrenergic receptor (Jensen et 
al., 2 0 0 1 ) added further evidence that an outward movement of the cytoplasmic region 
of TM6  follows agonist induced activation. Upon activation, helix 8 , lying parallel to 
the lipid membrane and perpendicular to the transmembrane helices, also undergoes a 
conformational movement. Movement of helix 8  of the rhodopsin receptor uncovers a 
crevice between TM7 and H8  that only becomes accessible to a monoclonal antibody 
upon light induced activation (Abdulaev and Ridge, 1998). The monoclonal Ab binds to 
an epitope that includes Tyr 418 part of the highly conserved NPXXY motif, 
characteristic of rhodopsin-like GPCRs, believed to be critical for G-protein activation. 
For a graphical description of the relative movements associated with receptor 
activation (see figure 1 .1 0 . panel a).
G-protein contact residues are located at the cytoplasmic end of TM3 TM5, TM6  and 
TM7 where they face inwards, away from the membrane. The intra-cellular loops 12 and 
13 and Helix 8  also harbour G-protein contact residues. An alanine scanning
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mutagenesis study (Lee et al., 1996) found that a series of conserved positively charged 
residues located in the 13 loop of the Mi mAChR, (K361K362AAR365) were important for 
maximal agonist activity. Another study of M2 receptor mutants co-expressed with the 
Mi, M3 and M5 specific Gaq sub-units (Kostenis et al., 1997) identified the same region 
as conferring selectivity to the coupling of either Gaq/n to Mi,M3 and M5 mAChRs or 
Goij to M2 and M4 receptors. The selective coupling of either Gaq/i 1 or Gaj-proteins to 
mAChR’s seems to be determined by the sequence in the 13 loop and TM5 as shown 
below highlighted in yellow.
Interestingly the specific interaction of G aq/n with Mi,M3 and M5 mAChRs and Gctj 
with M2 and M4 receptors can be reversed by switching just three amino acids at the C- 
terminus of the G-protein (Conklin et al., 1993) including a glycine residue that is 
thought to be important for specifying G-protein coupling interactions. Later 
mutagenesis studies of a-transducin (Onrust et al., 1997) and a yeast Got sub-unit 
(Kallal and Kurjan, 1997) predicted that a 45-amino acid sequence in the C-terminal of 
the Ga sub-unit form a surface that interacts with cytoplasmic domains of the receptor. 
Once the 2 angstrom resolution X-ray crystallographic structure of a G-protein 
heterotrimer was solved (Lambright et al., 1996) these residues mapped to the a4-p6 
loop, the P6  strand and the a5 helix of the C-terminal region of the G a sub-unit (see 
figure 1.10 panel b). In addition to these key contact sites other receptor-G-protein 
interactions are important to anchor the G-protein to the receptor. For example another
13 LOOP TM5
M / - E R K V T R T I F  A I L- 
M2 - E K K V T R T I L  A I L -
Couple to G a ;
M / - E K K A A R T L S A I L
/>- Couple to 
Gaq/i 1
Rho-E K E V T R M V I I M V  Couples to Transducin
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study using an environmentally sensitive fluorophore identified helix 8  as interacting 
with the py sub-units of transducin (Phillips and Cerione, 1992; Phillips et al., 1992) 
which also appear to enhance membrane binding of the a  sub-units (Clapham and Neer, 
1997). The binding site for Helix 8  may lay between blades 1 and 2 of the so-called P- 
propellor proximal to the famesylated C-terminus of the y sub-unit and the N-terminal 
helix of the a  sub-unit. The more structurally diverse py sub-units may confer added 
selectivity to receptor/G-protein coupling. For full reviews of G-protein-receptor 
coupling see (Clapham and Neer, 1997; Wess, 1998).
In summary, activation of muscarinic receptors may occur by the rupture of Wan der 
Waals contacts and re-arrangement of a specific hydrogen bonding network caused by 
the closing of the aromatic cage around the ACh head group. This could lead to 
mobilisation of the TM helices, in particular TM3 TM6  and TM7, resulting in the 
exposure of epitopes required for G-protein interaction. Specific residues in the 13 loop 
appear to confer the selective characteristic epitope that can discriminate which class of 
G-protein binds to which receptor. Structural elements of the G-protein provide a 
surface that allows both specific interaction and anchoring points that enables the 
receptor in the activated state to relay an agonist induced signal into an activated G- 
protein.
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Figure  1.9 Calcium  Ion Release via the A ctivation o f M uscarin ic  
R eceptors
Matur* Reviews | NaurMCanc*
The figure shows some of the signalling pathways initiated by the activation of 
muscarinic receptors. The receptor depicted in the figure is the M3 sub-type, but the 
pathway for Mi and M5 sub-types is analogous. Upon activation the release of the G- 
protein sub-units stimulates phospholipase C that in turn catalyses the breakdown of 
P I P 2  into I P 3  and diacylglycerol (DAG). I P 3  stimulates the release of calcium ions from 
the intracellular store in the endoplasmic reticulum and influx through the cell 
membrane. Im age taken  f r o m  N a tu re  r e v ie w s  n eu ro sc ien ce  v o l 2  p  3 8 7 -3 9 6  (Clapham, 
2001)
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1.10. R ecep to r G -protein  In teractions
N-termiaus (a)
^  ~  ^ ^  tC -term i n us 
- Blade<1+2
C-terminus
a4-(36 loop
a) G-protein recognition sites on the Mi mAChR viewed from the cytoplasmic surface. 
Residues with a positive charge on the 13 loop are shown in magenta and correspond to 
residues involved in G-protein coupling. Potential G-protein contact residues are 
highlighted in yellow. The completely conserved Arg at 3.50 (R123 in Mi) is idicated in 
red. Arrows indicate the relative outward movement of helices 6, 7 and 8 upon receptor 
activation, b) A theoretical model of the rhodopsin-transducin(G-protein) complex. 
Contact with the recptor is believed to be through the N and C-terminus of the Ga sub- 
unit.(shown in grey) between the a4-p6 loop. The Gy (blue) and Gp (yellow) sub-units 
of the transducin trimeric complex are also shown. Figure courtesy of Lu et al. (Lu et 
al., 2002).
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1.7. The Mi mAChR Transmembrane Binding Site
In rhodopsin, the ligand 11-cis-retinal, which acts as an inverse agonist, is covalently 
immobilised in the binding pocket. Photoisomeration of this molecule to the trans-form 
activates the receptor. By contrast, it is the binding of an exogenous ligand to a binding 
pocket which activates or inhibits the other receptors in the same class. The natural 
agonist for muscarinic receptors is acetylcholine. ACh is a ubiquitous neurotransmitter 
molecule, secreted from nerve terminals in the CNS and parasympathetic post­
ganglionic neurons. Affinity labelling and alanine scanning mutagenesis studies {Lu, 
2001; Hulme. E.C, 2003 #183; Kurtenbach, 1990) have revealed the binding site for N- 
methylscopolamine (NMS) and ACh. The binding pocket is located approximately one 
third of the way down the transmembrane helical domains. The most important 
residues, whose mutation gave greater than 30-fold reduction in ACh affinity in the 
ground state of the receptor, have been shown to be:- Asp 105, Tyr 106, Tyr 381, Tyr 
404 and Tyr 408 of TM’s 3, 6  & 7 respectively (see figure 1.11a).
Many of the amino acids participating in the binding site for the synthetic muscarinic
antagonist N-methylscopolamine (NMS) have been established. The important side
chains for NMS binding were revealed to be those of; Asp 105, Tyr 106, Tyr 381, Asn
382, Tyr 404 and Tyr 408 (See figure 1.11 b). The polar head group of the NMS
molecule is believed to fit into a charge-stabilised aromatic cage. Mutagenesis studies
suggest that the positively charged head group of ACh binds in a similar manner to that
of NMS but that the side chain of ACh does not extend as deeply into the TM region. In
fact alanine substitution of Val 113 and Phe 374, located further down the TM helices,
reduced the binding affinity of NMS more than 10-fold, not only did not reduced but
actually increased the binding affinity of ACh (Hulme E.C, 2003). Residues
homologous to those involved in ACh and NMS binding are found in other cationic
amine receptor family members (Shi and Javitch, 2002) supporting the view that
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particular sequence positions are critical for ligand binding and consequent receptor 
activation. There may be other aspects of ligand binding that must also be considered. 
Some residues may form part of an entrance channel into the binding pocket. In this 
study Asp 99 is hypothesised to be just such a residue. Residues of the 2nd extracellular 
loop of mAChRs may also be involved in ligand contact, by analogy with residues of 
the rhodopsin E2 loop.
Work in this laboratory has so far concentrated on the TM domains of the Mi mAChR. 
However the X-ray crystallographic structure of rhodopsin reveals that the extracellular 
domains are folded into a compact structure. A key element of this is the 2nd 
extracellular loop (E2 loop) which folds into a P-hairpin and penetrates into the binding 
pocket, located in the TM domains, where it is stabilised by the conserved disulphide 
bond. The analogy commonly used is that the E2 loop caps the binding pocket, acting as 
a lid to hold in the bound ligand. In rhodopsin residues of the E2 loop form part of the 
retinal binding site. The question is:- are the homologous residues in the muscarinic 
receptors also functioning as part of the binding site?
Residues involved in the binding of NMS are in very similar positions in the TM 
regions of the Mi mAChR as the residues of rhodopsin, which bind 11-cis-retinal. 
However this may not be true for all muscarinic ligands. Despite the similarity of their 
pharmacological actions different ligands may have different modes of binding. For 
example the antagonist 3-quinuclidnyl-benzilate (QNB) has a chemical structure 
analogous to NMS (see figure 2.1), but the binding affinity of QNB is not affected by 
replacement of Tyr 381 with alanine (Ward et al., 1999a). In contrast the replacement of 
this residue greatly reduces the affinity of NMS for Mi receptors.
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F igure  1.11. IVL M uscarinic  R ecep tor M odel Showing P red icted  
L igand B inding Sites fo r A cetylcholine & N -M ethvlscopolam ine
Y 4 0 4
Y408
Alanine scanning mutagenesis (ASM) studies have suggested many of the residues in 
the transmembrane domain involved in the binding of acetylcholine a) and N- 
Methylscopolamine b) Residues involved in the binding of the two molecules show 
some overlap. The positively charged head groups of both ACh and NMS are stabilised 
in an aromatic cage within the binding pocket. ACh has a shorter side chain which 
appears not to extend as deeply into the binding pocket as does the bulkier side chain of 
NMS. The phenyl ring of NMS is predicted to lie close to Asn 110, Val 113 and Phe 
374 as the substitution of these residues in ASM studies reduced the affinity of the 
receptor for NMS by approximately 10-fold (Hulme et al., 2003; Lu and Hulme, 1999; 
Lu et al., 2001)
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1.8. The Second Extracellular Loop
One of the most striking features of the second extracellular loop (E2 loop) modelled on 
the structure of rhodopsin is that it dives down into the transmembrane domains forming 
two beta strands (03 & 04). The sequence alignment for the E2 loop in both rhodopsin 
and the five mAChR sub-types are illustrated in table 1.3 and shows the position of the 
p3 & 0 4  strands in relation to the rest of the loop. In bovine rhodopsin one of these 
strands contacts retinal (Palczewski et al., 2000). It may be the case that the E2 loop is 
involved in agonist and/or antagonist recognition in small molecule aminergic receptors 
such as those of the muscarinic class. Evidence for a direct role for the E2 loop of 
mAChRs in ligand binding and receptor activation is sketchy. There is however 
evidence that the E2 loop of the dopamine D2 receptor (another small molecule 
aminergic receptor) does indeed line the binding site crevice and plays a role in ligand 
binding specificity (Shi and Javitch, 2004). Whereas the residues involved in ligand 
binding in the TM domains of rhodopsin-like GPCRs are relatively well conserved, the 
extracellular loops exhibit greater variation. This leads to the hypothesis that the E2 
loop in particular may offer a greater variety of ligand contacts, thus providing innate 
ligand specificity for receptor subtypes.
Further evidence for the involvement of the E2 extracellular loop in ligand contact has 
been provided by Wurch and colleagues (Wurch et al., 1998) using chimeric human 5- 
hydroxytryptamine receptors ( 5 - H T id  &  5 - H T - ib ) . Interchanging the E2  loops of one 
subtype with another exchanged the specificity for ketanserin (a 5-HT selective 
antagonist), implicating the E2 loop in the binding of ketaserin. In a very similar study, 
three adjacent residues, G196, V I97 and T198 of the 2nd EC loop in Pi-Adrenergic 
Receptors were determined to significantly change antagonist binding profiles (Zhao et 
al., 1996). These authors hypothesise that large antagonists bind to the surface of the p
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i-adrenergic Receptor via the E2 loop and extracellular TM 5 residues, in contrast to
smaller agonist molecules that bind within the TM binding pocket.
Leppik et al. have explored the possibility that larger allosteric antagonist molecules, 
such as gallamine, bind to the surface of mAChRs via the extracellular loops (Leppik et 
al., 1994). Gallamine allosterically modulates the binding of classical muscarinic 
ligands, showing selective binding with greater affinity at M2 mAChRs than at Mi. 
Substituting the acidic EDGE sequence in the E2 loop of the M2 subtype with the 
homologous uncharged LAGQ sequence of the Mi subtype led to an 8 -fold reduction in 
affinity for gallamine. Inserting the EDGE sequence into the Mi subtype gave an 
increase in gallamine affinity. This implicates the E2 loop, specifically the acidic 
residues, in the binding of the allosteric antagonist gallamine to the M2 mAChR.
Only one study has been performed that looked extensively at the 2nd extracellular loop 
of the Mi mAChR subtype. Matsui et al conducted agonist (ACh) and antagonist (NMS) 
affinity binding studies on alanine substitution mutants of eight residues in the E2 loop 
of the Mi mAChR. These were: - Trp 164, Gin 165, Gly 169, Arg 171, Thr 172, Gin 
181, Phel82 and Ser 184. The charged and polar aromatic residues, which are 
conserved in the different sub-types, formed part of a larger set that were potential 
candidates for the binding of allosteric ligands. NB from this point on when talking 
about residues or mutations used in this study the single lettetr amino acid code will be 
used for the sake of simplicity.
Overall these mutations had little effect on the expression of the receptor or on the 
affinity of agonist or antagonist binding. A small decrease in affinity was observed for 
acetylcholine for the W164A mutant, while Q181A showed a small increase in affinity 
for acetylcholine. Similarly, the binding of gallamine was largely unaffected to either
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occupied (with ligand) or unoccupied mutated receptors. In contrast, mutations W91A 
and W101 in the El loop and W400A and Y404A of the E3 loop had a much greater 
impact on the affinities of both acetylcholine and N-methylscopolamine and also on the 
allosteric kinetics involved in gallamine binding (Matsui et al., 1995).
The E2 loop of the Mi mAChR contains 22 amino acids and 12 of the 22 residues are 
conserved throughout the muscarinic family of receptors. There are two residues fewer 
in the E2 loop of rhodopsin at the position of El 70 and R171 in the Mi mAChR. Based 
on the rhodopsin homology model there may also exist a (33 and (34 strand formed by 
residues N-terminal and C-terminal to the conserved cysteine at position 178 (see table 
1.3). As in nearly all GPCRs there is a disulphide bond anchoring the E2 loop to the TM 
helices. In the case of the Mi receptor this S-S bond is formed between C98 at the top of 
Helix 3 and C l78 in the E2 loop. The precise nature of the E2 loop structure in the 
mAChRs is still in doubt and investigations of its role in ligand binding and function is 
the purpose of this study and as such is discussed in much more detail in the 
introduction, discussion and conclusion sections of the results chapters presented below. 
A homology model of the E2 loop showing the relative positions of the residues to be 
analysed in this study is shown below in figure 1 . 1 2
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Figure  1.12 E2 Loop Residues of the Mi m A C hR
The figure highlights the residues of the E2 loop of the Mi mAChR mutated to alanine 
in the present study. Acetylcholine is placed in a position approximating its true 
location in the ligand binding pocket. The E2 loop residues were positioned based on 
the rhodopsin homology model and then energy minimised to allow for the different 
properties of the individual amino acids. The figure serves to illustrate the potential for 
ligand contact residues being present in the E2 loop. However, this model may require 
refinement subsequent to the experimental data presented below.
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T able 1.3. Sequence A lignm ent fo r the E2 Loop in R hodopsin and 
M uscarin ic  Acetylcholine R eceptors
The table shows the sequence alignment of the five muscarinic sub-types compared to 
the E2 loop sequence from bovine rhodopsin, stretching between two highly conserved 
proline residues (green) at the tops of TM4 and TM5, from which the muscarinic 
homology models are derived. Highlighted with blue arrows are the residues that form 
the (33 and (34 strands. Residues highlighted in red indicate residues mutated to alanine 
in this study. The highly conserved cysteine residue that forms the disulphide bond is 
shown in yellow. Compared to rhodopsin the muscarinic receptors have extra two 
residues in the E2 loop, in Mi they are Glu and Arg, in M2 Val and Arg and in M3 , M4 
& M5 Lys and Arg. These extra residues form a distinctive bulge in the E2 loop that is 
not present in the rhodopsin loop.
P3 strand p4 strand
Bovine
Rhodopsin
|PLVGWSRYI PE--GMQCSC GIDYYTPHEETNNES FVIYMFWHFI
H&H
M,_RAT |AILFWQYLV GERTVLAGQC YIQFLSQ-----PII TFGTAMAAFY LjVTVMCT
m 2_r a t |AILFWQFIV- GVRTVEDGEC YIQFFSN---- AAV TFGTAIAAFY L|VIIMTV
m 3_r a t |AILFWQYFV GKRTVPPGEC FIQFLSE-----PTI TFGTAIAAFY MjVTIMTI
m 4_r a t |AILFWQFW GKRTVPDNQC FIQFLSN---- PAV TFGTAIAAFY L|WIMTV
m 5_r a t Ja i l c w q y l v GKRTVPPDEC QIQFLSE-----PTI TFGTAIAAFY I|VSVMTI
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1.9 Project Aims-
Overall, the role of the 2nd extracellular loop of the Mi mAChR is still to be 
conclusively determined. Studies on other small molecule aminergic receptors seem to 
suggest that the E2 loop does indeed function to add selectivity and provide contact 
residues for the binding of ligands. This study will attempt to provide further evidence 
to ascertain the function of the 2 nd extracellular loop of the Mi muscarinic receptor and 
by association the other 5 subtypes, by attempting to answer the following questions
1). Are there any residues in the E2 loop that are critical to, or involved in, the binding 
of various agonists, antagonists or allosteric modulators, either internally or exofacially 
to the receptor?
2). Does the E2 loop function as a ‘cap’ over the ligand binding pocket, by making 
contacts with the bound ligand?
3). Do the cysteine residues that form the disulphide link between the El and the E2 
loop contribute in any way to the binding of ligands?
4). Are there any residues of the E2 loop that are important in the activation of the 
receptor or maintaining the receptor in the deactivated state?
5). What residues, if any, might be involved in the binding of truly Mi selective 
ligands?
6 ). Can we refine the Mi mAChR model of the E2 loop based on the results produced in 
this study?
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The main approach to understanding the role of the E2 loop in Mi mAChRs in this 
study, is to use the technique of alanine scanning mutagenesis, effectively replacing 
individual residues of the E2 loop with alanine and observing the affect of the mutations 
on receptor expression, ligand binding, ligand dissociation and receptor activation. As 
with all mutagenesis studies the effect of a mutation on binding a ligand is open to 
interpretation. Does the mutation affect the binding of the ligand directly, or is the 
difference in affinity observed due to an indirect conformational change? Therefore the 
experimentalist must draw on a range of information and structural insights when 
interpreting the results. For instance, a large (> 100-fold) reduction in the affinity of an 
antagonist molecule may be compatible with a direct (first shell) interaction of the 
mutant side chain with the ligand molecule. A smaller effect may indicate a 
conformational perturbation (second shell effect). Nevertheless, without a definitive 
structure of the Mi receptor, alanine scanning mutagenesis provides the best method to 
understand the structural characteristics of the E2 loop and its function in the wild type 
receptor.
In addition to the selected E2 loop amino acids, mutations of three other non-E2 loop 
mutations will be analysed. They are: - D99A, a residue believed to be important for the 
channelling of ligands into the binding pocket and F197A and W378A believed to be 
important for the binding of NMS. These last two residues are located at the base of the 
binding pocket but their significance for antagonist and agonist binding needs to be 
confirmed. In our study I hope to clarify how all of these residues function in the 
structure and activation of the Mi mAChR. In the previous study by Matsui et al 
(Matsui et al., 1995) a complimentary group of residues of the E2 loop were mutated to 
alanine and general ligand binding characteristics were assessed. However no functional 
data was collected in that study. To redress this omission PI assays were performed on 
seven of the Matsui E2 loop mutants in this study to provide a more comprehensive
77
Chapter 1.
analysis of the role of E2 loop residues in receptor function. In the bigger picture this 
research aims to provide information that may be useful in the design of Mi selective 
ligands that in the future may alleviate certain diseases associated with the muscarinic 
cholinergic system, such as Alzheimers, epilepsy, chronic pain and smooth muscle 
disorders.
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Materials And Methods
2.1 Materials
The pCD expression vector containing the entire coding sequence for the rat Mi 
mAChR was originally a gift from Dr. NJ. Buckley (Bonner et al. 1987), formerly of 
NIMR. The construct was further modified in this laboratory by the insertion of unique 
restriction sites and is now denoted pCDE The QuikChange™ double-stranded site- 
directed mutagenesis kit was supplied by Stratagene. The Big Dye™ Terminator v l.l 
Cycle sequencing kit was purchased from Applied Biosystems and Long Ranger gel 
solution was supplied by Flowgen. Pellet Paint™ co-precipitant was provided by 
Novagen. Plasmid mini and maxi preps were supplied by Qiagen, as were gel extraction 
and min elute gel extraction kits. Restriction endonucleases Nhe I  & Sac I  were
T W
provided by Roche. The Fast-Link ligation kit was supplied by Epicentre
n r w
Technologies. SEA KEM Gold agarose gel was supplied by FMC Bioproducts. 
Bacterial growth media were supplied by media dept at NIMR. All other chemicals used 
were supplied by Sigma Aldrich, unless otherwise stated.
COS-7 cells (African green monkey kidney cells) came from The European Collection 
of Cell Cultures (E.C.A.C.C.). Tissue culture reagents were from GIBCO BRL 
Laboratories. Atropine, [3H]-(-)-N-methyl scopolamine 84 Ci.mmof1 and (-)- 
Quinuclidinyl-[phenyl-3H]-Benzilate 48 Ci.mmof1 were from Amersham Biosciences. 
National Diagnostics supplied liquid scintillation solution. All other reagents were 
purchased either from Sigma Aldrich or Promega. AC-42 was a gift from Accadia 
Pharmaceuticals inc. Oligonucleotides were manufactured and supplied by Sigma 
Genosys.
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Figure 2.1 Structures of Compounds Used for Radioligand Binding 
Studies
fl +/ CH3
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2.2 PCDE Expression Vector
The entire coding sequence of the rat Mi mAChR is contained within the pCDE 
construct (figure 2.2). The coding sequence is under the control of a Simian virus (SV) 
40 promoter and polyadenylation sequence, which allows high copy number of 
replication of the plasmid in COS-7 cells that express the SV40 large T-antigen. The 
plasmid also carries a pBR322 origin and ampicillin resistance genes as a selective 
marker and to allow propagation in a culture of E. coli cells. The mutations of the E2 
loop, TM3 and TM5 used in this study lie between Sac I and Nhe I unique restriction 
sites, a relative distance of 950bp.
2.3 Site Directed Mutagenesis
The mutations of the E2 loop and the single mutations in TM3, 5 & 6  were introduced 
into the pCDE vector using the QuikChange™ mutagenesis Kit. Simply, two 
oligonucleotides, one forward, one reverse, containing the desired codon change for 
each individual mutation (see table 2 .1 ) were annealed to the denatured double stranded 
wild type rMi sequence of the plasmid at 55°C, then extended using Pfu Turbo DNA 
polymerase. The syntheses of mutant strands were performed using the cycling 
conditions shown below.
Process No. Cycles Temp°C Time
Initial Denaturing 1 95 30 secs
Denaturing 1 2 95 30secs
Primer Annealing 1 2 55 1 min
Extension 1 2 6 8 4.48mins
This creates mutated complimentary strands containing staggered nicks. After 
temperature cycling the complimentary strands were digested with 1 pL Dpn I 
endonuclease for 1 hour at 37°C, which selectively digests parental, methylated DNA, 
enriching the mutated complimentary DNA strands ready for transformation of 
competent E. coli which is described below.
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2.4 Preparation of Competent E. coli
Competent DH5a cells were prepared by a modified version of the Hanahan method 
(Hanahan, 1983). DH5a stock was streaked onto a L-agar plate and grown overnight at 
37°C. A single colony was selected and used to inoculate lOOmL of L-Broth and grown 
to an O.D. of 0.25. The culture was cooled and spun at 4,000rpm, 4°C for 10 min. The 
pellet was gently re-suspended in 40mL of transformation buffer (30mM KOAc, 
lOOmM RbCl, lOmM CaCk, 15% (v/v) glycerol), pH 5.8 (acetic acid), filter sterilised) 
and cooled on ice for lOmin. The suspension was re-centrifuged 4,000rpm for 10 min 
and the pellet re-suspended in 2mL ice cold transformation buffer II (lOmM MOPS, 
75mM CaCh, lOmM RbCl, 15% (v/v) glycerol, pH 6.5 (KOH),filter sterilised). 100pL 
aliquots in Eppendorf tubes were snap frozen on dry ice and stored at -80°C.
2.5 Transformation of Competent Cells
lpL of DNA from the ligation procedure was added to 50pL of competent E. coli 
DH5a cells (thawed on ice), incubated on ice for 30 min, and then heat shocked at 42°C 
for exactly 45 seconds in Falcon tubes. Then, 500pL of SOC medium (SOB medium 
containing 1% 2.2M glucose) was added to the cells, which were then incubated at 37°C 
for 1 hour to allow expression of the ampicillin resistance gene. The culture was then 
plated out on 50pg/mL ampicillin agar plates and grown overnight at 37°C. Single 
colonies were picked for sequence analysis between the Sac I and Nhe I restriction sites 
to check for the desired mutation and any errors that may have been incorporated into 
the DNA.
2.6 Preparation of Plasmid DNA
Mini and Maxi scale preparations of the mutant plasmids were performed using the 
Qiagen Mini and Maxi prep kits. Both kits work using the same principles, only the 
scale differs. E. coli transformed with the mutant plasmids were cultured overnight at
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37°C in L-Broth supplemented with 50pg/mL ampicillin. The following day the cells 
were pelleted and lysed in 0.1 M NaOH, 1% sodium dodecyl sulphate (SDS) in the 
presence of RNAase. RNA was digested and plasmid & chromosomal DNA denatured. 
Neutralization was performed by addition of KOAc, precipitating chromosomal DNA 
and cell debris and SDS. Then, ~800pL of sample was loaded onto anion-exchange 
columns to bind the plasmid DNA in low salt buffer. Chromosomal DNA and cell 
debris was cleared from the column with a medium salt wash. The plasmid was then 
washed from the column with a high salt buffer. A sample of the recovered plasmid was 
run on a 1% agarose gel to check size and efficiency of recovery. For maxi-prepped 
plasmids purity and concentration were checked spectrophotometrically at 
260nm/280nm. A ratio value of 1.8 confirmed that the plasmid was uncontaminated 
with protein.
2.7 Sub-cloning of Mutant DNA
To circumvent the need to sequence the entire plasmid containing the mutation it was 
preferable to excise the region containing the insert and re-ligate it back into a 
correspondingly cut wild type vector. A 950 base pair region containing the mutated 
sequence was cleaved from the mutated plasmid DNA using the restriction 
endonucleases Sac I and Nhe I. The cleaved fragment was purified and identified on a 
1% Agarose gel. The gel slice was extracted and the insert recovered and purified using 
the Qiagen Min Elute™ kit. The gel was dissolved in guanidine thiocyanate (buffer 
QG) at 55°C to release the insert. The solution was loaded onto an anion exchange 
column binding the insert. Then a series of washes removed any trace of agarose and 
finally the insert was eluted in a high salt buffer. The Sac I -  Nhe I region of a wild type 
plasmid was excised using the same restriction endonucleases and then the vector was 
gel purified and recovered using the Qiagen Gel Extraction Kit in a method analogous 
to the recovery of the insert DNA. Then, ~1 pg of the mutated insert DNA was ligated to 
~0.5pg of the cut vector using the Epicentre Fast-Link Ligation kit. The ligation
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reaction was performed at room temperature for 2 hours using T4 DNA ligase and 
lOmM ATP. Competent DH5a cells were then transformed with lpL of the ligation 
reaction mix.
2.8 Sequencing of Mutants
Plasmids from resulting clones containing the desired mutation were identified using the 
Sanger dideoxy nucleotide sequencing method (Sanger et al., 1977) using Big DyeTM 
Terminators v l.l. Sample for sequencing were prepared as shown in the table below.
Step Action
Reagent Qunatity
1
Terminator ready reaction 
mix
8pL
Template DNA 200-500ng (lpL)
* Sequencing Primers 9.6pmol (lpL)
ddH20 lOpL
2 Mix well and spin
3 Place in Therrmal Cycler
* Sequencing primers
Forward 5 ’-G G C C T C C T G T C T C T A G C T A C A G -3’ (T m 6 3 .2 °C )  
Reverse 5 ’-C C C C T G G C T G T G A C C T C T C T C T G A G C -3’(T m 7 5 .1 °C )
Once prepared, samples were transferred to a MWG Biotech Primus 96+ thermal cycler 
and run as follows. Samples were run for 25 cycles:- 1) rapid thermal ramp to 96°C; 2) 
96°C for 10 secs; 3) Rapid thermal ramp to 50°C; 4) 50°C for 5 secs; 5) rapid thermal 
ramp to 60°C; 6) 60°C for 4 minutes. Samples were then spun briefly. Then 2pL of 2M 
NaAc and 50mL of 96% ethanol were added to each sequencing reaction and incubated 
on ice for 20-30 minutes to precipitate DNA. Samples were then spun at high speed 
(14,000 rpm) for 15-30 minutes to pellet DNA. Supematent was then aspirated and the 
pellet was washed with 70% ethanol and re-spun for 15-30 minutes and washed again 
and allowed to dry for ~30mins befor addition of 4mL of loading buffer (5:1 ration of 
formamide and 25mM EDTA (pH8.0) blue dextran). Samples were loaded onto and run 
on a 6 % polyacrylamide gel using the automated ABI 377 DNA sequencing system. 
Resultant sequences were analysed using DNA Star software, to confirm the presence of
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the correct mutated codon and to verify that no aberrant mutations had occurred. Below 
is an example of sequencing data for the 1180A mutant. Highlighted in yellow is the 
region of mutation. The WT rMi sequence (2nd row) shows the 1180 codon as ATC and 
the mutant sequences below are 1180 A showing the change of codon to GCC.
3660I . . 3670. , l ■ ■ 3 680■ . I , . 3 690. i i i , 3700■ i l . . 3710i i i i i i i I 372_1_ L±
T r a n s l a t e  r C o n s e n s u s TGGCAATAC C TAGTTGGGGAGC GGACAGTGC TGGC TGGGCAGTGC TAC GCC CAGTTC C TC T
rm l_pcde DNA sequence.SEQ(1>4812)' 
33% a5 ll8 0 A -3 -P F l.b in (1>669)
2 9 %a5118 0 A -2 -P F l.b in (l> 677)
25%a5I180A -l-PF l.b in(48>599)
TGGCAATAC C TAGTTGGGGAGC GGACAGTGCTGGC TGGGCAGTGC TAC ATC CAGTTC C TC T
TGGCAATACCTAGTTGGGGAGCGGACAGTGCTGGCTGGGCAGTGCTACGCCCAGTTCCTCT
A
TGGCAATAC C TAGTTGGGGAGC GGACAGTGC TGGC TGGGCAGTGC TAC GC C 0 AGTTC C TC T
TGGCAATAC C TAGTTGGGGAGC GGACAGTGCTGGC TGGGCAGTGCTACGCC CAGTTC C TC T
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Figure 2.2 The pCDE Expression V ector C ontaining the r a t  IVF 
m A C hR  G ene
Amp
pBR322
ori
early
_ , Hind I I I
sa i i , SV40ori «
Xho I &
B am H I , y v  p st I
pCDE rMi 
Vector Rml mAChR 
Insert
Nhe I
Xho I and Bam H I
Poly A
The diagram depicts the pCDE plasmid containing the entire coding sequence for the 
rMj mAChR. Two unique restriction sites S a c  I and N he I in the coding region allow 
cloning procedures without disturbing the expression and consequent function of the 
translated protein. The ampicillin resistance gene facilitates selection and replication 
within E .c o li cells. A high level of expression of the Mi mAChR in COS-7 cells is 
driven by the SV40 promoter through interaction with the large T-antigen present in the 
cell line.
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T able 2.1 M u tan t O ligonucleotides used fo r Q uikC hange Site D irected 
M utagenesis P rocedure
Each mutant was constructed using the oligonucleotides shown opposite within the 
parameters of the QuikChange™ protocol. For the protocol, oligonucleotides were 
required to be between 25 -  45 bases long, have a melting temperature of >75°C and 
generally a G-C content of 40%. All primers/oligonucleotides were required to start and 
end with a G or a C. The changed bases in each primer are shown in red and in all cases 
denote the codon for alanine.
M u tan t O lignucleotide
C98A
For-5 ’-GGGCACACTGGCCGCCGACCTCTGGCTGGCCCTG-3 ’ 
Rev-5 ’-GCC AAGGTCGGCGGCCAGTGTGCCC-3 ’
D99A For-5 ’-GGGCACACTGGCCTGTGCCCTCTGGCTGGCCCTG-3 ’ 
Rev-5 ’-CAGGGCCAGCCAGAGAGGGCACAGGCCAGTGTGCCC-3 ’
E170A
F or-5 ’ -GGC A AT ACCT AGTT GGGGCGCGG AC AGT GCT GGCTGGG-3 ’ 
Rev-5 ’-CCCAGCCAGCACTGTCCGCGCCCCAACTAGGTATTG-3 ’
R171A
For-5 ’-GGCA AT ACCT AGTTGGGGAGGCG ACAGTGCTGGCTGGG-3 ’ 
Rev-5 ’ -CCC AGCC AGC ACT GT CGCCGCCCC AACT AGGT ATT G-3 ’
Q177A
For-5 ’-CGG AC AGTGCTGGCTGGGGGCGTGCTACATCCAGTTCCTCTCC-3 ’ 
Rev-5 ’ ’ -GG AG AGG AACTGG ATGTAGC ACGCCCCAGCC AGC ACTGTCCGC-3 ’
C178A
For-5’-CGGACAGTGCTGGCTGGGGCAGGCCTACATCCAGTTCCTCTCC-3’ 
Rev-5 ’’-GGAGAGGAACTGGATGTAGGCGTCCCCAGCCAGCACTGTCCGC-3 ’
C178N
5’- GCTGGGGC AG A ACT AC AT CC AGTT CCT CT CC-3 ’ 
5’-GGAACTGGATGTAGTTCTGCCCAGCCAGC-3’
C98A/C178A
C98A Mutant vector was mutated again using the Cl 78A Oligo
Y179A
For-5 ’ -GCTGGCTGGGC AGTGCGCC ATCC AGTTCCTCTTCC-3 ’ 
Rev-5’-GGAGAGGAACTGGATGGCGCACTGCCCAGCCAGC-3’
I180A
For-5 ’-GGCTGGGCAGTGCTACGCCCAGTTCCTCTCCCAACCC-3 ’ 
Rev-5 ’ -GGGTT GGG AG AGG A ACTGGGCGT AGC ACT GCCC AGCC-3 ’
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F182A
For-5 ’-GGGCAGTGCTACATCCAGGCCCTCTCCCAACCC-3 ’ 
Rev-5 ’ -GGGTT GGG AG AGGGCCT GG AT GT AGC ACTGCCC-3 ’
F197A
F or-5 ’ -GGC AC AGCC AT GGCCGCCGCCT ACCTCCCTGTC ACGG-3 ’ 
Rev-5 ’-CCGTGACAGGGAGGTAGGCGGCGGCCATGGCTGTGCC-3 ’
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2.9 Electroporation of COS-7 Cells
COS-7 cells were grown in 30 mL of MEM alpha media supplemented with 10% heat 
inactivated New Bom Calf Serum and 1% Glutamate in 175cm2 culture flasks at 37°C 
in 5% CO2 until confluent. Cells were washed twice in Phosphate Buffered Saline 
(PBS) buffer then dislodged from the flask using a 5 min treatment with 3.5mL trypsin 
versene and then transferred in 5mL supplemented media (as above) to a 50mL coming 
tube and the volume was made up to 50mL. For each mutant transfection 1.5 flasks of 
cells were pooled, i.e. for the transfection of 4 mutant plasmids 6 flasks of COS-7 cells 
were pooled. Once collected, cells were spun at 3,000rpm for 3 min at 4°C to pellet. 
Cells were re-suspended in 50mL serum free media (ice cold, no supplements) then re­
spun as previously. Cells were then re-suspended in 0.8mL of ice-cold serum free media 
and added to a cold cuvette containing 15pg mutant DNA plasmid. The cells (approx 3 
x 107 per cuvette) were then electroporated using a BioRad Gene Pulser at the optimised 
setting of 260 volts, 960 microfarads and left to recover for at least 5 min. The cells 
were then re-suspended in 30mL warm supplemented media and plated onto 10cm 
diameter culture dishes. Cells were incubated at 37°C for 72 hours in 5% CO2 in a 
humidified incubator.
2.10 Preparation of COS-7 Cell Membranes
After incubation, transfected COS-7 cells were washed twice in PBS. lmL of harvesting 
buffer (20mM HEPES, lOmM EDTA, pH 7.5) was added to each dish and incubated at 
5°C for >15min. Cells were then scraped off the surface of the dish using a Teflon 
scraper and transferred to a glass or a mechanical homogeniser. After approx 20 strokes 
or 15 secs in the homogeniser cell membranes were transferred to 50mL polypropylene 
centrifuge bottles and spun at 17,000rpm in a Beckman J-17 rotor to pellet membranes. 
Membranes were then re-suspended in storage buffer (20mM HEPES, ImM EDTA, pH 
7.5) and further homogenised using a Polytron PT3100 at setting 10-12 for 30 secs.
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lmL aliquots were taken then snap frozen on dry ice and stored at -75°C. The protein 
concentration of each sample was determine by the BCA method (Smith et al., 1985) 
using 25pL of sample in a 96-well plate format
2.11 N-Methylscopolamine and Quinuclidinyl Benzilate Saturation 
Binding Assays
For binding assays membranes were prepared as follows. A lmL aliquot of a membrane 
preparation was spun at 14,000rpm in an Eppendorf 5415C centrifuge for 10-15 mins. 
Pelleted membranes were re-suspended in 50mL binding buffer (0.1M NaCl, 20mM 
NaHEPES, ImM MgCb pH 7.5) to a final concentration of total protein of 10-30pg / 
mL. The membranes were homogenised at Polytron PT3 100 setting 10-12 for 30 secs. 
For 3H-NMS saturation binding assays 8 concentrations of 3H-NMS were prepared in 
binding buffer, to give final assay concentrations (FAC) from 1 x 10‘nM -  3 x 10'9M. 
For 3H-QNB saturation binding assays 8 concentrations of 3H-QNB were prepared in 
binding buffer to give FACs from 1 x 10‘12-3 x 10'10M. lOpL of 3H-NMS or 3H-QNB 
which were pipetted into polystyrene tubes and lmL of membrane preparation added. A 
lpM atropine sample was prepared to determine non-specific binding. After mixing 
assays were incubated at 30°C for 2 hours (3H-NMS) or 4 hours (3H-QNB) in order for 
ligand association with receptors to reach equilibrium. Binding was rapidly terminated 
by vacuum filtration, using a Brandel cell Harvester, on to Whatman GF/B filter mats. 
Mats were pre-treated with 0.1%v/v polyethyleneimine for 30 min before use. 
Filtermats were washed three times with ~4mL ice-cold ddH20. Individual filters were 
punched into 5mL scintillation vials and mixed with 4mL liquid scintillation fluid. The 
vials were left overnight in a dark cupboard to allow the radioactivity to be extracted. 
The following day radioactivity was measured using a Wallac 1490 counter. Samples 
were counted for 5-60 minutes depending on the quality of the data. All H-NMS and 
3H-QNB saturation-binding assays were repeated at least 3 times, unless otherwise 
stated. This method was later developed by using the faster cleaner cheaper Tom-tec
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method. In principle the assay is the same, except that the binding reactions are 
conducted in deep 96-well plates. Membranes are harvested onto a 96-sample filtermat 
which were dried at 50°C for 30min. Instead of using liquid scintillation fluid, a solid 
scintillation product (meltilex) was then melted onto the filtermat containing the 
harvested membranes. Radioactivity was counted on a 1450 Microbeta Trilux counter. 
The counter was pre calibrated by comparison of three binding assays performed on the 
Brandell and the same assays read on the trilux. The difference between the two sets of 
repeated data was used to calculate the efficiency of the Microbeta counter.
2.12 Competition Binding Assays
Membranes were prepared as previously described in preceding paragraph. For 
acetylcholine competition assays a fixed FAC of 3H-NMS of between 3 x 10‘10M and 3 
x 10‘9M was used depending on the measured 3H-NMS affinities of the mutants. A 
series of dilutions of acetylcholine bromide or other agonist was prepared in binding 
buffer from stocks made up in binding buffer or DMSO to yield a FAC of 3 x 10'8M up 
to 3 x 10'1M. Total and non-specific binding (of 3H-NMS) were determined using buffer 
alone and 1 pM atropine respectively. Each acetylcholine or other agonist concentration 
was performed in quadruplicate. Samples were incubated for 2 hours at 30°C or 4 hours 
for 3H-QNB. Assays for each mutant were performed in triplicate unless otherwise 
stated. Procedure for 3H-QNB competition assays performed in the sam way except that 
[3H-QNB] ranged between 3 x 10_11M and 3 x 10‘10M dependant upon particular 
mutant.
2.13 Atropine Rescue of Poorly Expressing Mutants
In order to enhance expression levels of some mutants (e.g. FI97A), which were
expressed at low levels in COS-7 cells an atropine rescue procedure was used (Lu and
Hulme, 1999). Simply, cells were grown for 24 hours in supplemented a-MEM media.
After this the medium was changed to supplemented a-MEM media containing lpM
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atropine. Cells were then further incubated for 48 hours at 37°C. Membranes were 
prepared in the usual way except an extra three washes were done to ensure complete 
removal of excess atropine and binding assays performed as previously described.
2.14 Phosphoinositide Turnover Assays
Transfected cells were grown in 12-well plates at 37°C, 5% CO2 and labelled with 
lpCi/mL myo-D-3H-inositol after 24 hours. The cells were grown for a further 48 hours 
allowing incorporation of the myo-D-3H-inositol into inositol 4,5 bisphosphate (PIP2) 
within the cell. The medium containing the wyo-D-3H-inositol was removed and the 
cells were incubated for 30 min in warm Krebs-bicarbonate solution (120mM NaCl, 
3.1mM KC1, 1.2mM MgSC>4, 2.6mM CaCk, lOmM Glucose and 25mM NaHCOs, pH 
7.4) containing lOmM LiCl (to inhibit inositol phosphatase enzyme), that had been pre­
incubated for -18 hours at 37°C and 5% CO2 to ensure correct pH. The cells were 
incubated in this solution for 30 minutes at 37°C 5%CC>2. After incubation adding a 
series of increasing concentrations of acetylcholine, made up in the Krebs-bicarbonate 
solution, stimulated the cells to activate. The stimulation of PI hydrolysis was 
terminated by removal of the agonist containing medium, the addition of 5% ice-cold 
perchloric acid and incubation at 4°C for 20 minutes. 0.4mL of the lysate was then 
added to O.lmL of lOmM EDTA and 0.5mL of a 1:1 ratio (v/v) of tri-n-octylamine and 
1,1, 2 trichlorotrifluoroethane (freon) solution. The samples were then vortexed and 
centrifuged at 4,000rpm for 10 minutes in a Heraeus Megafuge to separate aqeous phase 
containing phosphoinositides from the non-aqueous phase. Then, 0.3mL of the aqueous 
upper phase was added to columns containing Dowex AG 1 x 8  resin (formate form dry 
mesh size 100-200). The columns were washed with lOmL CIH2O, then 25mM 
NH4COOH, and finally the 3H- inositol phosphates were eluted with 1M NH4COOH, 
0.1M HCOOH. lmL of the eluted sample was collected and lOmL Liquiscint 
scintillation fluid was added. Samples were counted on a Wallac 1409 counter for 
lOmin per sample.
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2.15 Dissociation Kinetics
Assays were performed on COS-7 cell membranes, prepared as described above, in 
deep, 1.2mL 96-well polypropylene plates (Receptor Technologies). 450pL of 
membranes in binding buffer (0.1M NaCl, 20mM NaHEPES, ImM MgCk pH 7.5) 
containing mutant or WT receptors were pre-incubated with lOpL of 2 x 10'9M 3H- 
NMS or 2 x 10'9M 3H-QNB for either 2 or 4 hours respectively in a water bath at 30°C. 
A reverse time course of dissociation was then performed, by addition of 440pL 
dissociation mix (pre-prepared in binding buffer) containing a FAC of 2 x 10'6M
2 c _atropine for dissociation of H-NMS or 10' M unlabelled NMS for dissociation of QNB. 
Samples were returned to a water bath at 30°C until the addition, at the appropriate time 
point, of the next volume of dissociation mix. At the final time point reactions were 
stopped by harvesting the membranes on to a 96-well filter mat, the filtermats were 
dried at 50°C for ~30mins before the addition of meltilex scintillation wax. 
Radioactivity was counted on a 1450 Microbeta Trilux counter.
2.16 Data Analysis
Data produced from binding assays was analysed using SigmaPlot™ for windows 
(Jandel Scientific). Data points were fitted to models using non-linear least square 
fitting using inverse standard error weighting.
2.16.1. Saturation Binding Data Analysis: The one site model of 
binding.
Data produced from 3H-NMS saturation binding assays was fitted to a one-site model of
K .
binding. A + R_<____  AR
k2
Where R = receptor, A = ligand, ki = rate of association constant of the forward 
rection and k2 = the rate constant of dissociation for the reverse reaction where the 
affinity constant is given as
93
Chapter 2
Ka = k\ /  k2 
Kd = k2 /  k\
[AR] = K[A][R];
where K is the affinity constant governing the binding of the ligand to the receptor.
The concentration of free receptor [R] may be calculated from the equation :
[R.] = [R] + [AR]
Where [Rt] = total receptor concentration.
Rearrangement gives:
[Rt]
fRl = 1 + K[A ] 0)
And hence:
[Rt]K[A\
[AR]= 1 + K[A]  <2>
Data fitted to this model generates estimates of the affinity constant, K and 
concentration of the binding sites [Rt]. During fitting, ligand concentrations and affinity 
constants were expressed in the form 10log[A] or 10logK respectively. In saturation binding 
experiments the analysis program used fitted non-specific and specific binding 
simultaneously (described by Hulme and Birdsall 1992). This method also takes into 
account ligand depletion (when a significant proportion of labelled ligand becomes 
bound to the receptor). In these experiments however, ligand depletion was minimal at 
<2%. A figure of <10% ligand depletion is acceptable. Values any greater than this 
might have distorting effects on the fitted data
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2.16.2. Competition Binding Assay Data Analysis.
Competition assay data was fitted using the model for the Hill equation:
US] (Kapp[ A ] f «  
[*(] “  \ H K app[A])”»
R = Receptor, A = Ligand [Rt] = Total receptor concentration,
Kapp = Apparent affinity constant of the competing ligand;
njj = Hill coefficient.
The Hill equation above shows the direct saturation form of the equation. Data was 
actually fitted in sigma plot using the following equation, where f  = the predicted fit in 
dpm for y values and produces an inhibition or competition binding curve.
f  = (bmax-bns)/(1+10(nh<pk+x)))+bns
The Hill coefficient is an indicator of how the ligand binds to the receptor. If the value 
is equal to 1 the competition curve is consistent with the ligands binding to a 
homogenous set of binding sites. If the value is greater than 1, then there maybe positive 
co-operativity of ligand binding. Conversely, if the value is significantly less than 1, 
then negative co-operativity may be occurring or the ligand could be binding to a 
heterogeneous population of receptors. The apparent affinity constant obtained from 
competition binding assays using the Hill equation or one site model were corrected to 
take into account the receptors affinity for the radioligand. This was achieved by using 
the Cheng Prusoff correction factor (Cheng and Prusoff, 1973). Thus:
Log K  = Log K app + Log ( 1 + K n m s [ N M S ] )
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K = Corrected affinity constant of competing lig a n d .(K B iN )
Kapp = measured apparent affinity constant of competing ligand 
K n m s = Affinity constant of [3H]-NMS
[NMS] = Concentration of [3H]NMS radioligand used in the assay. 
Competition assay data was fitted to the Hill equation.
2.16.3. Competition Binding Data -  Two-Site Model of Binding
Where appropriate data was analysed using a two site model of binding as described by 
Hulme & Birdsall 1992. The model generates two fractions of binding site, one having 
high affinity the other having low affinity for the ligand.
/  = (B max-BNS)
(1 + K H [A] 1 + KL [A]
+ BNS
[L*] is the concentration of radioligand and FrH and FrL represent the high and low 
affinity fraction of affinity states with Kh and Kl being their equivalent affinity 
constants. The binding constants were corrected for the Cheng Prusoff shift.
2.16.4. The Four Parameter Logistic Function: Analysis of
Phosphoinositide Turnover Data
Data from phosphoinositide turnover assays was fitted using a four parameter logistic 
function based on the Hill equation. (Wells, 1992) and fitted to the following equation.
(K[A])nH
dpm = (dpm total -  basal) --------------------- H basal
1 + (K[A\)nH
where; dpmtotai = total dpm; basal = basal level of PI hydrolysis; K= apparent 
association constant; nn = Hill coefficient
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2.16.5. Functional Analysis: Efficacy Calculation
An estimate of the efficacy of agonist to induce a signalling response was calculated 
using the following equation.
eA = /  R j 1 when Emax ~1v K-bin C1 _ basal) ,
Alternatively when Emax is significantly less than 1 e.g. for a partial agonist or a 
mutation that reduces maximum signalling the following equation is used to determine 
efficacy.
e A  =
f E max  ^
 ^1 -  E max j
1
R
Where:- eA = Agonist signaling efficacy parameter; Kact = Measured 1 / EC50 value for 
individual mutant or WT sample in each P.I. Assay; Kbm = Previously measured and 
corrected Acetylcholine affinity constant for individual mutant or wild type; Rt = 
estimate of the effective ratio of total receptor concentration to receptor-accessible G- 
protein [Rt]/[RG] and for WT over-expression in COS-7 cellsthis ratio has been 
estimated as 20 i.e. 20 receptors for every G-protein (Lu et al 1997). For mutations, this 
value was scaled in proportion to the level of expression measured by radioligand 
saturation assays
2.16.6 Statistical analysis of data.
Experimental data was treated in two ways. In the first instance ligand binding data and 
functional dose response data for new mutations was compared to well-established 
control values for NMS, QNB and ACh. Quinn and Keogh (2002) recommend that there 
“should be no adjustment for multiple testing if the tests represent clearly-defined and 
separate hypotheses”. Wild-type controls were included in virtually all experiments, and 
gave values not significantly different to previously measured values. Since each new 
mutant essentially represented an independent comparison, it was considered reasonable
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to analyse these results with standard paired t-tests against the matched control values 
using Excel. For each mutant, the means and SEMs are calculated for the whole group 
of measurements. The significance levels are given as P<0.05, or P<0.01. In fact a 1- 
way ANOVA (Excel) followed by Dunnett’s post-hoc test confirmed the significance 
values.
In the second group of experiments, a series of compounds were compared with one 
another using a selected set of previously-characterised mutant receptors including E2 
loop, transmembrane mutants, and the wild-type receptor. The compounds included 
novel and unconventional ligands as well as classical antagonists, agonists and partial 
agonists. In this case the null hypothesis is that the binding of each compound is not 
affected by the set of mutations, so a 1-way ANOVA was performed in each case. 
These were followed up with two-tailed t-tests to give an indication of the significance 
of individual differences to wild-type values. These are given as P<0.05, or P<0.01. 
More data is required in some instances to give a final picture.
2.16.7 Receptor Modelling : Analysis of Mutants
All Mi mAChR models were produced in house and are designated with the file names. 
MlModel042001.pdb, AChmodel.pdb, NMSdock042001.pdb and AChdockll04.pdb. 
Stuctures and models in this thesis were created using pyMOL vers. 0.98 and analysis 
of H-bond formation (Chapter 7) was performed using the modelling programme Web 
Viewer-Lite, with the detection threshold set at 2.2A±0.5 (min) and 2.7A±0.5 (max).
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Figure 2.3. The Extended T ern a ry  Com plex M odel and  P a ram e te rs  
O btained  from  B inding and  Functional S tudies
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ACh potency KAct (=1/EC50)
ACh signalling efficacy K G .aK /(l+  aK ) = (KAct/KBin(l-Basal) -1 )/RT 
Ratio o f functional R to G is ca. 20 for wild-type receptor in COS-7 cells.
The model describes algebraically the parameters that can be obtained from binding 
experiments on wild type and mutant receptors after expression in COS-7 cells. The 
extended ternary complex model describes the various states of the receptor and its 
ligand and G-protein complexes. The model describes how the parameters measured 
after expression of a mutant receptor in COS-7 cells relate to the underlying binding 
constants, and how they may be combined to give a measure of its signalling efficacy.
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Chapter 3.
Radioligand Binding Experiments
3.1. Introduction -
Few studies have examined the role of amino acids in the E2 loop of mAChRs. One of the 
earliest studies by Kurtenbach et al (Kurtenbach et al., 1990), using selective incorporation 
of 3H-N-ethyl maleimide (NEM) to label disulphide bonded cysteines and subsequent 
sequencing of cyanogen bromide cleaved labelled peptides, demonstrated the putative 
disulphide bond that anchors the E2 loop to the top of TM3. The conserved cysteine 
residues C98 and C l78 were identified as the likely cysteine residues that form the 
disulphide bond. In 1992 a mutagenesis study of the 9 cysteine residues of the Mi mAChR 
was performed by Savarese et al (Savarese et al., 1992). Included in the study, the 
disulphide bonded cysteine residues C98 (TM3) and C l78 (E2 loop) were mutated to serine 
and characterised for H-QNB binding and function using the agonist carbachol. These 
workers showed that point mutants of C98 and C l78 to serine lacked 3H-QNB binding and 
failed to mediate carbachol-stimulated phosphoinositides hydrolysis. The authors 
concluded that the disulphide bond formed between C98 and C l78 is critical for formation 
of the ligand binding domain and for correct folding of the receptor
A comprehensive study by Wess et al (Zeng et al., 1999) underlined the importance of the 
homologous cysteine residues C l40 & C220 in the M3 mAChR for proper cell surface 
localisation and 3H-NMS and carbachol binding. Using ELISA and radioligand binding 
techniques expression levels of the cysteine mutants were shown to be reduced 1 0 -2 0 -fold 
and drastic reductions in binding affinities for H-NMS at all three cysteine to alanine 
mutants (C140A ~ 140-fold, C220A ~860-fold, and C140A/C220A -50-fold) and carbachol
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(> 100-fold) binding affinities were recorded. Despite losses in expression and ligand 
binding affinities these authors were surprised to find that two mutants C220 and 
C140/C220 were able to mediate agonist-dependent PI hydrolysis, although with a huge 
decrease in potency (10,000-fold) compared to WT. So, despite improper folding, cysteine 
mutant M3 receptors that were present on the cell surface were able to elicit a functional 
response, albeit at greatly increased agonist concentrations. This report emphasised the 
importance of the conserved disulphide bond thought to be present in nearly all GPCRs. 
Zeng and Wess (Zeng and Wess, 2000) have also proposed the possible formation of 
oligomeric muscarinic receptors via cross linking between conserved cysteines. The 
formation of muscarinic receptor aggregates, they suggest, precedes inter-molecular 
disulphide cross-linking.
Two studies have looked specifically at the LAGQ sequence in the E2 loop (see figure 3.1.)
of the Mi mAChR and the corresponding EDGE sequence in the E2 loop of the M2
mAChR (Gnagey et al., 1999; Leppik et al., 1994) to determine their role in the binding of
the allosteric ligand gallamine. In both studies replacing the EDGE sequence of M2 with the
LAGQ sequence derived from Mi, gave an 8 -fold reduction in gallamine affinity at the
unoccupied receptor and a 4-fold reduction in gallamine affinity at the NMS occupied
receptor for the mutant M2 receptor. In the complementary experiment, gallamine affinity
was significantly increased by replacing the LAGQ sequence of the Mi mAChR with the
M2 EDGE sequence (Gnagey et al., 1999). Reductions in 3H-NMS affinity were also
reported by Leppik et al. for the LAGQ-EDGE Mi mutant (Kd WT = 52pM compared to
Kd mutant = 107pM). These complementary studies highlight the potential for the E2 loop
to bind ligands ectopically and influence the affinity of ligand binding to the orthosteric
binding site by allosteric mechanisms, as well as to reduce the affinity of orthosteric
ligands. Although no conclusions can be drawn about the role of the E2 loop in the
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orthosteric binding pocket these results do suggest that the E2 loop is important for the
binding of some allosteric ligands.
The study on the structure of rhodopsin and in particular the role and the structure of the E2 
loop of rhodopsin, highlighting the proximity of the E2 loop to the orthosteric binding site 
(Li et al., 2004 ; Palczewski et al., 2000) is of particular relevance to the present study. Mi 
mAChR E2 loop residues homologous to residues within rhodopsin that interact with the 
chromophore 11 cis retinal were chosen for mutation to alanine (see table 3.1 and figure 
3.1). The E2 loop of rhodopsin folds back into the membrane embedded domain of the 11 
cis retinal binding pocket and in particular the carboxylic side chain of Glul81 (El70 in 
Mi) points into the centre of the retinal polyene chain (Yan et al., 2002) affecting the 
retinylidene Schiff base in the meta-II rhodopsin state. Other E2 loop residues of rhodopsin 
have also been shown to participate structurally in the retinal binding pocket (Li et al. 
2004). The p3-p4 sheet, a feature of the E2 loop in rhodopsin, forms a “plug” at the top of 
the binding pocket which is secured to main chain atoms of Y10 in p2 of the pl-P2 sheet. 
Additional, water mediated H-bonds via G182, Q184 and Y192 of the p3-p4 sheet further 
secure the loop to the pl-p2 sheet and the transmembrane domain. A key rationale of the 
present study is to determine if the E2 loop of the Mi mAChR has similar structural 
properties to that of rhodopsin. Although Shi and Javitch (Shi and Javitch, 2002; Shi and 
Javitch, 2004), using substituted cysteine accessibility methods (SCAM), worked on the 
dopamine D2 receptor, their work seems to mirror the structural studies on rhodopsin (Li et 
al.2004), suggesting that the region C-terminal to the cysteine S-S bond of the E2 loop lies 
deeper within the transmembrane binding site............................... (continued on page 105)
102
Chapter 3
Figure 3.1 Alanine M utations of Residues in the E2 Loop of the Mi 
mAChR
Goodwin
S-S bond Leppik (1994) Ellis (2000) 
Matsui et al. (1995)
Snake diagram depicting E2 Loop amino acid sequence and secondary structure topology 
of the Mi mAChR, highlighting residues from this and previous E2 loop studies that have 
been mutated to alanine. C98 at the top of TM3 is disulphide bonded to C l78 in the E2 
loop. Also highlighted in yellow in TM3 is the critical ACh contact residue D105 and is 
shown to indicate the approximate depth of the ACh binding site. Residues F197 TM5 and 
W378 TM 6  are also depicted. NB some mutations overlap between the three studies, e.g. 
FI 82 A was analysed by Matsui et al and is also one of the subjects of the present study.
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Table 3.1. Com parison of Rhodopsin and Mi m AChR Binding Site 
Residues
Residues of the Rhodopsin binding site as reported by Jade Li et al (2004) are compared 
with Mi mAChR binding site residues taken from this study and previous work from this 
laboratory (Hulme and Lu, 1998; Kurtenbach et al., 1990; Lu et al., 2001) TM residues 
(yellow) and E2 loop residues (green) were mutated to alanine in this study. ♦Non­
highlighted residues have been studied by alanine substitution in previous studies
R etinal B inding site 
Residues
♦C orresponding 
Residues in 
M i m A C hR
W265 W378
Y268 Y381
T118 Y106
E122 WHO
M207 T192
F212 F197
Al 17 D105
K296 Y408
C187 ■ 1
F261 F374
A269 N382
F208 A193
A292 Y404
Y191 F182
G121 S109
H211 A196
G188 Y179
C167 L156
1189 1180
E181
S186 Q177
A272 V385
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crevice then the N-terminal region. The N-terminal residues of the E2 loop, they suggest, 
are located so as to protrude into the extracellular space. They concluded that it is the 
residues C-terminal to the conserved cysteine residue that are likely to contribute to ligand 
binding. Variations in the length of the E2 loop between different GPCRs probably reflect 
the variation in size of endogenous ligands. A larger ligand requires the E2 loop to be 
longer to accommodate it while a smaller ligand requires the geometrical constraint of a 
shorter E2 loop. The amino acid sequence of the E2 loop shows considerable variation 
across the class of rhodopsin-like GPCRs, however, the sequence C-terminal to the 
conserved cysteine is more highly conserved amongst functionally related receptors. 
Residues 1180, Q181, FI82 and SI84 of the Mi mAChR at this position are completely 
conserved in the corresponding positions in all five of the mAChRs sub-types. In addition, 
the residue C-terminal and adjacent to the C178 residue, is an aromatic amino acid in Mi- 
M4 receptors; only M5 has a charged polar side chain (Glu) at this position.
In another study (Klco et al. 2005), evidence was provided that the E2 loop is essential for
the activation of the complement factor 5a receptor (C5a). The authors demonstrated using
random saturation mutagenesis that the E2 loop of the C5a receptor acted, unexpectedly, as
a negative regulator of C5a activation. Furthermore, the authors found that the E2 loop of
the C5a receptor tolerated amino acid substitutions extremely well; in fact many mutations
resulted in a gain of function phenotype. Interestingly, the conserved cysteine residue Cl 8 8
(homologous to C l78 in the Mi mAChR) only tolerated a single substitution (C188M) in
the 29 receptors they generated by random saturation mutagenesis. These authors proposed
that the E2 loop of the C5a and perhaps other GPCRs stabilizes the inactive ground state of
the receptor, but could not suggest the molecular mechanism involved. There are a range of
studies that focus on the role of the E2 loop in other GPCRs which are reviewed
systematically by Shi and Javitch (Shi and Javitch, 2002). In summary, it appears that the
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role of the E2 loop in ligand entry and binding and in allosteric modulation may differ 
between different GPCRs. For example, the variation in the length and amino acid 
sequence of the E2 loop between different GPCRs is likely to significantly alter the role the 
E2 loop has to play in specific receptor-ligand interactions. In short, more detailed high 
resolution structural analysis and experimentation are required to reveal the role of the E2 
loop for specific GPCRs.
In this study, seven potential ligand contact residues of the second extracellular loop were
identified using the rhodopsin homology model (Palczewski et al., 2000) of mAChRs (see
figure 3.1 and table 3.1). The selected residues of the E2 loop of the Mi mAChR
homologous to the retinal contact residues were chosen for mutation to alanine. They
included the structurally important disulphide bonded cysteine 178. In addition to the seven
E2 loop residues mutated in this study, six other residues of the E2 loop, previously
characterized by Matsui et al (Matsui et al., 1995) have been included in this study for
analysis of their function in receptor stimulation (results in Chapter 4). It is hoped that these
data will provide a more complete understanding of the role of the E2 loop in Mi mAChR
ligand binding and stimulation. A double cysteine mutant (C98A/C178A) and a C178N
mutant were also constructed, in order to better understand the individual binding and
functional characteristics of the two cysteine residues. Mutation of C l78 to N replaces the
polarisable sulphur-containing side chain with a polar residue. Other mutations of C l78
were planned, Cl78V for example, was chosen because it has a bulky hydrophobic non-
polarisable side chain, to gain a better insight into the contribution C l78 makes to the
binding of ligands. Unfortunately, however, after several attempts at mutating C l78 to
other amino acids only the C178A and the C178N mutants were successful and viable. Four
residues in the TM domain were also chosen for mutation to alanine. FI97 (TM5) and
W378 (TM6 ) help complete the picture of ligand contact residues within the defined
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binding pocket. D99 has been proposed to act as a ligand docking residue in mAChRs and
other 7-TM receptors (Jakubik et al., 2000). C98 was also mutated to alanine because it is
the other cysteine involved in the disulphide bond.
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3.2 Results
3.2.1. Effects of mutations on 3H-NMS and 3H-QNB Binding: 
Characteristics; Technical Issues.
The binding of increasing concentrations of 3H-NMS or 3H-QNB to Mi mAChRs 
transiently expressed in COS-7 cell membranes exhibits a saturable and a non-saturable 
component. The saturable component can be suppressed by the inclusion of a sufficient 
amount of unlabelled competing ligand, such as atropine. Atropine therefore provides the 
non-specific binding values. Analysis of saturation curves using a simple 1 site model for 
binding yields estimates of total concentration of binding sites (Bmax) for the tritiated 
ligand and of its affinity constants. Certain mutations cause receptors to be expressed at 
very low levels, C l78A for example, making characterisation extremely problematic. Three 
methods were employed to rescue poorly expressed mutant receptors. Firstly, atropine was 
added to the culture media 48 hours prior to harvesting. Atropine, a high affinity inverse 
agonist, is similar in structure to NMS, except that it contains a tertiary amine head group 
instead of a quaternary group. This allows atropine to access the cytoplasm where it is 
believed to act like a molecular chaperone (Lu and Hulme, 1999). Binding to and 
stabilizing the nascent receptor on its journey through the endoplasmic reticulum and the 
Golgi network, it allows poorly-expressing mutants to reach the plasma membrane. Once in 
the membrane the mutant receptors can be harvested and characterized. Indirect saturation 
binding curves provided a second approach to overcome poor expression of mutants or 
mutants with significantly reduced affinity compared to WT. In this instance unlabelled 
NMS is used to compete with the tritiated ligand (3H-NMS), in hot-v-cold assays. This 
allows us to determine Kd values for poorly expressing and low affinity mutants. If a 
mutant has an extremely low affinity for a particular ligand then it is possible that the native 
residue in question participates in the binding of that particular ligand.
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A third approach to characterising low expressing mutants was the use of a second 
radioligand, 3H-QNB. This ligand has a 3-fold higher affinity than 3H-NMS for the wild 
type mAChR and potentially binds to a different set of contact binding residues. That is, a 
specific mutation may reduce the affinity of NMS but not QNB. In addition, the antagonist 
3H-QNB, like atropine is also able to penetrate lipid membranes, allowing it to enter 
vesicles, which can be formed when preparing membranes for analysis. Receptors can 
become trapped within these vesicles, effectively eliminating the entry of hydrophilic 
quaternary amines such as NMS. Hence the use of 3H-QNB instead of NMS can overcome 
some of the problems caused by poor expression and low affinity.
Summaries of expression levels and binding affinities of NMS and QNB binding sites of 
mutants compared to wild type can be seen in table 3.2 and an example of mutant 
expression before and after atropine treatment can be seen in figure 3.2.
109
Chapter 3
Table 3.2. Sum m ary of NMS and QNB Affinity C onstants and Expression 
Levels: All M utants
NMS QNB
E2 Loop 
Mutants
n
Expression
%WT
pKd 
-log M
n
Expression
%WT
pKd 
-log M
WT 17 100±5.3 9.87±0.04 9 100±9.7 10.63±0.04
C98A/C178A*§ 7 53.3±7.8 8.37±0.1a 3 26.3±9.6 8.80±0.1a
E170A 5 46.6±24.4 9.75±0.1 3 39.9±3.3 10.83±0.1
R171A 4 45.2±27.7 9.25±0.03a 3 40.8±2.2 10.45±0.1
Q177A 4 51.3±31.3 9.82±0.03 3 57.6±0.43 10.57±0.2
C178A*§ 8 43.1±7.1 8.77±0.1a 3 48.5±19.0 9.27±0.04a
C178Af 3 4.8±0.5 ND ND ND ND
C178N*§ 5 45.9±8.4 8.56±0.1a 3 49.8±4.2 9.45±0.1a
Y179A 3 60.3±6.7 9.44±0.1a 3 81.6±6.4 10.39±0.1
1180 A 3 67.35±8.4 9.46±0.03a 3 72.1±7.5 10.53±0.3
F182A 3 56.5±9.1 9.37±0.04a 3 70.5±15.0 10.94±0.2
TM
Domain
Mutants
C98A*§ 6 16.1±3.1 8.28±0.1a 3 19.6±4.5 9.16±0.1a
D99A*§ 4 9.6±1.7 8.81±0.1a 3 15.0±11.2 1 0 .1 0 ±0 .1 b
D99Af 2 4.3±1.2 ND ND ND ND
F197A*§ 3 66.3±10.0 7.89±0.1 a 3 16.1±7.2 10.35±0.2
F197Af 3 4.3±3.0 ND ND ND ND
W378A| 3 N.D 7.25±0.1a 4 125.4±12.5 9.62±0.1a
♦Denotes poorly expressing atropine Rescued Mutants 
t  Indicates Non-atropine treated values 
§ pKd Values Determined by Hot-v-cold Experiments
% Denotes pKd Value determined by 3H-QNB-v-NMS competition experiments 
Statistical Significance (t-test) ap<0.01 and bp<0.05 wrt WT values.
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Figure 3.2. A tropine T reatm ent of G row th M edia Rescues Poorly 
Expressing C178A M u ta n t
2500
•  C178A + Atropine
2000  -
•  C178A No Atropine
Z
I
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2oI-
0.0 5.0e-10 1.0e-9 1.5e-9 2.0e-9 2.5e-9 3.0e-9 3.5e-9
[3 H-NM S] (M)
Representative 3H-NMS saturation binding assay on COS-7 cell membrane preparations 
transiently expressing the poorly expressed C178A mutant with or without 10'6M atropine 
added to the growth media. It can be seen that cells treated with atropine improve 
radioligand binding to the C178A mutant receptor. The data is representative of at least 
three independent experiments and all data points are the mean of quadruplicate assays 
±S.E.M.
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3.2.2 Determination of NMS and QNB Affinity Constants
In the Top Panel of figure 3.3 representative 3H-NMS saturation curves from primary data 
are shown for wild type, R171A and C178A. The curves show mean total and non specific 
binding. The figure serves to highlight the low affinity of C l78A for 3H-NMS and its 
relatively poor expression level. The binding of 3H-NMS to C l78A failed to reach 50% 
saturation making it difficult to obtain precise values for expression and affinity using 
standard radioligand saturation binding assays. By comparison curves for R171A of the E2 
loop reached over 80% saturation, allowing a more confident calculation of expression 
levels and affinity, to be made.
The majority of E2 loop mutants showed small but statistically significant (2-4-fold) 
reductions in 3H-NMS affinity. In contrast the E2 loop mutants showed no significant 
decreases in affinity for H-QNB compared to wild type levels of expression of QNB 
binding sites were in agreement with those of NMS apart from C l78A. Representative 
primary data for 3H-QNB saturation binding assays for some E2 loop mutants and the 
cysteine mutants are shown in figure 3.5. In contrast to the other E2 loop mutants the 
cysteine mutants showed large decreases in binding affinity for both NMS and QNB as 
determined by hot-v-cold competition binding assays (figure 3.4). C98A showed ~40-fold 
reduction in NMS affinity and ~30-fold reduction in QNB affinity. C178A showed -10- 
fold reduction in NMS affinity and ~20-fold reduction in QNB affinity. C178N gave 
comparable reductions in both NMS and QNB affinity (to that of C178A). The double 
cysteine mutant, C98A/C178A showed -30-fold reduction in NMS affinity and ~70-fold 
reduction in QNB affinity, three times the reduction in QNB affinity shown for C l78A 
(p<0.05). Cysteine mutant affinity constants are also summarised in table 3.2.
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Figure 3.3 R epresentative 3H-NMS Radioligand Binding C urves for E2 
Loop M utants
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3H-NMS saturation binding assays were performed on membrane preparations of receptors 
transiently expressed in COS-7 cells. Protein concentration was 10-30 jagmL . a-c represent 
total and non-specific binding plotted against increasing 3H-NMS concentration. Values are 
the mean of quadruplicate points ± S.E.M. Full binding curves show the fits to a 1-site 
model of binding
a. WT pKd = 9.85±0.01 b. R171A pKd = 9.15±0.14. c. C178A pKd = 8.22±0.16 d. Curves 
from a,b & c plotted on log concentration (M) scale in relation to the estimated receptor 
occupancy
113
Chapter 3
Figure 3.4. Representative Hot-v-Cold NMS Com petition Binding Curves 
to Determ ine NMS pKd for Cysteine M utants.
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Hot-v-cold NMS competition curves were performed on COS-7 cell membranes transiently 
expressing mutant or WT receptors. Protein concentration was 10-20fig/mL. Concentration 
of 3H-NMS used for WT = 3 x 10' 11 M and for cysteine mutants = 3 x 10' 9 M. W T  (red) 
pKd = 9.5±0.04; C98A (green) pKd = 8.30±0.07; C178A pKd = 8.40±0.05 and 
C98A/C178A pKd = 8.23±0.09. Points are mean of quadruplicate assays and are shown ± 
S.E.M. All points were fitted to a 1-site model of binding and corrected using the Cheng 
Prusoff correction factor. Data is representative of at least three independent experiments.
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Figure 3.5. R epresentative 3H-ONB Binding Curves for E2 loop and 
Cysteine M utants
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3H-QNB saturation binding assays were performed on membranes from cells transiently 
expressing wild type or mutant receptors. Protein concentration was 10-30 pg/mL. a. E2 
loop mutants. WT pKd = 10.82±0.09; E170A pKd = 10.98±0.03; R171A pKd = 
10.54±0.03; Q177A pKd = 10.86±0.07. b. Cysteine mutants. WT pKd = 10.82±0.09; 
C98A pKd = 9.31±0.06; C178A pKd = 9.22±0.08; C98A/C178A pKd = 8.60±0.13. All 
points are the mean of quadruplicate assays ± S.E.M and are representative of at least three 
independent experiments.
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The TM domain mutants D99A, F197A and W378A had a significantly greater effect on 
the affinity of NMS than QNB. Figure 3.6 shows representative data used to accurately 
determine pKd values for the TM domain mutants that showed severe reductions in NMS 
affinity. D99A has just sufficient affinity for NMS for its binding constant to be determined 
by an NMS saturation binding assay (panel a). For F197A (panel b) a series of hot-v-cold 
NMS experiments were able to determine a more accurate measure of NMS affinity. In the 
case of W378A (panel c) the >400-fold loss of 3H-NMS affinity required the use of a 
competition assay using 3H-QNB as the radio ligand to be competed off by unlabelled 
NMS to determine NMS affinity for W378A. D99A showed ~10-fold reduction in affinity 
for NMS and of the three TM domain mutants was the only mutant for which a pKd for 
NMS could be measured using standard saturation binding assays. Interestingly, D99A only 
reduced QNB affinity by 3-fold. F197A reduced NMS affinity ~ 100-fold but for QNB only 
2-fold. W378A reduced QNB affinity by 10-fold compared to wild type.
In summary, R171A, Y179A, I180A and F182A caused relatively small but significant 
reductions in the binding constant for 3H-NMS, without having the corresponding effect on 
the binding of 3H-QNB. The cysteine mutants produced larger and significant reductions in 
both 3H-NMS and 3H-QNB affinity. Both F197A and W378A significantly reduced 3H- 
NMS binding affinity, but only W378A significantly affected the binding of 3H-QNB
3.2.3. Determination of Expression Levels
Once reliable pKd values had been obtained for those mutants with low expression and low 
NMS affinity, specifically the Cys mutants, FI97A and W378A, it was possible to calculate 
a more precise estimate of the total number of NMS binding sites. This was achieved by re- 
analysing the original 3H-NMS saturation binding data using constrained pKd values which 
were obtained by indirect means (hot-v-cold NMS assays and H-QNB-v-NMS competition
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assays). This was not possible for W378A because of the ~500-fold reduction in NMS 
affinity. Thus, expression levels for this particular mutant could only be calculated using 
3H-QNB saturation binding assays. Low expression levels and low affinity for NMS meant 
that for the mutant F197A in particular calculation of meaningful expression levels were 
difficult. Indeed, reliable estimates of Bmax for all mutants are reliant on sufficient binding 
affinity of the tracer ligand and the ability of the receptor to locate correctly in the 
membrane. Calculating the expression level for F197A by extracting the Bmax value by 
constraining data from Hot-v-cold NMS experiments inevitably led to a somewhat skewed 
Bmax value (-66% of WT expression). Data for F197A QNB binding was more accurate 
since QNB affinity was not affected by this particular mutant. Therefore the levels of 
expression of QNB binding sites was slightly more accurate (-16% of WT with a range of 
7% - 46%) since Bmax could be measured by direct 3H-QNB saturation binding assays.
In general it was shown that the E2 Loop mutants expressed at levels greater than 50% of
WT, the exception being C178A which expressed at -25%, even after atropine rescue. For
the TM domain mutants, expression was more variable, probably due to the need for
atropine rescue. For example, C98A (12% of WT) and D99A (-8% of WT) were the lowest
expressing mutants of all those analysed. Interestingly the C178N mutant expressed both
NMS and QNB binding sites at -50% of WT values. The biggest surprise was that the
double cysteine mutant C98A/C178A expressed NMS binding sites at higher levels (-50%
of WT) than either of the single cysteine mutants. This was in contrast to QNB binding
sites which were shown to express at only -25% of WT levels for the C98A/C178A mutant
but at similar levels for the single cysteine mutants. Another surprise was that W378A
showed expression levels of QNB binding sites greater than wild type levels (125%). All
expression levels, along with summary affinity data for NMS and QNB are shown in table
3.2. The comparisons of Bmax values for all mutants obtained from NMS and QNB
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binding experiments (where possible) are in relatively good agreement with the exceptions
of C98A/C178A and W378A.
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Figure 3.6. R epresentative Binding Curves for D eterm ination of NMS
Affinity C onstants for TM  Dom ain M utants
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All assays were performed on COS-7 cell membranes transiently expressing WT or mutant 
receptors. Total protein = 10-30 pg/mL a. NMS saturation assay. pKd WT = 9.86±0.02, 
Bmax = 21.9fmol/mL; pKd D99A = 9.03±0.05; Bmax = 4.4fmol/mL. b. Hot-v-cold NMS 
competition assay; pKd WT = 9.60±0.02; F197A pKd = 8.08±0.20; c. 3H-QNB-v-NMS 
competition assay; WT pKd = 9.43±0.02; W378A pKd = 7.20±0.02. Data points are mean 
of quadruplicate measurements and are shown ±S.E.M and are representative of at least 
three independent experiments and are corrected using the Cheng Prussof Correction 
Factor. Data is representative of at least 3 independent experiments.
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Figure 3.7. Representative i3Hl-QNB Saturation  Binding C urves for TM  
Domain M utants
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Representative 3H-QNB Saturation Binding Curves for TM Domain Mutants. All assays 
were performed on membranes from COS-7 cells that transiently express WT or mutant 
receptors. Protein concentration was = 10-30pg/mL. Data points are the mean of 
quadruplicate measurements ±S.E.M and are representative of at least three independent 
experiments.
a. WT pKd = 10.60±0.11; Bmax = 59.8fmol/mL D99A pKd = 10.10±0.02; Bmax = 
15.3fmol/mL (with atropine rescue).
b. F197A pKd 10.08±0.04; Bmax = 3.9fmol/mL (with atropine rescue) W378A pKd = 
9.77±0.11; Bmax = 59.5fmol/mL. Data is representative of at least 3 independent 
experiments.
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3.3. Acetylcholine Competition Binding Experiments
Competition assays were designed to analyse the binding of ACh to mutant Mi mAChRs. 
Analysis was performed in the first instance using the Hill Equation, providing apparent 
affinity constants (pIC5o) and a slope factor (nH) describing the steepness of the curve. A 
slope factor greater than 1 indicates positive co-operativity, a slope factor = 1 indicates no 
co-operativity and a slope factor less than 1 indicates negative co-operativity, or the 
presence of two separate populations of binding site. Appropriate concentrations of either 
3H-NMS or 3H-QNB were used in competitive experiments with ACh depending on the 
NMS and QNB binding characteristics of the individual mutant. For example, the 
acetylcholine binding characteristics of the W378A mutant were measured using 3H-QNB 
as the radioligand due to the severe loss of NMS affinity for this particular mutant. The 
radioligand used in competition assays is clearly stated in the following representative 
figures. Again atropine was used to provide the non-specific component for the analysis. 
The model for analysing acetylcholine affinity differs from the simple 1-site model in that 
the Hill equation allows for the slope of a curve to be greater or less than 1. Representative 
curves for E2 loop mutants are presented first, followed by illustative data for the cysteine 
mutants and TM domain mutants.
3.3.1. E2 Loop Mutants-ACh Binding
The acetylcholine competition binding curve for wild type gave a pK value = 5.00 with a 
mean slope factor of 0.84±0.03 and ACh reduced the percentage of specific binding of 3H- 
NMS to zero at -lmM  ACh. Two of the E2 loop mutants showed significant reductions in 
acetylcholine affinity, namely R171A (~7-fold) and I180A(~5-fold). The majority of E2 
loop mutants returned pICso values approximating wild type values. Example ACh
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competition data is shown in figure 3.8 and mean pICso and Hill coefficient values for wild
type and all mutants are given in table 3.3.
Table 3.3 Sum m ary D ata of ACh Affinity Constants: All M utants.
n Mean IC50+/- S.E.M Hill coefficient
Wild Type 24 5.00±0.05 0.84±0.03
E2 Loop M utant
C98A/C178A 6 3.10±0.10a 0.95±0.22
E170A 4 5.19±0.18 0.75±0.04
R171A 4 4.17±0.15a 0.93±0.21
Q177A 4 5.14±0.10 0.88±0.04
C178A 6 3.18±0.14a 1.25±0.15
C178N 5 2.94±0.07a 0.80±0.14
Y179A 3 4.75±0.18 0.74±0.11
I180A 3 4.35±0.18b 0.85±0.03
F182A 4 5.08±0.06 0.80±0.07
TM Domain Mutants
C98A 6 3.90±0.18 0.47±0.06a
D99A 4 3.65±0.12a 0.77±0.11
F197A 4 4.76±0.24 0.72±0.37
W378A§ 7 3.86±0.09a 1.34±0.09a
t  Atropine Rescued Mutants
Statistical Significance (2-tailed t-test) ap<0.01 and bp<0.05 with respect to WT values 
§ pKa values obtained using 3H-QNB as competing radioligand.
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Figure 3.8. Representative ACh Com petition Curves for E2 Loop 
M utants.
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Assays were performed on COS-7 cell membranes transiently expressing WT or Mutant 
receptors. Protein concentration was 10-30pg/mL. Data points are the mean of 
quadruplicate measurements ±S.E.M and curves were fitted using the Hill equation. 
Binding curves have been subject to Cheng Prusoff correction. 10'6M Atropine used for 
non-specific controls [3H-NMS] used for WT = 10’10M and for Mutants = 3 x 10'10M. WT 
pIC50= 5.06±0.03, nH = 0.9; Q177A pIC50 = 4.91±0.01, nH = 0.89; I180A pIC50= 
4.00±0.03, nH = 0.87; Y179A pIC50= 4.52±0.03, nH = 0.93.
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3.3.2. Cysteine Mutants-ACh Binding
The ACh binding data from individual experiments for the cysteine mutants when analysed 
using the Hill equation and a single site model of binding showed apparent poor fits to the 
collected data (figure 3.9). This was due to low expression levels, low affinity and low 
specific binding. That is, the curves did not fit as well to the plotted data as would be 
consistent with a homogeneous population of receptors with a single binding site. Also, 
there was an apparent difference in the reduction of ACh affinity and Hill coefficients 
between C98A (mean pK = 3.90±0.18 and nH = 0.47±0.06) and C178A (mean pK= 
3.18±0.14 and nn = 1.25±0.15). These mean values for pK and nn indicate a larger effect of 
the C l78A rather than the C98A mutation on ACh affinity and C98A has a lower mean Hill 
coefficient than C178A of 0.47±0.06. This significantly (p«0.01) low Hill coefficient 
might be consistent with the presence of two populations of ACh binding sites for the 
C98A (and possibly the C178A mutants) which may have similar affinities for the 
antagonist but different affinities for the agonist. Although the mean Hill coefficient for 
C178A was 1.25, there was a range of values from nn =0.58 to nn = 1.77
To provide a better insight to the possibility that the C98A mutant gave rise to two distinct 
populations of receptors ACh competition data for C98A was pooled and analysed using a 
2-site model of binding and is presented in figure 3.10. Data was pooled and normalised by 
taking the ratio of mean dpm minus non-specific binding to mean dpm for total specific 
binding for each ACh concentration and calculating a mean value for the whole data set. 
Analysis of the pooled data showed that C98A gave a larger fraction of high affinity sites at 
60% than low affinity sites at 40% of the total population. The mean pKH (affinity constant 
of the high affinity sites) was 4.33±0.22 and the mean pKl (affinity constant of the low 
affinity sites) was 2.58±0.21.
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To further analyse the C98A mutant a more detailed experiment was performed using a 
wider range of ACh concentrations and to provide different radioligand occupancies of the 
two populations of sites (see figure 3.11). This data was then analysed by using a 1-site 
model and a 2-site model of binding and compared. The wild type competition data was 
consistent with the results reported in table 3.3. The data for C98A did not fit well to the 1- 
site model (figure 3.9) but better fitted the 2-site model (shown in figure 3.11). C98A 
shows a population of receptors with a mean pKu = 5.13±0.03, and a mean pKl= 
2.27±0.03, in roughly equal proportions (-50%) and the residuals in this analysis were 
randomly distributed (data not shown). The possibility of that the C178A mutant also 
produces two populations of binding site requires further investigation.
3.3.3. Transmembrane Domain Mutants-ACh Binding
Of the TM domain mutants D99A displayed the largest effect on acetylcholine binding with 
a -20-fold reduction in affinity but with an nH value (0.77±0.11) close to wild type 
(0.84±0.03). An example of an ACh-v-3H-NMS competition assay for D99A is shown in 
figure 3.12 (panel a). The reduction in ACh affinity for D99A was twice the reduction in 
affinity noted for NMS for this mutant. For F197A and W378A 3H-QNB was used as the 
radioligand for ACh competition assays, see figure 3.12 (panel b) for representative data. 
FI97A only had a very minor (<2-fold) effect on the affinity of ACh, in contrast to the -14 
fold reduction observed for W378A The mean slope factor for F197A was unchanged. A 
Hill coefficient greater than 1 was consistently observed for W378A in ACh competition 
assays and the mean nn value was 1.34, hinting at the possibility that this mutant may 
display co-operativity for ACh binding.
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Figure 3.9. Representative Acetylcholine Com petition Binding Curves for 
Cysteine M utants
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Assays were performed on COS-7 cell membranes transiently expressing WT or Mutant 
receptors. Protein concentration was 10-30p.g/mL. Data points are the mean of 
quadruplicate measurements ±S.E.M and represent at least three independent experiments. 
Curves are fitted using the Hill equation. Binding curves have been subject to Cheng 
Prussof correction. 10‘6M Atropine used for non-specific controls. [3H-NMS] used for WT 
= 10‘10M and for Mutants = 3 x 10'9M . W T  pIC50= 4.51±0.01, nH = 0.95; C 9 8 A / C 1 7 8 A  
pIC50 = 2.90±0.04, nH = 1.73; C 9 8 A  pIC50= 3.96±0.10, nH = 0.65; C 1 7 8 A  pIC50= 
3.29±0.08, nH = 0.65.
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Figure 3.10. Analysis of Pooled D ata for C98A ACh Com petition Binding 
E xperim ents (2-site model).
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ACh Competition data for C98A was collected and pooled from 8 independent experiments 
±S.E.M Analysis using a two site model o f binding gave: C98A Fr (H) 60.7±9.1 pKH = 
4.33±0.22 pKL =2.58±0.21. Data was pooled and normalised using the percentage o f the 
ratio o f mean dpm minus non-specific binding and the mean dpm for specific binding for 
all ACh competition data. i.e. (mean dpm -  B n s) /  ( B t o t  -  B n s ) x  100
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Figure 3.11. Detailed ACh Com petition Binding Experim ent to F u rth e r 
C haracterise  the C98A M utan t Using a 2-Site Model of Binding
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2-site analysis of competition binding curve for C98A and WT control. Assays were 
performed on COS-7 cell membranes transiently expressing WT or mutant receptors. 
Protein concentration was = 10-30|ig/mL. Samples counted for 60 min. Data points are the 
mean of quadruplicate measurements ±S.E.M and curves are fitted using a 2-site model of 
binding, where Fr(H) = fraction of high affinity sites. Two 3H-NMS concentrations were 
used for WT = 10'nM, for A high [3H-NMS](solid blue points and line) = 2 x 10' 9 M and a 
low [3H-NMS] = 2 x 10'10M (dark blue dashed line) WT high [3H-NMS] pICso = 
4.88±0.06,nH = 0.71 ±0.06, WT low [3H-NMS] pIC50 = 4.85±0.07; nH = 0.70±0.06; C98A 
high [3H-NMS], FrH = 0.37±0.01; high affinity site pIC50 = 5.11±0.002 pKL= 
2.23±0.002; C98A low [3H-NMS] Fr(H)=0.48±0.03, pKH = 5.17±0.03, pKL = 2.30±0.03.
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Figure 3.12. Representative Acetylcholine Com petition Binding Curves 
for TM  Domain M utants,
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Representative acetylcholine competition binding curves for TM domain mutants. Assays 
were performed on COS-7 cell membranes from cells transiently expressing WT or mutant 
receptors. Total [protein] 10-30 jag/mL. Data points are the mean of quadruplicate 
measurements ±S.E.M and curves are fitted using the Hill equation. pICso values are 
corrected using the Cheng Prusoff correction factor. Curves are representative of at least 3 
independent experiments.
a. WT IC50 = 5.21 ±0.02, nH =0.84±0.01; D99A IC50 = 3.85±0.03. nH =0.86±0.02.
b. WT IC50 = 4.70±0.01, nH =0.83±0.02; F197A IC50 = 4.11±0.01, nH =1.19±0.03; W378A 
IC50 = 3.68±0.02, nH =1.44±0.04
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3.4 -  Discussion and Conclusions
A graphical summary of the effects of mutations in the E2 loop on NMS affinity is 
presented in figure 3.13. and compared with the effects on ACh affinity In general the E2 
loop (excepting C l78A) mutants expressed well and at levels close to wild Bmax values. 
There was a slight discrepancy between the expression levels for NMS and QNB binding 
sites for some mutants. The Bmax relates to the number of complete or viable binding sites 
expressed at the receptor surface or at least that are accessable to the ligand. Any receptor 
binding sites that may be trapped in vesicles may be accessable to QNB but not NMS. 
Since QNB is a tertiary amine and hydrophilic it is therefore able to penetrate vesicles and 
bind to receptors that have their binding site located inside a vesicle. This may account for 
the small differences in NMS and QNB binding site expression. Mutations of the E2 loop 
had a limited (< 10-fold) effect on the affinity of the antagonist NMS. Collectively this 
suggests that E2 loop residues have limited role in the binding of NMS and are unlikely to 
make highly specific direct contacts with the antagonist. They may be similar to certain 
residues found in the second shell of the Mi mAChR centrally located transmembrane 
binding site (Lu et al., 2001), for example, mutations of residues LI02 and A103 of TM3, 
1161 and LI62 of TM4 and V409 and S411, all in close proximity to the binding site, but 
whose mutation to alanine reduced NMS affinity less than 10-fold. The data presented in 
this thesis supplements the previous study of Matsui et al (1995) which showed the effects 
of other E2 loop mutations on ACh and NMS binding affinity. Mutation of cysteine 178 to 
alanine did show a ~ 10-fold reduction in affinity for NMS, but this is much less than that 
reported for the homologous mutation in the M3 mAChR (Zeng et al., 1999) where a 8 6 6 - 
fold reduction in NMS affinity was observed for the analogous mutant. It must be noted 
there were differences in the buffering conditions used for this study and that of Zeng et al. 
That is the buffer used by Zeng et al contained 25mM sodium phosphate, 5mM MgCl2 and
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no HEPES unlike the binding buffer used in this study (see methods section 2.11). This 
affected the free ion concentrations and consequently affected binding affinities. Mutation 
of the conserved C98 residue significantly reduced the affinity (~40-fold) of NMS again, 
less than reported by Zheng et al (Zeng et al., 1999) in the analogous C140A mutant. The 
results of the present study are consistent with the role of the S-S bond in maintaining 
receptor stability and therefore stability of the binding site, as mutation to alanine severely 
reduced receptor expression and effected a significant loss of affinity for NMS, QNB and 
ACh, although these effects are not necessarily related.
Consistent with Savarese et al and Zeng et al (Savarese et al., 1992. Zeng et al., 1999) the 
maintenance of the S-S bond is critical for correct folding of the protein In our study even 
after atropine rescue C98A and C l78A expressed NMS & QNB binding sites at only ~40% 
of WT levels. The paradox here is the somewhat better expression of the double cysteine 
mutant C98A/C178A which expressed at -70% of WT levels (when the growth media was 
supplemented with atropine). The implication is that without either C98 or C l78 the 
receptor is able reach the plasma membrane in the correct orientation more often than if one 
or other of the S-S bonded cysteine is singularly present. There is the possibility that the 
single cysteine, becoming randomly bonded to other proteins in the endoplasmic reticulum 
by a process described as thiol dependent retention (Reddy and Corley, 1998), negates 
receptors ever reaching the cell surface, instead remaining trapped in the intracellular 
milieu. Hence, without either cysteine present as in the C98A/C178A mutant, the 
opportunity for thiol dependent retention is prevented, allowing a greater ratio of atropine 
rescued double cysteine mutant receptors to correctly fold and reach the membrane surface 
properly orientated. Nevertheless, it was expected, having rescued expression of the S-S 
bond mutants, that the disruption of the S-S bond would have a more pronounced effect on
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the binding of NMS because of the large reductions in NMS affinity witnessed by Zeng et
al (Zeng et al., 1999) for the analogous mutations of the M3 receptor.
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Figure. 3.13. Effects of E2 Loop Mutations on NMS and ACh Affinity
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Effects of Mutations of E2 loop residues of Mi mAChR on the binding affinities of NMS 
and ACh. Results are mean ±S.E of at least three determinations. Bars represent log 
difference in binding affinity compared to WT and includes data from Matsui et al(Matsui 
et al., 1995). E2 Loop residues on the X-axis are represented with the single letter code. 
Both decreases and increases are shown, a. Effects of mutations on the affinity of NMS, 
mean pKd of NMS at WT receptors = 9.87±0.05. b. effects of mutations on the affinity of 
ACh, mean pICso of ACh at WT receptors = 5.00±0.04.
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The double cysteine mutant C98A/C178A showed a similar reduction in NMS affinity to 
C98A and slightly greater than that of the C178A and C178N mutant. The fact that the 
binding affinity of NMS was not as strongly reduced by Cl 78 A, suggests that the integrity 
of the TM domain residues (D105, Y106, FI97, N382, Y381, W378) (Hulme and Lu, 
1998) is more critical for NMS binding than is the maintenance of the S-S bond. The ~3- 
fold reduction in affinity found for R171A, II80A, FI82A (all conserved in the mAChR 
sub-types) and Y179A, provides evidence that these residues may play a secondary role in 
forming and augmenting the environment for the NMS binding site. In general, these 
observations may be consistent with the role of homologous E2 loop residues that are in 
close proximity to the retinal binding pocket of rhodopsin (Li et al.2004). The E2 loop may 
form a second shell of contacts that help maintain the correct conformation of the binding 
site required for the agonist to fit most efficiently.
The much larger effect of F197A (>100-fold) and W378A (>400-fold) mutations on NMS
affinity are consistent with the theory that the NMS side chain penetrates and binds deep
inside the transmembrane domain. According to the homology model both FI97 and W378
(both highly conserved residues in the rhodopsin family of GPCRs) lie at the base of the
binding pocket, where they may participate in Pi-Pi bond interactions with the phenyl ring
of the NMS side chain. Looking at the relative positions of the benzene ring of NMS in
relation to the phenyl ring of F197 and the indole ring of W378 in the Mi homology model,
it is possible that a T-shaped benzene-phenol dimer interaction is possible with FI97 and a
sandwich benzene dimer pi-pi bond is possible with W378 (Sinnokrot and Sherrill, 2004).
The T-shaped dimer is thought to have a lower binding energy than the sandwich dimer and
the results of the present study support this in that mutation of W378 caused a greater loss
of NMS affinity than did FI97A. This finding is consistent with the W378F mutation
studied by Wess et al (Wess et al., 1993) which gave less than 10-fold reduction in the
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affinity of NMS, thus confirming the importance of the presence of an aromatic residue at 
this critical position in the transmembrane domains of the rhodopsin-family of GPCRs. 
Interestingly, F197A and W378A had much smaller effects (2-fold and 10-fold 
respectively) on QNB binding as previously reported for other mutations of certain TM 
domain residues, Y381A, Y404A, C407A and Y408A (Lu et al., 2001) (Ward et al., 
1999a). This highlights the different modes of binding of NMS and QNB and reflects their 
differing molecular structures. A graphical summary of antagonist binding data for TM 
domain mutants is presented in figure 3.14.
Apart from the effect of removing the S-S bond via the cysteine mutants, point mutations of
the E2 loop had virtually no effect on the binding of QNB with all E2 loop residues
showing less than 3-fold reduction in affinity for QNB. Evidence provided by this study
supports the theory of different modes of binding of NMS and QNB. In addition D99A
reduced the affinity of NMS more than 10-fold, whereas the reduction in QNB affinity was
only ~3-fold. This finding may suggest an alternative mode of entry into the binding site for
the hydrophobic QNB molecule, perhaps via the lipid membrane region through the TM
domains. This idea is based on the proposal that D99 is part of an initial ligand docking
mechanism (Jakubik et al., 2000) for hydrophilic ligands such as NMS. Therefore it is very
unlikely that any residues of the E2 loop make pivotal binding contacts with QNB.
Mutation of central binding site residues D105, Y106 (TM3) (Lu and Hulme, 1999a) and
N382 (TM6) (Ward et al., 1999a) all caused large reductions in 3H-QNB affinity,
suggesting that QNB also binds in the central binding cavity of the Mi mAChR. C98A and
C178A reduced QNB affinity ~30-fold, C178N 15-fold and the C98A/C178A mutant -60-
fold. Although significant reductions in affinity were seen for C98A, C l78A and C178N
and C98A/C178A, it is suggested that this loss of affinity is symptomatic of the
perturbation of the integrity of the central binding site, effectively “taking the lid off’ the
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Mi mAChR binding pocket perturbs the binding of QNB. Since mutation of FI97 and 
W378 at the base of the binding cavity cause only minor reductions in affinity, but the 
disruption of the E2 loop structure caused greater reductions in affinity, it may be supposed 
that QNB binds more superficially in the binding pocket than NMS. This is further 
supported by the finding of the present study, where the reductions in QNB affinity were 
greater than that of NMS for the cysteine mutants This implies that maintenance of the 
overall E2 loop structure, rather than individual amino acid side chains, is somewhat more 
important for the binding of QNB than for NMS. Figures 3.13 and 3.14 summarise the 
NMS, ACh and QNB binding data for C98A and C178A.
The effects of E2 loop point mutations on ACh affinity were comparable to those mutations 
of “second shell” residues of the TM domains, LI03, SI09 and L386 for instance. 
Significant reductions in ACh affinity were recorded for R171A (~7-fold) and I180A (~5- 
fold). figure 3.13 (panel b) summarises the effects of mutations of E2 loop residues on ACh 
affinity and includes the data collected previously by Matsui et al (1995). Looking at figure 
3.13 it appears that that mutation of E2 loop residues produce both selective increases and 
decreases in ACh affinity. It is interesting to note that none of the E2 loop mutations caused 
an increase in NMS affinity whereas alternation between increased and decreased affinity 
was observed for ACh, most significantly by the Q181A mutant from the Matsui study 
which increased ACh affinity 5-fold. Although minor, the slight increases and decreases in 
affinity noted for the E2 loop mutants may continued on page 138
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Figure 3.14. Sum m ary Binding Data for TM  Domain M utants
C98A D99A F197A W378A
-3
Effects of C98A, D99A, F197A and W378A mutations on NMS (black bar). ACh (grey 
bar) and QNB (white bar) binding affinity. Results shown are the mean ±S.E. of at least 
three determinations. Bars represent the log difference in binding affinity relative to WT 
binding affinity constants, where, WT- pKd NMS = 9.87±0.04, pIC5o ACh = 5.00±0.05 and 
pKd QNB = 10.68±0.04
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be consistent with a tertiary structure similar to that of rhodopsin. This pattern of affinity 
changes might be consistent with a p-strand structure for the residues C-terminal to C l78 
whereby inwardly facing mutations cause a loss of affinity and in contrast mutation of 
outwardly facing residues cause minor increases in affinity.
It has been suggested in this study that E2 loop mutations lying C-terminal to the conserved 
cysteine residue have more of an effect on ACh than on NMS binding. These residues are 
predicted to form the p-4 sheet alluded to at the beginning of this chapter and support the 
conclusions of Javitch et al (Shi and Javitch, 2004) that it is the p-4 sheet structure 
protruding into the central binding cavity that may assist the correct binding of ligands. 
Indeed, in rhodopsin it is the analogous polar residues (Carravetta et al., 2004) and 
associated water molecules (Okada et al., 2002) of the E2 loop, folding into the retinal 
binding crevice that assist the rapid photoisomerisation of the retinylidene chromophore. 
Residues of the E2 loop of rhodopsin (in both P3and p4) achieve this by stabilising the 
developing partial positive charge at the centre of the polyene chain by solvation via a 
functional water molecule hydrogen bonded to the binding pocket via E2 loop residues 
(Carravetta et al., 2004). Although some reductions in affinity for both ACh and NMS (but 
not QNB) were observed for the analogous residues in the p-3 and p-4 sheet of the Mi 
mAChR, the reductions were not of an order of magnitude that would suggest critical roles 
in ligand binding for the E2 loop in the central binding site. However a significantly 
different role is played by the Glu 181 residue of rhodopsin than that of the apparently 
redundant analogous Mi mAChR residue, E l70. In rhodopsin the Glul81 residue is central 
to the environment of the retinylidene Schiff base in the active metarhodopsin II 
photoproduct (Yan et al., 2002).
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The cysteine mutants, C178A, C178N and C98A/C178A reduced ACh affinity ~70-fold, 
~ 100-fold and ~80-fold respectively. Disruption of the S-S bond reduced the binding 
affinity of the agonist significantly and these effects are comparable with the mutation of 
the binding site residues Y106 and Y381. What still remains to be resolved however, is the 
question of whether or not the sulphur atom of the cysteine at position 178 in The Mi 
receptor is itself involved in the binding of acetylcholine, or whether it is the global 
destabilising effect of the removal of the S-S bond on the transmembrane domain that 
accounts for the loss in ACh affinity. The fact that the C l78A mutation reduces ACh 
affinity~70-fold, compared to only a ~10-15-fold loss in NMS affinity supports the idea 
that C l78 is a more important residue for the binding of ACh than NMS. The alternative 
scenario is that C l78A destabilises the ACh binding conformation to a greater extent than 
the NMS binding site without actually making any critical contact with ACh itself.
As the data suggested in the results section (figure 3.10 and 3.11), the C98A and mutant
may express both a high and low affinity site for the binding of ACh. Further evidence for
two populations of binding sites for the C98A mutant are seen in the consistently low Hill
coefficients (mean nn = 0.47±0.06) for this mutant. As has been shown by Avlani et al
(Avlani, 2005), unusual intramolecular disulphide bonding may be possible between the
cysteine of the E2 loop and either of the two cysteines in the E3 loop. It is possible
therefore to imagine that for the C98A mutant where the C l78 residue is free to form a
non-native disulphide bond with either C391 or C394 of the E3 loop that multiple
populations of receptors with different binding sites may exist. The data suggests that two
populations of binding sites do exist, one of high affinity with pK = 4.7 and a low affinity
site with pK = 2.5. The other possible explanation of the low Hill coefficient seen for C98A
is that of negative co-operativity, possibly as a consequence of intermolecular S-S bond
formation with an adjacent free C l78 residue, effectively forming a dimeric receptor
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complex. Due to the length of the E2 loop, it is more likely that an intramolecular S-S bond 
creates the two binding site phenotype of the C98A mutant. Data for the double cysteine 
mutant suggests that without either cysteine, no unusual disulphide bonds could be made, 
since the double cysteine mutant did not require analysis by a 2-site model of binding. This 
adds more weight to the existence of unusual S-S bond formation for the single cysteine 
mutants and the consequent generation of two seperate populations of receptors with two 
distinct binding sites.
The hypothesis that ACh binds more superficially in the binding pocket, than NMS, is
borne out by the finding that neither F197A nor W378A caused a dramatic loss of affinity
seen for NMS. This is analogous to the N382A mutation (Ward et al., 1999a) which caused
~4000-fold loss of NMS affinity but only a 5-fold reduction in ACh affinity. The
conclusion to be drawn from this is that neither FI97 nor W378 are critical for the binding
of ACh, although W378 may play a more important role as part of the aromatic cage. The
mutation of D99A caused a larger effect on the affinity of ACh (>20-fold) than NMS (10-
fold). These effects are larger than reported for the analogous mutation from aspartate to
the uncharged polar asparagine residue in the Mi or M2 receptor (Fraser et al., 1989; Vogel
et al., 1999) and are consistent with the proposition that D99 may act as a primary ligand
docking residue. From the homology model it appears that D99 lies too far from the
internal aromatic cage residues of the core ligand binding site to have any direct contact
with bound ligand. To account for the losses in ACh and NMS affinity seen for D99A in
this study, it would be reasonable to imagine that D99 participates in the initial binding of
ligands prior to their displacement to the central binding pocket. W157 (conserved in all
mAChR subtypes), another residue proposed to act in conjunction with D99, is also
postulated as a primary docking residue (Lu et al., 2001) and displays large reductions in
ACh and NMS affinity (~ 100-fold) (Lu et al., 2001). A mechanism for the mandatory
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docking step was proposed by Lu et al. (Lu et al., 2001) and expounded by Heitz et al. 
(Heitz et al., 1999), whereby an indirect conformational switch provided by PI59 
interfacing with the ligand leads to the contribution of W157 to high affinity binding and 
receptor activation. Our results suggest that D99 may also participate, although to a lesser 
extent, in a similar mechanism of ligand docking whereby the negatively charged polar side 
chain of D99A stabilises acetylcholine as it binds with high affinity to W157 before the 
ligand is transferred into the core binding pocket. It may now be appropriate to revise the 
Mi mAChR homology model to incorporate the new evidence and that reflect the binding 
energies documented here. The E2 loop may pack against the upper regions of the 
transmembrane domains, helping to complete the environment of the agonist and antagonist 
binding site. The differences in binding energies, caused by alanine substitution of the E2 
loop apply to the ground state of the receptor only. It is likely that these interactions might 
well be different in the activated state of the receptor
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Chapter 4. 
Functional Studies
4.1. Introduction.
G-protein coupled receptors can exist in multiple states, minimally in an inactive state 
that can be stabilised by the binding of antagonists and an active state stabilised by the 
binding of agonists. A network of van der Waals contacts and hydrogen bonds between 
the transmembrane helices, often between conserved residues, is responsible for the 
maintenance of the inactive state. These links are described in the rhodopsin model 
(Palczewski et al., 2000) and the Mi homology model (Hulme et al., 2003). An active 
conformation can be promoted by the binding of agonists that disrupt this system of 
inter-helical interactions, creating a revised system of interactions that promote the 
stabilisation of an active conformation of the receptor. More specifically, it has been 
suggested by mutational studies (Lu and Hulme, 2000) and disulphide cross-linking 
studies (Sheikh et al.,1996; Han et al., 2005) that it is the agonist-induced relative 
movement of TM3, TM6 and TM7 that characterises the active conformation of 
GPCRs. Recently, it has also been proposed that conformational changes at the interface 
of dimeric receptor also plays an important role in receptor activation (Guo et al., 2005). 
However, the details of the mechanistic process remain to be elucidated.
The binding of an agonist, such as acetylcholine, at the exo-facial side of the receptor 
activates the selection of specific classes of hetero-trimeric G-proteins on the 
cytoplasmic surface of the receptor. Conformational rearrangements following agonist 
binding expose residues on the intracellular surface that promote dynamic and selective 
interaction with a set of G-proteins. In particular, intracellular loops 12 and 13 determine 
the specific interactions that determine which G-proteins are activated. These 
interactions are extensively reviewed by Wess et al (Wess et al., 1996; Wess et al.,
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1998). Furthermore, which class of G-protein is activated may depend on the activating 
agonist Akam and colleagues (Akam et al. 2001) demonstrated, using 35S-GTPyS 
binding studies that M3 receptors preferentially selected Gja over Gq/n when stimulated 
with pilocarpine as opposed to methacholine. The binding of G-protein to the 
cytoplasmic surface of the receptor catalyses the release of GDP from the G-protein, 
enabling the binding of GTP which in turn promotes the release of the G-protein from 
the receptor. The activated G-protein then continues the signalling pathway via effector 
proteins, located in the membrane, specific to the receptor and G-protein sub-types.
The endogenous activation of the mAChR class of GPCRs is mediated by the small 
neurotransmitter molecule acetylcholine. ACh consists of an acetoxy side chain and a 
trimethylammonium head group (see figure 2.2 in Chapter 2 Methods). Site-directed 
mutagenesis studies in this lab (Hulme and Lu, 1998; Lu et al., 2002) have suggested 
that an aromatic cage consisting of residues Y106A, Y381, W378, Y404 and Y408 is 
critical for the binding of ACh and consequent activation of the receptor. Close 
proximity of the trimethylammonium head group of a bound ACh molecule to the 
residues of the aromatic cage suggest the potential mechanism for activation. It is 
believed that it is the tightening of the aromatic cage around the trimethylammonium 
head group that disrupts the hydrogen bond and van der Waals network that stabilises 
the inactive ground state, leading to conformational re-alignment of the inter-helical 
contacts into the activated state capable of G-protein interaction (Han et al., 1996a; Han 
et al., 2005).
The extended ternary complex model of receptor activation (see Materials and Methods 
figure 2 .2 ) is a useful model to help us understand the effect of point mutations on 
receptor-G-protein interactions. In the basic scenario, assuming a predefined 
conformational equilibrium is in operation, agonists bind with greater affinity to the
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activated state than the inactive ground state. This gives two conformational states, a 
low affinity state, and a high affinity state, the switch from one state to the other is 
determined by the product of the conformational constant K and the cooperativity factor 
for agonist binding, a  G-proteins couple selectively to the activated state of the 
receptor, with an affinity constant Kg Accepting that the bound G-protein is in the 
GDP-bound state, the exchange of GDP-GTP is governed by the rate constant Kcat
Using an evolutionary trace approach and correlation of published mutational studies 
Madabushi et al (Madabushi et al., 2004) identified commonly important residues in a 
diverse set of GPCRs. They showed that there may be generally conserved mechanisms 
for GPCR signal transduction. The binding of a ligand to the receptor induces 
conformation changes, leading to G-protein coupling and activation. The mechanism of 
activation is mediated by 3 main regions of the receptor, described (Madabushi et al., 
2004) as trigger, linking core and coupling regions. Residues in the region of the ligand 
binding pocket, on binding ligand, tend to act as triggers of ligand induced 
conformational change. Mutation of these residues mainly reduces the affinity of 
ligands. Residues of the linking core region lie in between the binding site and the G- 
protein binding surface. Reductions in activation, expression and incorrect folding are 
associated with mutants found in this region because these residues tend to make 
interactions between the TM Helices. The coupling region found at the cytoplasmic 
interface is important for G-protein interactions and many mutations in this region can 
create constitutively active mutants.
The substitution of a particular amino acid with a methyl group-containing alanine 
residue effectively removes the side chain of the native residue effectively leaving an 
inert stub or hole. This can have, basically, four possible consequences (Hulme et al.,
1999) (summarised in figure 4.1). Firstly the mutation can have no effect. This suggests
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that the substituted residue is inconsequential in terms of receptor structure and may be 
described as a filler residue. The second possible outcome is that the mutation 
destabilises the active and inactive conformations of the receptor, without actually 
reducing the signalling capacity of those receptors that were properly expressed. In this 
case it is implied that the substituted residue makes an important contact necessary for 
the structural stability of the receptor, and it may be described as-a stabiliser residue. 
Subsets of this category are the ligand anchor residues that reduce ligand binding 
affinity without affecting signal efficacy. The implication is that, although the ligand 
has a lower affinity for the receptor, the ligand contact residue is not selectively 
important for the signalling conformation. Thirdly, mutated residues that selectively 
destabilise the ground state while simultaneously increasing ligand affinity, basal 
activity and signalling efficacy fall into the category of constraining residues. The 
characteristics of this type of residue suggest that they are involved in intra-molecular 
bonding networks that maintain stability of the ground state but are broken or attenuated 
in the activated state. In the fourth category mutations of activator residues cause loss of 
signalling efficacy, but do not affect levels of expression or stability. There is potential 
for this type of residue to fall into three different sub-groups of activator residues: i) the 
intra-molecular activator residues that make contacts that stabilise the active state at the 
expense of the inactive ground state; ii) The ligand transducer, whereby the residue 
only forms an inter-molecular contact with the ligand in the active state; iii) The G- 
protein transducer residue, which forms inter-molecular contacts with the G-protein in 
the activated state. In addition to the types of residues mentioned it is also possible to 
imagine residues that fulfil dual roles. For example a residue may exert a constraining 
function stabilising the ground state but alter roles when the receptor is activated, 
turning into a residue important for G-protein binding or signal transduction, for 
example.
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The Mi, M3 and M5 mAChR subtypes activate the Gq/n class of G-proteins stimulating 
phospholipase Cp isoforms to break down inositol 4, 5 bisphosphate (PIP2). Breakdown 
of PIP2 liberates two second messengers, diacylglycerol leading to activation of protein 
kinase C and inositol triphosphate (IP3) that acts to mobilise intracellular stores of 
calcium modulating slow potassium and calcium conductances. IP3 is then sequentially 
degraded by a series of phosphatase enzymes back into inositol which is then re­
incorporated back into phosphatidylinositol in the membrane to begin the process anew. 
It is the turnover of phosphoinositides that can be measured to gain insight into the 
functional characteristics of mutant receptors. The PI assay, developed by Berridge et 
al. (Berridge et al.1983) is a robust method of measuring the accumulation of total 3H- 
inositol labelled phosphoinositides. Essentially, by blocking phosphatase enzymes with 
lithium chloride, phosphoinositides produced upon acetylcholine stimulation of the 
receptor, are prevented from being recycled and can be collected and counted after 
elution from an anion exchange column (see Methods section 2.14).
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Figure 4.1. Possible O utcom es o f A lanine Scanning M utagenesis on 
R eceptor F unction .
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Classification of the function of amino acid side chains in GPCR activation by alanine 
scanning mutagenesis. The four main categories being, f i l le r , s ta b ilis in g , co n stra in in g  
and a c tiv a tin g .!d k zn  from (Hulme et al., 1999). See text for more detailed explanation.
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Presented in the this chapter are representative data, complete tabulated results and 
analysis of functional studies for E2 loop mutants, (including a set of six mutants from 
the Matsui study (Matsui et al., 1995) where collection of functional data remained 
outstanding) and TM domain mutants, C98A, D99A, F197A and W378A. ACh dose 
response curves were created by plotting the mean increase of counts per minute of total 
phosphoinositides (dpm) as a function of the increase in acetylcholine concentration. 
Basal signalling, maximal signalling, the slope of a dose response curve and the EC50 
value were determined using a four parameter logistic function combining the 
parameters with an agonist affinity constant and an estimate of expression in relation to 
wild type allows a measure of agonist efficacy to be calculated (Methods 2.16.5). Thus, 
it is possible to calculate an estimate of the signal efficacy for a particular mutant. 
Efficacy may be defined as “the effective affinity of the G-protein for the activated state 
of the receptor weighted by the fraction of receptors that are in the activated state when 
the receptors are fully occupied by the agonist and multiplied by (1 +Kc^/K^)” where 
KCat is the catalytic rate constant of GTP-GDP exchange of the ARG ternary complex 
and Kh is the rate constant of GTP hydrolysis by the G-protein. (Hulme, 2005). The 
ACh signalling efficacy is determined by the ratio of ACh signalling potency to ACh 
affinity constant adjusted for the level of receptor expression and the basal signalling 
activity. Data analysis took into consideration the expression levels of each particular 
mutant in relation to WT by performing, where possible, NMS saturation assays on 
residual transfected cell membranes to obtain Bmax values from which the level of 
functional expression can be calculated for use in the calculation of efficacy. Where 
NMS saturation assays were impractical levels of expression were derived from 
previously performed QNB saturation assays, for example, for the W378A mutant.
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4.2. Results
4.2.1. Basal and Maximum Signalling and Potency
Initially an assay was performed using plasmid DNA encoding WT Mi mAChR to 
determine the optimal amount of plasmid DNA required for transfection into COS-7 
cells to maximise the signalling response. For comparison with mutant DNA, where 
expression of mutant receptors required atropine rescue, the experiment was performed 
on cells grown to confluence in media alone or media containing atropine (10_6M). The 
atropine was carefully washed off the cells by at least four changes of PBS before 
conducting the PI turnover assay. The data presented in figure 4.2 emphasises that 
optimising the plasmid concentration for transfection of cells was necessary. It can be 
seen that 30pg of DNA actually reduced the maximum PI signal of wild type receptors 
by ~1500dpm (~40%-50%) compared to transfection with 7.5pg DNA plasmid. 
Furthermore it was shown that wild type basal activity could be inhibited by subjecting 
receptor expressing cells to a dose of 10'6M atropine. This reduced dpm by ~20%-40% 
of background signalling for the whole range of DNA concentrations. This experiment 
also illustrates that basal signalling of WT could be quite high. Throughout the course 
of the PI turnover assays there were occasions when the basal activity of wild type 
receptors was unexpectedly high, although, not consistently so. Overall, mean basal 
activity of wild type was 682.7± 107.4 dpm and mean ACh stimulated maximum 
response was 3150±451 (n= 29) Null transfections were used to determine the 
background signal. Mean dpm for null transfections were 250±23.1 (n=3). Corrected for 
the null background, the basal signalling activity of the WT receptor was 432 dpm and 
the mean ACh stimulated maximum signalling activity was 2984 dpm.
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Figure 4.2. O ptim isation o f DNA Plasm id C oncen tra tion  fo r 
T ransfection of COS-7 Cells fo r PI T u rn o v er Assays
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Determination of optimum concentration of plasmid for transfection into COS-7 cells 
for PI assays. The PI Assay was performed on live COS-7 cells grown in media alone or 
containing 10‘6M atropine as described in methods 2.13 Amounts of plasmid DNA used 
were, Opg (null transfection), 3.5pg, 7.5pg, 15pg and 30pg of plasmid. Levels of basal 
signalling (red points), maximal signalling using 10"3M ACh (blue points) and 10'6M 
atropine inhibited signalling (green points) were recorded. All points are the mean of 
quadruplicate measurements.
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Figure 4.3. Exam ple of W ild Type Basal and  M axim al Signalling
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Example of a typical ACh stimulated dose response curve for WT Mi mAChR 
showing maximal and basal signalling. Assays were performed on viable COS-7 
cells grown in media alone and PI assay was conducted according to the 
protocol in methods 2.14. WT ACh stimulated Emax = 4452±47.8 dpm, Basal = 
1144±17.3 dpm,. pECso = 7.20±0.05, nH = 1.10±0.09. Basal signalling activity 
was inhibited by increasing concentrations of atropine. Basal signalling was 
reduced from 1176±39.2 dpm to 761.8±5.3 dpm, pICso = 8.25±0.02. All points 
are the mean of quadruplicate measurements and are shown ±S.E.M
•  WT-ACh Stimulation
•  W T- + Atropine
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The established laboratory protocol uses 15pg of DNA. The experiment shown in figure 
4.2 is in reasonable agreement with this. COS-7 cells transfected with WT Mi mAChR 
plasmid DNA generally gave excellent phosphoinositide responses when stimulated 
with acetylcholine. For a typical example of a Mi mAChR wild type ACh dose response 
curve see figure 4.3. There was however, a large degree of variability seen in the basal 
to maximal signalling ratios for both wild type and mutants, even within individual 
experiments. However, there was a positive correlation between WT basal and maximal 
signalling values as shown in figure 4.4, suggesting that variation in transfection 
efficiency may account for the variability of basal and Emax values. This made 
calculating mutant stimulation as a percentage of wild type stimulation problematic. The 
variability of wild type constitutive activity exacerbated the problem of analysis. To 
address these inconsistencies in mutant and wild type basal and maximum signalling the 
following approach was used to better interpret the actual data.
Mutant Basal and Emax values were determined as ratios to contemporaneous wild type 
control values, where RB = ratio of basal values and RE = ratio of Emax values 
Thus;
BasaljYT
_ BasalMut and Rfi = E max Mut 
Emaxjyr
Taking the mean of individual separately determined values
Values were then corrected to account for the null signalling background
Thus, for example
Basal * Mut + Null _ E max*^/Wf +Null
  = ---------------------------------------
Basal *WT+Null E m a x WT+Null
where Basal* Mut and Basal* WT are the intrinsic signalling activity of the mutant and
wild type receptors.
So, it is easy to show that;
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Basal* Mut = RB{X + Null ) Null
Since,
Basal *WT Basal *jyr Basal
Nul1 =0.58
Basal *WT
Basal* Mut = 158 j?g_ 058 
Basal *WT
As an example for W164A
Basal Mut Emax Mut
Basal jjrp E max
Mean RB from 4 separate experiments = 0.481 
Mean RE from 4 separate experiments = 0.883
Basal* Mut = j _5 8x0,4 81 _ 0-58 = 0 18
Basal *wr
Emax.*Mut = j 084xo.883- 0.084 = 0.873
E max*jyT
Thus W164 basal activity ratio relative to WT = 0.18±0.20 (virtually no basal activity) 
And a maximum signalling activity ratio relative to WT = 0.87±0.
Basal and Emax values for all mutants are shown in table 4.1.
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T able 4.1 Sum m ary  of Phosphoinositide Signalling P a ram ete rs: All 
M utan ts
Mutant n pECso Emax MutEm axjyj1
BasalMut
Basal]YT
Wild Type 29 7.03±0.1 1.0 1.0
E2 Loop Muts
W164A 4 5.61±0.04a 0.87±0.5 0.18±0.2*
Q165A 3 6.53±0.20b 1.60±0.4 0.43±0.3
G169A 3 6.49±0.02a 1.30±0.2 0.30±0.03*
E170A 3 6.99±0.20 1.08±0.4 0.89±0.04
R171A 6 6.31±0.10a 0.91±0.4 0.69±0.1
T172A 3 6 .71± 0 .05b 1.33±0.3 0.64±0.08
Q177A 5 6.32±0.10a 0.96±0.30 0.65±0.10
Y179A 3 6.39±0.20 1.23±0.40 0.75±0.10
I180A 3 6 .29± 0 .05a 1.39±0.60 0.44±0.10*
Q181A 3 6.86±0.20 1.24±0.40 1.41±0.50
F182A 4 6.90±0.04 1.22±0.30 1.06±0.30
S184A 3 5.84±0.20 0.86±0.20 0.07±0.10*
Cys Muts
C98A 3 3 .56± 0 .10a 0.40±0.06f 0.00*
C178A 4 3.51± 0 .03a 0.57±0.02f 0.73±0.40
C178N 3 3.62± 0 .10a 0.41±0.05f 0.00*
C98A/C178A 3 3 .54± 0 .10a 0.65±0.02f 0.22±0.10*
TM Muts
D99A 8 5.13±0.01 1.09±0.10 1.01±0.06
F197A 3 5 .54± 0 .10a 1.67±0.50 1.70±0.30
W378A 3 4 .51± 0 .10a 0.78±0.10 0.078±0.10*
§,See Text for details and exam ple calculations
pECso statistical significance ap<0.01, bp<0.05 w ith respect to W T values 
* Basal levels o f  signalling clearly reduced relative to W T in all comparisons (p<0.05) 
f  Emax clearly reduced relative to W T in all comparisons (p<0.05)
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Figure 4.4.. C orrela tion  of W ild Type Basal and  E m ax Values
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The graph correlates all 29 recorded Basal and Em ax signalling activity values for the 
wild type Mi m A ChR The trendline is fitted to the equation y = 0.2177x which gives an 
R2 value = 0.4611. Correlation o f  Basal and Em ax values could be explained by the 
variation in plasm id transfection. A correlation betw een Basal and Em ax signalling 
activity would support this and the graph shows a correlation factor o f  0.68, suggesting 
that there is a correlation betw een Basal and Em ax signalling activity.
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4.2.2. £2 Loop Mutants-Signalling
Table 4.1 shows pECso and basal and maximum signalling activity relative to wild type 
for all E2 loop and cysteine and TM mutants. Generally all E2 loop (except C l78) 
mutants gave a maximum signalling response to ACh stimulation close to maximum 
wild type levels. No E2 loop mutants showed significantly reduced maximum signalling 
activity. Three E2 loop mutants showed significantly reduced basal signalling W164A 
(18%), G169A (30%) and S184A (7%). The ratio of Q181A basal to WT basal was 
1.41±0.50 and possibly indicates a constitutively active mutant. The Q181A mutant 
gave large increases in basal activity with respect to the co-transfected wild type in two 
out of three experiments, hence the relatively large S.E.M
The concentration of acetylcholine required to elicit 50% of the maximal signal from 
the wild type receptor was 93 pM (pECso 7.03). Broadly speaking, pECso values for the 
E2 loop mutants were between 6.0 and 7.0 with a couple of exceptions. W164A gave a 
pECso value of 5.61 and S184A gave a pECso of 5.84 which is a 20-30 fold reduction in 
potency relative to WT values. Other mutations which significantly reduced pECso 
values were R171A, Q177A and I180A which all reduced ACh signalling potency by 
~6-fold relative to WT. G169A and Q165A also showed significantly reduced pECso 
values of 4-fold relative to WT (p<0.05). Representative signalling data for E2 loop 
mutants is shown in figure 4.5
4.2.3. Cysteine Mutants-Signalling
All cysteine mutants showed consistent and statistically significant reductions in 
maximum signalling activity ratios compared to wild type. Generally, maximum 
signalling of the cysteine mutants was half that of WT receptors. Apart from C178A 
where inconsistency was observed, basal signalling of the cysteine mutants was also 
reduced to background signalling levels. Although in all experiments for C178A basal 
signalling values were low, corresponding wild type basal values were also unusually
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low in two out of three experiments. Since all basal levels for C l78A were at or below 
null transfection dpm values it is assumed that no basal signalling was apparent for 
C178A. All cysteine mutants produced pECso values >2500-fold reduced from WT 
pEC50 values that is, pECso values for C98A = 3.56, for C178A =3.51, C178N = 3.62 
and C98A/C178A = 3.54. Representative signalling data for cysteine mutants is shown 
in figure 4.6 (b).
4.2.4. TM Domain Mutants-Signalling
Maximum signalling activity ratios compared to wild type were not reduced by D99A, 
F197A or W378A mutants The apparent increase in basal signalling activity for F197A 
(basal ratio to WT = 1.70±0.30) is a reflection of the unusually low WT basal signalling 
in three experiments and in reality the basal signalling of F I97A is not believed to be 
significantly different from WT levels. However, W378A did reduce basal signalling 
activity to null background levels and basal activity was statistically different from wild 
type for this mutant. In general, pECso values were reduced more dramatically than for 
the E2 loop mutants. D99A reduced the pECso for ACh to 5.13, a 90-fold reduction in 
potency from WT. F197A reduced the pEC5o for ACh to 5.54, a 34-fold reduction and 
W378 reduced pECso for ACh to 4.51, a 370-fold reduction from wild type values. 
Representative signalling data for TM domain mutants is shown in figure 4.6 (a).
4.2.5 Comparison of Mutant Signalling Profiles
Figure 4.7 below highlight four mutations that have shown different ACh signalling 
profiles during the present study and indicate which mutations do or do not have a 
deleterious effect on signalling efficacy. E170A is an example of a mutation that does 
not reduce potency or ACh affinity compared to wild type. I180A is a mutation that 
reduced both agonist affinity (~8-fold) and as a consequence signalling potency (~6- 
fold). Q177A is an example of a mutation that did not significantly reduce ACh affinity
157
Chapter 4.
compared to WT but did show a significant (p«0.01) reduction in potency (5-fold) and 
indicates that this mutation may also show a reduction in efficacy. C l78A is an example 
of a mutation that significantly reduced both agonist affinity (~60-fold) and caused very 
large reductions in ACh signalling potency (~3000-fold). The next section evaluates the 
efficacy of ACh signalling for all mutants.
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Figure 4.5. R epresentative Phosphinositide Dose Response C urves fo r 
E2 Loop M utan ts
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Representative acetylcholine dose response curves for E2 Loop mutants. COS-7 cells 
were transfected with 15pg of WT or mutant plasmid DNA and stimulated with 
increasing concentration of acetylcholine. Data points are mean of quadruplicate 
readings ±S.E.M and represent data from at least three independent experiments. 
Atropine at 10‘6M provided background counts.
a. Transfected using rat Mi containing plasmid WT pECso = 7.26±0.04, Emax = 2882, 
Basal = 474.9; E170A pEC50 = 6.86±0.05, Emax = 5364, Basal = 428.8; R171A pEC50 
= 6.35±0.05, Emax = 2652, Basal = 319.8; Q177A pEC50 = 6.77±0.07, Emax = 3319, 
Basal = 357.4.
b. Transfected using human Mi containing plasmid WT pECso = 7.55±0.07, Rmax = 
2882, Basal = 474.9; G169A pEC50 = 6.65±0.07, Emax = 1563, Basal = 217.0; T172A 
pECso = 6.77±0.05, Emax = 2661, Basal = 400.3; S184A pECso = 5.73±0.07, Emax = 
1770, Basal = 389.8. Full curves are fitted to the four parameter logistic function. All 
Slope values » 1
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Figure 4.6. R epresentative Phosphoinositide Dose Response C urves fo r 
Cysteine and  TM  Dom ain M utan ts
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Representative acetylcholine dose response curves for E2 Loop mutants. COS-7 cells 
were transfected with 15pg of WT or mutant plasmid DNA and stimulated with 
increasing concentration of acetylcholine. Data points are mean of quadruplicate 
readings ±S.E.M and represent data from at least three independent experiments. 
Atropine at 10'6M provided background counts.
a. TM Domain mutants WT(rMi) pECso = 7.36±0.04, Emax = 3111, Basal = 452.9; 
D99A pECso = 4.44±0.05, Emax = 2835, Basal = 309.1; F197A pEC50 = 5.53±0.05, 
Emax = 3106, Basal = 369.1; W378A pEC50 = 4.70±0.04, Emax = 3324, Basal = 217.2.
b. Cysteine Mutants WT(rMj) pECso = 7.30±0.03, Emax = 4678, Basal = 1031; C98A 
pEC50 = 3.75±0.02, Emax = 1859, Basal = 182.9; C178A pEC50 = 3.51±0.01, Emax = 
2657, Basal = 208.4; C98A/C178A pEC50 = 3.40±0.07, Emax = 1549, Basal = 470.2. 
Full curves are fitted to the four parameter logistic function. All Slope values » 1
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Figure 4.7. C om parison of Acetylcholine B inding C urves and  Dose 
Response C urves fo r E2 Loop M utan ts
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ACh binding and PI Assays performed as described in Methods 2.12 and 2.14 
respectively. ACh binding curves (blue) are compared with ACh dose response curves 
(red) for WT controls (dashed line) and mutants (solid line).
a. E170A is an example of a mutation that changes neither the ACh affinity constant or 
the potency of the receptor compared to WT. b. I180A is an example of a mutantion that 
reduces both the affinity of ACh and as a consequence reduces ACh signalling potency,
c. Q177A is an example of a mutation that does not reduce ACh affinity but does reduce 
the potency of the receptor compared to WT, indicative of a reduction in efficacy, d. 
C178A is an example of a mutation that reduces both ACh affinity and ACh potency 
relative to WT.
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4.2.6. Calculations of signalling efficacy
Effects of mutations on agonist signalling efficacy can be estimated by using equations 
derived from the extended ternary complex model, (see Materials and Methods figure
2.3). It is assumed that the signal generated is proportional to the sum of receptor/G- 
protein and agonist/receptor/G-protein complexes. These equations apply when the 
effective concentration of receptor is greater than the effective concentration of G- 
protein. i.e. when the ratio of receptor to G-protein is >1. Taking into account relative 
levels of mutant expression to wild type expression a measure of agonist signalling 
efficacy can be calculated using the following equation
Ca = (Kact / (Kbin(l-Basal)) - 1 )  / Rt (when Emax ~1)
Alternatively, when Emax is significantly less than 1 e.g. for a partial agonist or a 
mutation that reduces maximum signalling the following equation is used to determine 
efficacy.
Ca = (Emax / (1- Emax)) /R t 
Where Kact is equal to the I/EC50 value, i.e. the effective potency of an agonist at a 
particular receptor and Kbin is equal to the affinity constant of the agonist at the same 
receptor. The values of R t in this equation are the estimated functional ratios of 
receptor:G-protein. Experiments in which this ratio has been deduced by blockade of 
the receptor with the irreversible antagonist PrBCM (Lu et al., 1997b) have allowed us 
to estimate Rt = 20 for the wild type receptor which is over expressed in COS-7 cells. 
Simply, efficacy values (eA) are a measure of how effectively agonist occupied receptor 
assemblies can promote G-protein binding to form a ternary complex that subsequently 
catalyses GDP-GTP (measured by the rate constant Kcat) exchange to elicit a 
transducable signal.
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Efficacy values obtained for all mutants in this study are shown in table 4.2 below. A 
good indication of a mutant that reduces agonist efficacy is one that reduces the pECso 
of an agonist but does not significantly reduce the agonist affinity constant as seen for 
the Q177A mutant.
4.2.7. E2 Loop Mutants-Efficacy
Most of the E2 loop mutants signalled with an efficacy comparable to wild type. 
Notable reductions in efficacy (<10-fold) were observed for W164A (7-fold) and 
Q177A (5-fold). Larger reductions in efficacy were seen for Q181A (11-fold) and 
S184A (17-fold). Q181A is a particularly interesting mutant since it increases ACh 
affinity (5-fold), does not significantly affect signalling potency but does reduce ACh 
signalling efficacy.
4.2.8. Cysteine Mutants-Effiacy
Substituting the cysteine side chains with alanine had greater effects on efficacy. The 
double cysteine mutation C98A/C178A reduced efficacy 48-fold whereas the single 
cysteine mutant C178A reduced efficacy of G-protein coupling by 8-fold. The C178N 
mutant reduced efficacy by 15-fold. Only one site (low affinity site) could account for 
the signalling efficacy of the C98A mutant. However, taking into account reduced 
expression and reduced ACh affinity at the low affinity site, C98A showed a signalling 
efficacy close to the WT value i.e. log eAmut / eAWt was 0.21. The efficacy value for 
C98A is open to question since it does not obey the equation shown above, because the 
recorded Kbin value is greater than the value for the high affinity site. Thus, it is not 
possible in terms of the ternary complex model to estimate an efficacy value for the 
high affinity site proposed to exist for the population of C98A mutant receptors. If the 
alternative equation used for measuring signal efficacy, based on the Emax of C98A, is 
applied, then C98A reduces signalling efficacy to much the same extent as the other 
cysteine mutants. If however the low affinity site is actually the site responsible for 
signalling then the signalling efficacy for C98A is much higher and shows no difference
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from WT efficacy values. Figure 4.8 below shows that the high affinity site can not be 
responsible for signalling since the affinity constant of the high affinity site is greater 
than the pECso.
4.2.9. TM Domain Mutants-Efficacy
D99A had no effect on ACh stimulated signalling efficacy, whereas F197A and W378A 
reduced efficacy more significantly by 12 and 13-fold respectively.
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Table 4.2. Sum m ary  of Functional D ata fo r all M utan ts
Rt pECso pKa eA
e A m u t
e A W T
Wild Type 2 0 7.03 5.00 5.31
E2 Loop Mutants
W164A 17.5 5.61 4.43 0.81 -0.82
Q165A 12.3 6.53 5.33 1.28 -0.62
G169A 12.3 6.49 4.61 6.17 0.07
E170A 14.4 6.99 5.19 4.31 -0.09
R171A 14.0 6.31 4.17 9.79 0.27
T172A 22.5 6.71 5.13 1.69 -0.50
Q177A 15.4 6.34 5.14 1 . 0 0 -0.73
Y179A 18.7 6.39 4.75 2.28 -0.37
1180A 2 0 . 8 6.29 4.35 4.14 -0 . 1 1
Q181A 28.6 6 . 8 6 5.68 0.49 -1.03
F182A 1 2 . 6 6.90 5.08 3.75 -0.15
SI 84 A 30.0 5.84 4.87 0.28 -1.23
Cysteine Mutants
C98A(low) 2.43 3.56 2.43 5.13 -0.01
C98A(high) 2.43 3.56 4.16 0.30* -1.25*
C178A 3.08 3.51 3.18 0.55 -0.9
C178N 10.3 3.62 2.94 037 -1.15
C98A/C178A 16.7 3.54 3.10 0 . 1 1 -1 . 6 8
TM Domain Mutants
D99A 2.5 5.13 3.65 2.25 -0.32
F197A| 11.3 5.54 4.76 0.44 -1.08
W378A 2 2 . 2 4.51 3.86 0.40 -1 . 1 2
♦Calculated using alternative eA equation. eA=(Emax / 1-Emax) x 1/Rt
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Figure 4.8. C om parison of A Ch B inding C urve (2-Site M odel) and  
Dose Response C urve for C98A
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The graph illustrates the 2-site fit ACh binding curve of C98A in comparison to the 
dose response curve for the same mutant. The figure highlights the fact that it cannot be 
the high affinity population of C98A receptors responsible for the ACh induced 
signalling activity since the pKn is greater than the mean pECso value. Thus the low 
affinity (pKl) site must be responsible for signalling activity. Therefore, an efficacy 
calculation could not be made for the high affinity population of C98A mutants. pECso 
= 3.58±0.05. pKn = 5.02±0.002, pKl = 2.13±0.002. Fraction of high affinity sites = 
0.46.
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4.3 Discussion and Conclusions
One of the problems interpreting the functional data stemmed from the fact that there 
was a large degree of variation in basal and maximal signalling between each 
experiment. Correlation of the basal activity with the Emax (figure 4.3) but not with the 
EC50 values (data not shown) of wild type receptors is consistent with variation in the 
number of responsive cells per well in the assay. It is also consistent with variation in 
the specific activity of PIP2 labelling in the cells. However, it is not consistent with the 
variation in the concentration of receptors expressed or major variations in the G-protein 
concentrations. An increase in the concentration of receptors would be expected to 
affect the EC50 of the ACh induced response by showing increases in potency. Variation 
in G-protein content must also affect potency. No substantial variations in potency were 
observed for the wild type receptors which gave a fairly consistent pECso value of 7.00. 
Thus it must be concluded that inefficiencies of transfection, leading to variability of the 
number of responsive cells or inefficient labelling of PIP2 were responsible for the 
variations in basal and maximum wild type signalling.
4.3.1. £2 Loop Mutants
Summary potency and efficacy data for all E2 loop mutants are shown in figure 4.9 
(page 171). Three mutations, G169A, E170A and F I82 had very little effect (<3-fold) 
on ACh affinity or signalling efficacy and may be regarded as null mutations. 
Furthermore, these mutations did not significantly reduce expression, basal and 
maximal signalling or ACh potency. Therefore, it is the conclusion of this author that 
the native residues G169, E170 and F182 behave like filler residues that appear to have 
no particular function in the Mi mAChR. By analogy, since G169 and F I82 but not 
E l70 are conserved in the other 5 mAChR sub-types, the corresponding residues in the 
other sub types may also be non-functioning filler residues. It may have been better to 
substitute G169 with a residue other than alanine, since alanine and glycine are both
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small amino acids and thus alanine substitution of G169 may not invoke significant
differences in phenotype. F182A did have a small effect on NMS affinity but does not
appear to be important for the binding of ACh or ligand transduction.
Two E2 loop mutations, R171A and I180A significantly reduced ACh affinity and 
potency but did not reduce signalling efficacy or seem to have any effect on basal and 
maximum levels of signalling. These characteristic are consistent with native residues 
that are important for ligand interaction or ligand anchoring. If 1180 is part of the p4 
sheet that dives down into the transmembrane binding pocket, analogous to the 1184 
residue in the D2 dopamine receptor (Shi and Javitch, 2004), it is conceivable that it 
does play some role in the stabilisation of ACh in the binding pocket via a second shell 
interaction. The side chain of R171 appears in the homology model of the Mi mAChR 
to protrude in to the extracellular space and it is difficult to imagine R171 being able to 
make contact with ACh in the binding pocket. The data however seems to imply that 
R171 is in some way involved in the stabilisation of ACh in the binding site. It is 
possible that the homology model needs some revision, perhaps re-orientating R171 so 
that it is positioned so as to face into the binding site. The fact that both these residues 
are highly conserved amongst all mAChR subtypes supports the theory that these 
residues have a role to play in the binding of ACh, although they are not critical contact 
residues.
During this study it was observed that the mutations W164A and SI84A reduced 
signalling efficacy more than any reductions in ACh affinity. In fact both mutations had 
very small (<4-fold) effects on the binding of ACh and yet reduced signalling potency 
26 and 15-fold, translating into reductions of signalling efficacy of 7-fold and 17-fold 
respectively. This was in conjunction with a strong reduction of basal signalling activity 
compared to WT. W164 and SI84 are highly conserved residues in mAChRs. In
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rhodopsin, W175 is homologous to W164 at the N-terminal end of the E2 loop and a 
threonine residue, T193, also with a hydroxyl group in its side chain is analagous to 
SI 84 at the C-terminal end of the E2 loop. The characteristics of W164A and S184A are 
consistent with activator residues. The fact that these mutations cause the loss of basal 
signalling and reduce potency and efficacy, but do not affect expression levels or ACh 
affinity, suggests that they are intrinsic in the activation process of the receptor. The fact 
that the analogous residues in rhodopsin can form a hydrogen bond network with 
proline residues at the top of TM4 and TM5 suggests that these residues may be 
involved in the conformational reorganisation of the receptor upon ACh-induced 
activation. Thus it seems likely that W164 and SI84 are also part of a H-bonding 
network important for the active state of the receptor. It would be interesting to see if 
mutation of SI84 to threonine would re-instate wild type signalling activity. Perhaps to 
a lesser extent Q165, Q177 and Y179 may also be regarded as activator residues since 
they share similar characteristics of loss of signalling potency and efficacy, but have 
less of an affect on basal signalling.
Q181A showed high basal activity. The substitution of Q181 with alanine had the effect 
of unleashing the receptor from its predominantly inactive state, causing it to signal at 
>150% of WT basal levels in the absence of any ACh stimulation. However, this effect 
was observed in only two out of three experiments and so unfortunately, definitive 
statements about this mutation cannot be made and this accounts for the large standard 
error in the recorded mean Emax (1.41±0.50) seen in table 4.1. Perhaps poor 
transfection in one of the assays may account for the inconsistency. Nevertheless, Q181 
is also completely conserved amongst the muscarinic receptor sub-types and therefore is 
likely to be an important residue, in this case, for maintenance of the inactive state. Klco 
and colleagues (Klco et al. 2005), using random saturation mutagenesis of the E2 loop 
of the C5a receptor (similar in length to the E2 loop of the Mi receptor), showed that
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-80% of mutants displayed constitutive activity, implicating the E2 loop as a stabiliser 
of the inactive conformation of the receptor and suggesting that this may be the case for 
other GPCRs. This theory cannot be corroborated, since the majority of E2 loop mutants 
analysed in the present study did not show any apparent increase in constitutive activity 
and this may reflect differences in the structure of the E2 loop of mAChRs and C5a 
receptors. Furthermore, in the Klco study (Klco et al., 2005) multiple substitutions were 
of E2 loop residues were made whereas in the present study only point mutants were 
studied. However, in the case of the Q181 residue there may well be a case for 
implicating this particular residue as important for the preservation of the inactive 
ground state of the Mi receptor. The mechanism by which Q181 is able to do this is 
open to speculation and may require a revision of the Mi homology model to determine 
possible ground state contacts made byQ181. Q181A fulfils two of the three accepted 
requirements of a constitutively active receptor, it increases agonist affinity (5-fold) and 
it increases basal activity (300%) but surprisingly the AR complex couples less 
efficiently to G-protein, as the 5-fold reduction in agonist signalling efficacy indicates. 
Q181 lies at the C-terminal end of the E2 loop beyond the proposed (3-4 sheet close to 
the top of TM5 where it may serve to constrain a reorganisation of the E2 loop required 
for activation by forming a hydrogen bonding network with surrounding residues. The 
raised basal activity seen for Q181A resembles similar increases observed for S120A 
and LI 16 (Lu and Hulme, 1999a) and may also indicate a selective destabilisation of the 
inactive ground state due to this mutation. It may be suggested therefore that the native 
Q181 residue may act as a constraining residue in the wild type receptor. Further 
functional analysis of Q181A is required to verify the points made above.
Receptor constitutive activity, whereby a receptor is functionally active in the absence 
of an agonist, was a component of original receptor theory before modem biochemical 
and cloning techniques substantiated the premise (Costa and Cotecchia, 2005). It is now
170
Chapter 4.
an accepted phenomenon. With relevance to this study, constitutive activity of mutant 
muscarinic receptors has been described previously by Jakubik et al and Spalding et al 
(Jakubik et al., 1995; Spalding and Burstein, 2001) showing that M 1-M4  subtypes were 
constitutively active in CHO cell lines and that the basal activity could be reversed by 
atropine binding, which switched the receptor back to an inactive conformation. 
Similarly, inhibition of WT basal activity was achieved in the present study (see figure
4.3) by binding of increasing concentrations of the antagonist atropine, proving that the 
constitutive activity seen was a real phenomenon. Spalding and Burstein (Spalding and 
Burstein, 2001) also showed that mutations in TM 3 and TM6 and the 2nd intracellular 
loop all increased constitutive activity and that ~ 20-30% of those mutations in the 2nd 
intracellular loop and TM6 respectively raised constitutive activity up to 30% of the 
total cellular response. Constitutive activity occurs because receptors can exist in 
spontaneous equilibrium between the active and inactive conformation in the absence of 
ligand. Assuming the G-protein preferentially interacts with the active conformation, it 
can be imagined that an increase in the concentration of G-protein in the cell for 
whatever reason could lead to an increase in basal activity. This finding was confirmed 
by Burstein et al (Burstein et al., 1997), where they showed that over expression of the 
Gq class of G-proteins did indeed raise basal activity, since increasing the G-protein 
concentration allows more interactions with receptors that spontaneously assume the 
active conformation. Thus, it can be seen that constitutive basal activity of the Mi wild 
type receptor and indeed most other GPCRs, is a well defined and accepted component 
of receptor function. The subject of GPCR constitutive activity is concisely reviewed by 
Millligan (Milligan, 2003).
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Figure 4.9 Sum m ary  of C hanges in ACh Signalling Potency and  
Efficacy for E2 loop M utan ts
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Overview of the effects of E2 loop mutations on ACh signalling potency (a) (EC5 0) and 
efficacy (b). Bars represent the log reduction in potency or efficacy compared to wild 
type and are given with error bars (where applicable) indicating S.E.M and statistical 
significance where;* p = <0.05 and ** p = <0.01 ***p<0.001 with respect to WT 
values.
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4.3.2 Cysteine Mutants
Summary data for potency and efficacy for the cysteine residues is shown in figure 4.10 
(page 174). It appears that the removal of the conserved disulphide bond has dramatic 
consequences for the binding of ACh. All the cysteine mutants showed severely reduced 
ACh affinity and greatly reduced basal activity and signalling potency. This is 
consistent with a major perturbation of the transmembrane binding cavity caused by the 
loss of the stabilising disulphide bond. During the course of evolution the mAChRs 
have been selected to bind the relatively small ACh molecule. The fact that ACh is a 
small molecule means that in order for it to bind effectively, it must make specific and 
direct contacts with particular residues. A larger molecule has the potential to make 
more contacts and the loss of some contacts may not disrupt its binding. However, ACh 
being a small molecule, has the potential to make less contacts, so that any perturbation 
of the binding site residues has a more dramatic effect on its binding. The effect of the 
cysteine mutations in general is comparable to the mutation of important TM domain 
residues such as Tyr 381 (Ward et al., 1999a) and Asn 414(Lu et al., 2001) and so must 
be regarded as highly significant to receptor activation. In addition to the losses of ACh 
affinity and potency the cysteine mutants C178A and C98A/C178A also reduced 
signalling efficacy by 10 and 50-fold respectively. This implies that not only is the 
disulphide bond important for the integrity of the transmembrane binding site it is also 
important for the efficient transduction of ACh induced signalling. Thus, C l78 may be 
characterised as a stabiliser residue and as a transducer residue important for the active 
conformation of the receptor.
As regards efficacy, C98A is a special case and is discussed separately below. The data 
supports the notion that the maintenance of the E2 loop structure is essential for Mi 
mAChR activation and that a disulphide bond between C98 and C l78 now seems 
unambiguous since there appears to be no additative effect of mutating both C98 and
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C l78 together, as comparded to the point mutants. Baneres et al (Baneres et al., 2005) 
have now provided direct evidence showing that removal of the S-S bond in the 5-HT4 
receptor produced a significantly different CD spectra of the E2 loop to that of the wild 
type receptor. Perturbation of the E2 loop structure caused by the disruption of the 
disulphide bond clearly has dramatic effects on the signalling efficiency and potency of 
the mACh receptor. The inability of the cysteine mutated E2 loop to facilitate the 
conformation changes required for the active state indicates the importance of the E2 
loop to a fully functional receptor. In terms of the ternary complex model mutation of 
the cysteine residues affects the conformation constant aK i.e. the change from the 
inactive ground state to the active conformation. It is surprising that the cysteine 
mutants can actually function at all, albeit at a much reduced level than that of the wild 
type receptor. It may have been expected that the cysteine mutants would completely 
abolish signalling as was seen for the D105A mutation (Lu and Hulme, 1999a). This 
proved not to be the case however with all three cysteine mutants signalling at more or 
less the same levels (see figure 4.6). Thus, removal of the disulphide bond perturbs the 
E2 loop structure and severely reduces signalling but does not abolish it, again 
supporting the idea that the E2 loop plays an important role in allowing the induction of 
the active conformation of the receptor.
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Figure 4.10. Sum m ary of Changes in A Ch Signalling Potency and  
Efficacy for Cysteine M utan ts
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Overview of the effects of cysteine mutations on ACh signalling potency (EC50) (a) and 
efficacy (b). Bars represent the log reduction in potency or efficacy compared to wild 
type and are given with error bars (where appropriare) indicating S.E.M and statistical 
significance where *** = p<0.001 with respect to wild type.
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4.3.3. The C98A Mutant is a Special Case
It has been shown in results Chapter 1 that the ACh binding curve for the C98A mutant 
is complex, showing the presence of two binding sites, a high affinity site and a low 
affinity site. The ternary complex model dictates that it must be the low affinity site that 
is responsible for activation. Figure 4.8 above illustrates the point. Since the pEC5o of 
the C98A mutant lies to the right of the high affinity ACh binding site it must be the 
low affinity site responsible for the observed activation. Therefore taking the mean 
value of the low ACh affinity site binding constant (pK = 2.43) and using this figure for 
the efficacy calculation the efficacy value (ca) for C98A turns out to be 5.13, practically 
the same as the wild type receptor. Accepting this logic, although ACh affinity at this 
site is reduced, this population of receptors is able to assume an active conformation on 
agonist binding and is able to effectively couple to G-protein and ellicit a response. The 
problem with this reasoning is that the existence of two binding sites has not been 
demonstrated in intact cells and therefore requires further investigation.
The existence of the two separate populations of binding sites apparent for C98A, could 
be explained by the formation of a non-native disulphide bond between the free C l78 
residue and other non disulphide bonded cysteines. The free cysteine could theoretically 
participate in S-S bonds either with free C l78 residues from adjacent receptors, 
effectively creating a dimer or a non-native disulphide bond could be created within the 
same receptor. The third extracellular loop of the Mi mAChR contains two cysteine 
residues at C391 and C394. Thus the possibility exists that different combinations of 
disulphide bonding could be created by the free C l78 residue. The existence of 
alternative S-S bonding is not unprecedented. Noda et al (Noda et al., 1994) performed 
a systematic mutagenesis study on the p2  adrenergic receptor, which contains three 
cysteine residues in the E2 loop (C l84, C l90 and C191) and one at the top of TM3 
(C l06), analogous to C98. By antagonist binding, DTT reduction and thermal stability
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studies they showed it was possible to create either high affinity sites or low affinity 
sites depending on which cysteine was mutated to alanine. They concluded that in the 
wild type p2 adrenergic receptor two S-S bonds are likely to exist, C106-C184 and 
C106-C191. So, it is possible that the C98A mutant in the Mi receptor allows the free 
C l78 residue to form disulphide bonds with the cysteine residues of the E3 loop thus 
creating a hybrid receptor with two binding sites with different agonist affinities. The 
formation of a dimeric receptor, whereby the free C l78 residue of one receptor forms a 
S-S bond with another free C l78 residue or even with the E3 loop cysteines of an 
adjacent receptor could also allow the creation of two binding sites. This possibility has 
been suggested by Zeng and Wess (Zeng and Wess, 1999) who were able to show 
through immunoblotting and systematic mutation of cysteine residues of the M3 
receptor that the receptor is capable of forming disulphide linked dimers and multimers 
as well as non-covalently linked dimers. It is suggested that these S-S bonds are formed 
during transit through the ER and Golgi bodies.
Our data suggests that it is the low affinity site that allows coupling to G-protein. 
Further investigation would be required to reach a more definitive conclusion as to 
which possible structure is responsible for the creation of a high and a low agonist 
affinity binding site. The same potential for the creation of two binding sites does not 
exist for the C l78A mutant because it is unlikely that the free C98 residue would be 
accessible to either the cysteines of the E3 loop or the analogous free C98 of an adjacent 
receptor, therefore negating the possibility of an anomalous S-S being formed. 
Similarly, removal of both cysteine residues would also exclude the possibility of 
extraneous S-S bonds being formed. There is no substantial evidence from the data that 
two binding sites exist for the C178A mutant, but the possibility that C178A also 
creates two populations of receptors with different agonist affinities, cannot be 
excluded.
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4.3.4. TM Domain Mutants
In the transmembrane domain, D99 seems to behave like a ligand anchor residue in that 
the D99A mutation significantly reduces ACh affinity and as a consequence potency, 
but it has little effect on ACh signalling efficacy or basal activity. This evidence may 
support the notion that D99 is part of a ligand access channel, anchoring the agonist to 
the receptor before translocation of the agonist to the transmembrane binding pocket. 
Once acetylcholine reaches the binding site a full signalling response is seen and the 
efficacy of signalling is very similar to wild type, only a ~2-fold reduction in eA. So, it 
can be imagined that substitution of the D99 residue with alanine hinders the initial 
contact of ACh with the receptor, thus requiring a higher concentration of ACh to 
activate the receptor, but once bound ACh is able to induce the conformational change 
required for activation, despite the loss of the D99 residue. Expression of D99A was 
also reduced significantly. Taken together these data suggest that D99 may play a dual 
role, as part of the supporting structure and as a ligand anchor residue.
F197A and W378A both reduced potency, 34-fold and 371-fold respectively and 
efficacy ~9-fold and -10-fold (see figures 4.6 and 4.11 and table 4.2). W378 displays 
good expression but reduced agonist affinity and potency and a reduction in efficacy, 
the hallmarks of a residue important for activation. Proposed to sit at the base of the 
binding pocket W378 is positioned towards the cytoplasmic end of TM6 , its side chain 
facing into the core of the receptor. W378 may be involved in an intra-molecular 
hydrogen bonding network, linking core regions beneath the binding pocket, the re­
organisation of which is required for activation. The analogous residue in rhodopsin is 
W265 which forms a water mediated H-bond with Y301 (Li et al., 2004), the conserved 
tyrosine residue in the NPXXY motif found in TM7. The outward movement of TM6  
and mobilization of TM7 are thought to occur on disruption of the hydrophobic latch 
structure by the closure of an aromatic cage around the compact tetra-methylammonium
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head group of ACh (Hulme. E.C et al, 2003). Both the H-bonding network and the 
hydrophobic latch structure are required to change for receptor activation. Thus, W378 
not only seems to be important for the binding of agonist, since the alanine mutant 
causes losses in ACh affinity (13-fold) but also crucial to receptor activation, qualifying 
this residue as a member of the ligand activator category as described in section 1 of this 
chapter (see figure 4.1). F197A on the other hand did not reduce ACh affinity 
significantly and is likely not to be a ligand activator. Thus it can be concluded that 
F I97 behaves like an activator residue, probably involved in the re-organisation of the 
TM helices upon receptor activation. W378 seems to behave like a ligand transducer 
residue involved in both ACh binding and in receptor activation and its phenotype 
resembles that of the important binding site residue Y381.
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Figure 4.11 Sum m ary  of C hanges in ACh Signalling Potency fo r TM  
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w ild type and are given w ith error bars (where appropriate) indicating S.E.M  and 
statistical significance where;* p = <0.05 and ** p = <0.01 ***p<0.001 with respect to 
w ild type.
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4.3.5. Summary
The majority of the E2 loop mutants had a relatively minor impact on both potency and 
signalling efficacy. Q177A may be important for the conformational realignment of the 
E2 loop for the activated receptor. Some evidence does exist that Q181A which showed 
an increase in basal activity compared to wild type, although more experiments are 
required. It is possible that this mutation created a constitutively active receptor. 
W164A and S184A both significantly reduced potency and efficacy. However, these 
mutations did not significantly reduce ACh affinity or expression levels and therefore 
are likely not to be important for the structural stability of the receptor. Both these 
residues seem to be more critical for the transduction of the activated conformation of 
the receptor into a signal. These residues may form part of a “connecting rod” 
analogous to the structure described by Baneres et al (Baneres et al., 2005) in the 5 -HT4 
receptor, that realigns the E2 loop upon agonist induced activation. Even more dramatic 
perturbations to the E2 loop structure were caused by the removal of the S-S bond 
between C98 and C l78, evidence for which was shown by the large reductions in ACh 
affinity, potency and efficacy, particularly by C l78A and C98A/C178A. The 
maintenance of the E2 loop structure is vital for the efficient activation of the Mi 
mAChR, because it probably maintains the transmembrane domains in the correct 
conformation required for consequent activation induced by the binding of ACh. The 
C98A mutant seems to be a special case in that it displays characteristics of having a 
high and a low affinity binding site, perhaps because of the non-native creation of S-S 
bonds either intra-molecular or with adjacent mutant receptors. Evidence provided for 
D99 is consistent with the theory that this residue is part of a ligand access channel. 
W378 is important both for ligand binding and activation, suggesting that it can be 
classified as a ligand activator residue. F I97, having little effect on ACh binding or 
potency but reducing efficacy, may participate in a supporting network of bonds.
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Chapter 5 
Kinetics of Ligand Binding
5.1 Introduction
In order to fully characterise the mutants discussed in this study and to better understand 
binding modalities it was decided to conduct experiments examining the kinetics of 3H- 
NMS and 3H-QNB binding. For each individual mutant of the E2 loop, the TM domain 
mutants and also a selection of important binding site mutants,Y106A, Y404A, Y408A 
and N382A a series of measurements were taken to determine differences in 
dissociation rate constants for 3H-NMS. However, the low 3H-NMS affinity of Y106A, 
Y404A, Y408A and N382A precluded them from 3H-NMS dissociation experiments. 
Only a few, although detailed, studies have previously described the dissociation and 
association kinetics of NMS (Waelbroeck et al., 1989; Waelbroeck et al. 1987) and 
QNB (Waelbroeck et al., 1991) at muscarinic receptors. Earlier evidence (Fields et al., 
1978b; Yamamura and Snyder, 1974) suggested that there is a rate limiting step for 
antagonist dissociation from muscarinic receptors, involving a two step process and 
receptor isomerization. Receptor isomerization, the change in receptor conformation 
induced by binding of a ligand in a two-step binding process, can be detected by 
biphasic dissociation kinetics. However for H-NMS these authors found no evidence of 
biphasic dissociation from muscarinic receptors, and concluded that H-NMS follows a 
simple monophasic model of dissociation. Walbroek et al (Waelbroeck et al., 1991) 
explained that the biphasic kinetics seen for H-QNB in the earlier experiments by 
Fields and Yamamura (Fields et al., 1978a), was probably due to the existence of 
several muscarinic subtypes present in the rat brain tissues used and the use of the (R) 
and (S) -  enantiomers of QNB. However, evidence provided by Galper et al (Galper et 
al., 1982) using chick embryo hearts (containing only M2 mACh receptors) showed that 
the dissociation kinetics of 3H-QNB was indeed biphasic and that receptor isomerization
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was the explanation for the biphasic kinetics observed. The binding kinetics of a ligand 
also depends on the stereoisomer of the ligand used. Since dissociation rate constants 
depend on the breaking of specific short range interactions between ligand and receptor, 
stereo-selectivity of the receptor is a key element determining the dissociation kinetics 
of the receptor. Thus it can easily be imagined that incorrect sub-optimal interactions 
would increase dissociation rate constants. Walbroek et al demonstrated that the binding 
kinetics of the (R) and (S) enantiomers of 3H-QNB were in fact different as are the 
antagonist dissociation kinetics between the muscarinic sub-types (Waelbroeck et al., 
1991). The (S) enantiomers of 3H-QNB dissociate faster than (R)-enantiomers this can 
be explained by the lower affinity of the (S) enantiomer for muscarinic receptors. The 
experiments described in the present study use the (R) (-) enantiomer of 3H-QNB and 
the (S)(-) enantiomer of NMS.
The rate constants of ligand binding to a receptor depend on the size, hydrophobicity 
and the general chemical characteristics of a ligand. The addition of extra chemical 
groups, such as methyl groups etc, all influence the rate at which the ligand can 
associate with the receptor. In the case of the Mi mAChR the maximum association rate 
constant of a ligand binding to the receptor is determined by the collision or diffusion 
limited rate constant which turns out to be 107M sec'1 (Abbott and Nelsestuen, 1988). 
Ligands are not observed to associate with the receptor at rates faster than the diffusion 
limited rates. This could be consistent with the existence of an evolutionarily tailored 
entrance channel. The simple model L + R <-► LR describes the binding of ligand to a 
receptor. In order for a receptor ligand complex to form or break down, reactants must 
acquire sufficient energy to surmount the activation energy barrier. The net formation of 
specific bonds between residues and the ligand upon binding contribute to the energy 
required to break the activation barrier for the reverse reaction. The mutation of those 
specific interacting residues should increase the rate of dissociation, since the removal
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of specific interactions reduces the amount of energy required for the reverse reaction. 
In contrast, mutation of residues that help maintain the structure of an entrance channel, 
or facilitate the the entry and exit of ligand molecules from the binding site might be 
expected to raise the activation barrier for both association and dissociation. The rate at 
which a ligand/drug dissociates from the orhosteric binding site has implications for the 
functional effectiveness of the receptor.
In recent years there has been considerable research on the effectiveness of allosteric 
modulators which can have profound effects on the association and more importantly on 
the dissociation rate constants of ligands from 7-TM receptors. For a full review of 
allosteric modulators see references (Birdsall and Lazareno, 2005; Christopoulos and 
Kenakin, 2002). With particular significance to this study, there is evidence from 
studies of the M2 mAChR that the EDGE sequence (LAGQ in Mi) of the E2 loop is 
involved in the binding of the allosteric modulator gallamine (Gnagey et al., 1999; 
Leppik et al., 1994) and a report by Ellis and Seidenburg also provided evidence that the 
E2 loop of the M2 mAChR sub-type was important for binding the allosteric ligand 
alcuronium. (Ellis and Seidenberg, 2000) Most allosteric modulators for muscarinic 
receptors, when bound, slow rates of 3H-NMS dissociation to immeasurably low levels, 
but other modulators have lesser effects. Obidoxime for example only weakly inhibits 
the dissociation of 3H-NMS from M2 receptors and furthermore interacts competitively 
at the same site as gallamine. Similarly, another allosteric modulator, 3,4,5 
trimethoxybenzoic acid 8-(dimethylamino) octyl ester (TMB-8) also has a weaker effect 
on the dissociation of 3H-ACh, also from M2 receptors (Gnagey and Ellis, 1996).
Allosterism at GPCRs is of growing interest, as the expanding literature on the subject 
testifies. Increasingly, allosteric modulators are being championed for their potential 
therapeutic benefit due to their inherent sub-type selectivity, their ability to enhance or
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“de-tune” the effectiveness of endogenous ligands, such as ACh and provide further 
selectivity for optimally active receptors due to local ACh depletion. (Birdsall, 2005). 
Although interesting, a detailed discussion of allosterism is beyond the scope of this 
study. However, considering that many allosteric modulators cause inhibition of ligand 
dissociation, it was considered interesting to try to identify which residues may be 
involved in the indigenous molecular mechanisms involved in ligand association to and 
dissociation from the Mi mAChR. Affinity constants are directly proportional to the 
ratio of the rates of association and dissociation of ligand and it would be expected 
therefore that mutations that decrease affinity constants are likely to also increase 
dissociation rate constants but not necessarily affect association rate constants. Thus 
dissociation experiments were conducted to try and corroborate and support affinity 
constant data collected for the mutants in this study.
In this study, dissociation assays were performed ( as described in Methods 2.15) and 
using the resulting data equations as described below were used to evaluate both the kon 
(association) and k<>ff (dissociation) rate constants, In nearly all cases the kon and koff 
were calculated using the simplest assumption of a 1-step binding process. The kinetics 
for radioligand binding have been predicted by the laws of mass action (Motulsky and 
Mahan, 1984). Using equations derived from the simple binding model (shown below) 
it is possible to determine dissociation and association rate constants, assuming that the 
radioligand (L) and the competing ligand (I) bind reversibly to the receptor (R) 
following the laws of mass action with kinetic constants (k).
k: k3
R + L ( "* RL R +1 ( > RI
k2 k4
The symbols ki and k3 relate to the association rate constants, whereas k2 and k4 relate 
to the dissociation rate constants. In the experiments described in Methods 2.15 an 
excess concentration of competing ligand (10'5 M atropine) is added to a mixture of pre-
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bound radioligand and receptor negating the forward re-association of R + L, so that 
only the dissociation reactions are possible. Since the receptor saturating concentration 
of atropine prevents the forward association of R with L, the reaction is essentially 
irreversible. Thus, as the atropine replaces radioligand in the receptor binding site over 
time (t), so [RL] declines exponentially and radioligand dissociates from the receptor 
(figure 5.1). k2 (dissociation rate constant) can be determined by the following equation: 
(omits the terms that describe the forward association of R+L).
where [RLo] is the amount of radioligand associated with receptor at the start of 
dissociation (addition of atropine),. In our experiments [RL] and [RLo] are measured as 
dpm, hence.......
dpm  = dprriQ.e ^  ..(lb)
This is the formula which is used by the fitting program in Sigma Plot to derive a value
for k2, the dissociation constant.The time it takes for 50% of radioligand to dissociate, is
given by........
t 1/2 =  0 .6 9 3 /k 2....(2).
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Figure 5.1. An Exam ple G rap h  R epresenting  the P a ram ete rs  O btained  
From  Dissociation E xperim en ts.
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T i m e  in Min
A graph showing radioligand dissociation time curves in the presence of excess 
competing ligand obtained as described in detail in the text. An increase in the 
dissociation rate constant causes an increase in the initial slope of the curve. The black 
symbols represent typical data obtained from experimental data fitted by a curve with k2 
= 0.0347 (t 1/2 = 20min). The blue symbols represent an increase in the dissociation rate 
constant fitted by k2 = 0.0867 (t in  =  8 min). [RLo] is the concentration of [3H]- 
Radioligand bound to receptor at time 0. For presentational purposes the data are 
normalised by division by RLo
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From the same initial model of ligand binding shown at the beginning of the chapter it 
is also possible to derive an expression describing the rate of ligand association.
So if
*1 V
R  +  L  ^ * R L
ki
Then
d[RL] = kl[R][ l ] -k2[RL\......(l)
dt
subject to the conservation equation [R] + [RL] = [Rt]
And if
[R] =  [Rt ] -  [RL] (2)
where [R] = free receptor concentration 
Substituting (2) into (1) gives...
= *,[Z]([i?r] -  [RL]) ~ k2[RL] (3)
at
Solution of this first order differential equation (not shown) yields an expression that 
describes the rate of formation of the receptor ligand complex.......
i _ e - W  + * 2 ) ' ) . . . . (4)
k][L\ + k 2 
Thus we arrive at the equation....
[RL] = M lW ( l _ e- ( k l [L] + k2 )t .....
K a [L] + 1
where Ka is the affinity constant (measured and known) and l-e‘(kl[L1+k2)t is the
exponential increase in [RL] over time. Increasing [L] increases the rate of [RL]
formation. Association rate constants (ki) can be determined experimentally by using
equation (5) to fit curves derived from experimental data, since Ka, [L], [Rt] and k2 are
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all known quantities. At low concentrations of ligand the rate of equilibration of the 
ligand is dependant upon the off rate. Effectively, at sub-saturating levels of ligand 
concentration only dissociation rates can be measured since there is not enough ligand 
to reach equilibrium quickly and this explains why an increase of ligand concentration 
increases the association rate. Hence, experimentally, at low ligand concentrations 
incubation times for saturation binding assays must be extended to ~5 times dissociation 
half times (~2hrs for NMS) to allow the system to reach equilibrium. From the simple 
one step model of binding it is shown that the affinity constant K a (or K d) is equal to 
the ratio of the rate of association (k\) and the rate of dissociation (hi) of the ligand....
k'yKD = -“-....(6)
*1
In terms of the rate of association (M'1 sec'1)
kl=KAJc2 (7)
Using this equation, estimates of association rate constants for our mutant and wild type 
receptors can be made, using just the data gained from dissociation assays. Still, it must 
be assumed that the binding and release of ligand is a monophasic process and that 
receptor isomerization on binding ligand is not an issue. This assumption may not be 
appropriate since evidence of a biphasic process has been reported by Walbroeck et al 
(Waelbroeck et al. 1989) and more recently and comprehensively by Jakubik et al 
(Jakubik et al., 2000). Nevertheless, a monophasic model of binding was assumed for 
the calculation of association rates in this study simply because time restrictions did not 
allow experimental association assays to be performed. Moreover, any significant 
differences observed for dissociation rate constants should be reflected in the calculated 
association rate constant values since k\ = K a  x  ki despite the reservations noted above. 
Of particular interest and a further aim of these assays is to provide supporting evidence 
that D99 is indeed part of an access channel.
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5.2 Results of Kinetic Studies
Tables 5.1 and 5.2 summarise the binding kinetic data for NMS and QNB for all 
mutants. All dissociation assays were performed on membranes from COS-7 cells 
transfected with the mutant or wild type rat Mi mAChR gene. Since rates of ligand 
dissociation are sensitive to changes in temperature all NMS dissociation assays were 
performed at between 28-30°C, unless otherwise stated, in quadruplicate. All data, 
without exception, for H-NMS dissociation was analysed and fitted to a single 
exponential model of dissociation. The mean rate of dissociation of 3H-NMS from wild 
type receptors was kj =0.066±0.001 min'1 ( 1.1 x 10'5 sec'1), which equates to a mean 
half time of dissociation of 10.5min from a range of half times between 8min and 
14min. The value for 3H-NMS dissociation rate constants from WT Mi receptors 
compares favourably with a ki value = 0.076±0.003 (ti/2 = 9.1 min) previously obtained 
by Lazereno and Birdsall (Lazareno and Birdsall, 1995). For wild type, the association 
rate constant was calculated as described above where k\ is equal to 8.02 x 106 M^sec'1 
(4.81 x 108 M 'W n '1).
For the E2 loop mutants small increases in dissociation rates were noticed compared to 
wild type. The most notable increases in the dissociation rate constants for NMS were 
seen for R171A ki = 0.1494 min'1 (ti/2 = 4.6min), I180A ki = 0.156 min'1 (ti/2 4.3min) 
and F182A ki = 0.156 min'1 (ti/2 4.4min). (see figure 5.2) This coincided with small 
reductions in the calculated association rate constants. For the cysteine mutants C178A 
and C178N dissociation rate constants were increased ki = 0.160 min'1 and 0.158 min'1 
respectively (ti/2 = ~4min), but for C98A a more pronounced increase in the dissociation 
rate was seen with fe = 0.313 min'1 (ti/2 ~2min). These increases in dissociation rate 
constants were accompanied by ~8-fold reductions in the association rate constants for 
all the cysteine mutants analysed.
190
__________________________________________________________ Chapter 5.
F igure 5.2 R epresentative 3H-N M S Dissociation C urves fo r E2 Loop 
C ysteine and  D99A M utan ts
a.
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Representative dissociation curves for E2 loop and cysteine mutants. Assays were 
performed on transfected COS-7 cells membranes and contained ~10pg/mL.of protein 
[3H-NMS] was 2 x 10*9M. Membranes and were equilibrated at 28°C-30°C with 3H- 
NMS for a minimum of 20 minutes before addition of 2 x 10'6M atropine dissociation 
mix.
a.E2 loop mutants. Wild type &2 = 0.0489 min'1, (ti/2 = 14min); Y179A k i =  0.0531 min 
\  (ti/2 = 13min); I180A &2 = 0.1049 min'^ti# = 7min). F182A &2 = 0.0942 min-l(ti/2 = 
7min).
b. Cysteine mutants. Wild type &2 = 0.0638 min'^ti# = 1 lmin). C98A &2 = 0.159 min" 
1 (ti/2 = 4min); D99A &2 = 0.058 min'^ti^ = llmin); C178A &2 = 0.158 min*1, (ti^ = 
4min). Full curves represent the fit to a single exponential model of ligand dissociation.
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There was no data recorded for the double cysteine mutant C98A/C178A. The large 
reduction in NMS affinity caused by the F197A and W378A mutations meant that 
dissociation experiments were not attempted. D99A gave a dissociation rate constant of 
0.088 min"1 (ti/2 = 7.9min). A slower association rate was calculated for D99A, k\ = 
9.46 x 10'5M"1sec-l which is a >8-fold reduction in the association rate constant 
compared to WT. The H-NMS dissociation data for all of the mutants studied is 
presented in table 5.1 below and representative dissociation curves are shown in figure 
5.2. For most of the E2 loop mutants calculated association rate constants were similar 
to wild type giving a range of k\ = 3.44-7.64 x 106M“1sec'1. There was no evidence of 
biphasic dissociation for NMS at either mutant or wild type receptors.
The rate of 3H-QNB dissociation from wild type receptors was substantially slower than 
that of 3H-NMS. All wild type data was fitted to a mono-exponential model of 
dissociation and all data for wild type fit the model well, with no evidence of biphasic 
dissociation. Wild type gave a mean half time of dissociation ki = 0.0019 min'1 or 3.16 
x 10'5sec'! (ti/2 = 5 hours 51 min), similar to Walbroeks reported value of 5.3 x lO^sec'1 
(Waelbroeck et al., 1991), with a corresponding association rate constant of 1.40 x 
106M'1sec'1, which is also in good agreement with the association rate constant for (R)- 
QNB reported by Walbroek et al (Waelbroeck et al., 1991) as 1.6 x 106M"1sec'1. The 
effect of the E2 loop mutations on 3H-QNB dissociation was varied with some mutant 
showing slow, WT-like dissociation kinetics whereas a few showed faster rates of 
dissociation (see figure 5.3). All data was fitted to the single exponential model of 
dissociation, except for C98A which better fitted the double exponential model of 
dissociation (see figure 5.4). E170A and Q177A had little effect on QNB dissociation 
with a mean half time of dissociation of ki = 0.002mm'1 (t|/2 = -5-6 hours for both 
mutants), similar to that of the wild type. This is in direct contrast to the mutated residue 
R171A which increased the rate of dissociation of QNB with a ki value = 0.013mm'1,
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equating to a mean half time of just 54 minutes. Less dramatic than R171A, Y179A,
1180A and F I82A also increased QNB dissociation rates ^  = 0.013, 0.006, 0.004 and
0.005 min'1 respectively (ti/2 = ~l-3 hours).
Initial 3H QNB dissociation experiments for C98A and C l78A using single exponential 
fits, failed to produce meaningful estimations of dissociation rate constants. This was 
due to the fact the more than 50% of the radio ligand had dissociated before the first 
time point (30min) was recorded. Thus it can only be stated that the half time of QNB 
dissociation for these mutants was less than 30 minutes. Since it was shown in Chapter 
3 that C98A had the potential to produce two separate populations of receptor, a more 
detailed dissociation experiment was performed and analysed using a double 
exponential fit to account for the possible biphasic nature of QNB dissociation from the 
cysteine mutants. In the detailed experiment where more time points over a shorter 
period of time were analysed and assessed using a double exponential model of 
dissociation, a better fit for the C98A and C l78A data was made. The fast component 
for C98A giving a kj = >0.40 min"1^  < 5 min) and the slow component gave a ki value 
= 0.007 min'1, (ti/2 = ~98min) the fast component was 31% of total sites (69% slow). 
For C178A the fast component was too fast to determine Xm <5 min and the slow 
component ki = 0.218 min'1 (ti/2 = -32 min) the fast component was 83% of total sites 
(17% slow). Figure 5.4 shows the comparison of mono and double exponential fits for 
3H-QNB dissociation at both C98A and C178A mutant receptors. The calculated 
association rate of QNB to WT receptors was 1.4 x 106M'1sec'1 which is ~ 10-fold 
slower than the diffusion limited rate constant of 1 x 107M-1sec'1. Calculated association 
rates for mutants of the E2 loop were in the range of 1.2 -  6.5 x 106M’1sec'1. Most 
interesting is the 6-fold increase in the calculated association rate constant for R171A 
(k\ = 6.1 x 106M'1sec'1) and the 5-fold increase in the association rate constant for 
F I82A (ki = 6.49 x l O ^ s e c '1).
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Figure 5.3. R epresentative 3H-ONB Dissociation C urves fo r E2 Loop 
M utan ts
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Representative dissociation curves for E2 loop mutants. Assays were performed on 
transfected COS-7 cells membranes and contained ~10pg/mL protein. [3H-QNB] was 3 
x 10'10M. Membranes were equilibrated with 3H-QNB at 28°C-30°C for minimum of 
240 minutes before addition of 10'5M unlabelled NMS dissociation mix.
a.E2 loop mutants with slow 3H-QNBdissociation kinetics: Wild Type = 0.0025min' 
\ t m  = ~5 hours); E170A k2 = 0.003 min'^ti# = -4  hours); I180A k i =  0.006 min ^ 1/2 = 
~2 hours); Q177A k j =  0.003 min'1^  = ~4 hours).
b. E2 loop mutants with fast 3H-QNB dissociation kinetics: Wild Type = ND. 
R171A k2 = 0.024 min'^ti# = 30 min); Y179A kj =  0.011 m in1 (ti/2 = -60 min).Full 
curves represent the fit to a single exponential model of ligand dissociation.ND= Not 
determined (<50% dissociation after 180 min(3hrs)
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Figure 5.4 C om parison  of Single and Double E xponential M odels to F it 
3H-Q NB Dissociation C urves fo r C98A and  C178A
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Representative dissociation curves for Cysteine mutants. Assays were performed on 
transfected COS-7 cells membranes and contained -lOpg protein. [3H-QNB] = 3 x 10' 
10M. Membranes were equilibrated with 3H-QNB at 28°C-30°C for minimum of 240 
minutes before addition of 10'5M unlabelled NMS dissociation mix.
a. Wild type = ND (<50% dissociation). C l78A using single exponential fit (solid 
blue line) k i =  >0.3 (>50% dissociation after 5 min) U/2 <5 min and double exponential 
fit (dotted blue line) fast k2 = ND(too fast) slow k2 = 0.0218 min'1(ti/2 = -32 min) ratio 
fast to slow = 4:1 (80%). slow component = 17% of total sites Span 1 (fast) = 38.7dpm, 
Span 2 (slow) = 8.1 dpm plateau = 9.7
b.Wild type (as above). C98A single exponential fit (dotted green line) k i = 0.184 min' 
1 (t 1/2 = <4 min) and double exponential fit (solid green line) fast k i = 0.40 min'!(ti/2 = 
1.7min) and slow k i = 0.007 min'^tj^ = 98min) slow component = 69% of total sites 
Span 1 (fast) = 17.5dpm, Span 2 (slow) = 39.3 dpm plateau = 9.7
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Figure 5.5, R epresentative 3H-ONB Dissociation C urves fo r TM  
D om ain M utan ts .
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Representative dissociation curves for TM Domain Mutants. Assays were performed on 
transfected COS-7 cells membranes and contained ~10pg/mL protein. [3H-QNB] was 3 
x 10'10M. Membranes were equilibrated with 3H-QNB at 28°C-30°C for minimum of 
240 minutes before addition of 10'5M unlabelled NMS dissociation mix
a. TM Domain mutants. Wild Type k i =  ND, Y408A kj = 0.033 min'‘(ti/2 = 21 min); 
F197A k i = 0.028 min'1(ti/2 = 25 min).
b. TM domain mutants. Wild Type k2 = ND, W378A ki = 0.111 min-l(ti/2 = 6 min); 
Y106A > 0.525 min'1^  = <2 min). Y404A = 0.036 min'1^  = 20 min). Full
curves represent the fit to a single exponential model of ligand dissociation. ND = Not 
Determined (<50% dissociation after 180 min (3hrs).
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The other E2 loop mutants gave association rate constants for 3H-QNB at values similar 
to WT, and between 5-10-fold slower than the rate constantfor 3H-NMS. Calculating 
association rate constants for C98A and C178A using the single exponential fit the 
dissociation rate constants was not possible since >50% of ligand had dissociated 
beforethe first time point i.e Xm < 5 min. The same is true of then fast component using 
the double exponential fit. However the calculated association rate for the slow 
component for C98A was 1.68 x 105 M'1 sec"1, and for the slow component of C l78A 
the association rate constant was calculated to be 6.70 x 105 M'1 sec'1.
Four additional Mi transmembrane binding site mutants (Y106A, Y404A, Y408A and 
N382A) were also assayed along with the other TM-domain mutants to evaluate the role 
of these endogenous transmembrane binding pocket residues in securing the antagonist 
in the central binding pocket. In fact, all mutations of residues in the TM domain 
involved in ligand binding drastically accelerated the rate of H-QNB dissociation with 
a range of ki values between 0.024 and 0.332 min'1 (ti/2 between 30 and 2 minutes). The 
most significant increase in the dissociation rate was effected by Y106A {ki = 0.332min' 
l) -170-fold faster than 3H-QNB dissociation from wild type receptors. W378A also 
caused a significant increase with a = 0.086mm'1 a -40-fold faster rate of QNB 
dissociation than from the WT receptor. The other TM domain mutants all increased 
QNB dissociation rates between 10 and 25-fold (ti# = between 15-30mins) (see figure 
5.5). A 3-fold reduction in calculated H-QNB association rates compared to wild type 
was found for D99A, (k\ = 5.1 x 105M'1sec'1). By contrast, the rest of the TM domain 
mutants increased the calculated association rate constants. Y404A (k\ = 1.18 x 107M' 
W 1), Y408A (k\ = 1.6 x l O V W 1) and F197A (ki = 7.31 x l O ^ s e c '1) and 
W378A (k\ = 5.98 x lO ^ ^sec '1) all increased the calculated association rate constants 
for QNB between 5-11-fold, approaching association rate constants at the diffusion 
limited rate.
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T able 5.1. S um m ary  of Dissociation R ate C onstants and  C alculated  
Association R ate C onstants fo r 3H-NM S
3h -n m s
Mutant n
Half
Time
(min)
Mean
k i
(m in1)
Log
k im u t lk iw t
Calculated
k \
(M^sec-1)
Wild Type 13 10.5 0.066±0.01 0 8.02E+06
E2 Loop Mutants
E170A 3 8.8 0.079±0.01 0.078 7.33E+06
R171A 3 4.7 0.149±0.04w 0.35 4.45E+06
Q177A 3 9.9 0.070±0.01 0.024 7.64E+06
Y179A 3 9.2 0.076±0.02 0.06 3.44E+06
1180 A 3 4.3 0.161±0.03w 0.39 7.68E+06
F182A 3 4.5 0.156±0.03"’ 0.37 6.13E+06
Cysteine Mutants
C98A 3 2.2 0.313=1=0.11™ 0.68 1.00E+06
C178A 3 4.3 0.160±0.01*" 0.38 1.77E+06
C178N 3 4.4 o.i58±o.o4"’ 0.38 9.61E+05
TM Domain Mutants
D99A 4 7.9 0.088±0.03 0.12 9.46E+05
W378A 1 37.5 0.019±nd ND 5.48E+03
Student T-Test (two-tailed equal variance) p<0.05*, p<0.01** and p<0.001, *** with 
respect to wild type values.
k i = dissociation rate constant, k\ = association rate constant
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T able 5.2. Sum m ary of D issociation R ate C onstants and C alculated  
A ssociation R ate C onstan ts fo r 3H-ONB
3h -q n b
Mutant n Half Time (min)
Mean
*2
(M^min1)
Log
A2mut/Ar2Wt
Calculated
( M 'W 1)
Wild Type 4 352 0.002±4.0E-04 0 1.40E+06
E2 Loop Mutants
E170A 3 288 0.002±6.0E-03 0.08 2.64E+06
R171A 3 54 0.013±0.006 0.82 6.10E+06
Q177A 3 350 0.002±0.0005 -0.02 1.23E+06
Y179A 3 119 0.006±0.002 0.47 2.41E+06
I180A 3 189 0.004±0.001 0.27 2.07E+06
F182A 2 154 0.005±0.001 0.36 6.49E+06
Cysteine Mutants
C98A* 3 <30 ND ND ND
C178A4: 3 <30 ND ND ND
C98A§(f) 1 <5.0 >0.40 2.30 ND
C98A§(s) 1 98 0.007 0.54 1.68E+05
C178A§(f) 1 <5.0 >0.30 ND ND
C178A§ (s) 1 32 0.0218 1.04 6.70E+05
TM Domain Mutants
D99A 3 288 0.002±3.0E-03 0.09 5.09E+05
Y106A 2 <5.0 >0.332±0.15* 2.23 7.63E+06
F197A 3 35.4 0.020±0.004** 1.00 7.31E+06
W378A 4 8.1 0.086±0.03* 1.64 5.98E+06
N382A 2 <5.0 0.139±0.09 1.85 1.25E+06
Y404A 2 24.1 0.029±0.006** 1.16 1.18E+07
Y408A 2 29.5 0.024±0.007* 1.08 1.60E+07
Student T-Test (two-tailed equal variance)
} Cys muts using single exponential fit
§ Cys muts detailed experiment using double exponential fit.(f) fast component and (s) 
slow component.
p<0.05*, p<0.01** and p<0.001***
hi = dissociation rate constant, k\ = association rate constant
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5.3 Discussion and Conclusions
The dissociation kinetics of N-methylscopolamine have been described previously for 
wild type M1-M4 mAChRs (Lazareno and Birdsall, 1995) where Mi, M3 and M4 give 
dissociation rate constants equal to ~0.08min'1 which equals a half time of dissociation 
of ~10 minutes. However, NMS dissociates more rapidly from M2 receptors ki = 
~0.4min 1 (ti/2 = ~2min) The dissociation rate constant for NMS at wild type receptors, 
were shown in this study to be in good agreement with previous data (Lazareno and 
Birdsall, 1995). Perturbations of the E2 loop caused by alanine substitutions had the 
general effect of accelerating the rate of 3H-NMS dissociation, although the increased 
acceleration was little more than 2-3-fold from WT rates of NMS dissociation. The 
increase in dissociation rate constants induced by R171A, I180A and F182A were 
significant (see table 5.1).
A plot of the changes in the dissociation rate constants compared to the changes in 
affinity constants (figure 5.6) suggests that the magnitude of the changes are consistent 
with a decrease in binding energy resulting from these mutations. Q177A, E l70A, 
I180A and F182A follow the ki versus K trendline for NMS. E170 and Q177 behave 
like null residues in terms of kinetic and equilibrium binding. This supports evidence in 
Chapter 4 that also suggested E l70 was a null residue in terms of activation. 1180 by 
contrast shows a phenotype consistent with its being ligand anchor residue for NMS, 
similar to its role in binding ACh as shown in Chapter 4.
Figure 5.7 shows the correlation between changes in dissociation rate constants and
changes in affinity constants for QNB. It can be seen that R171 and F I82 in the E2 loop
and Y106, F I97, W378, Y404 and Y408 all lay well below the 1:1 trendline. In Chapter
3 it was shown that R171A, F I82A and F197A did not significantly reduce QNB
binding affinity constants. Thus, the acceleration of QNB dissociation seen for these
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mutants implies that they cause perturbations in the structure of the receptor, decreasing 
receptor stability. The same is true for Y404A and Y408A. Y106A and W378A both 
significantly reduce the binding affinity of QNB, implicating them as ligand binding 
residues, but the larger effect on the QNB dissociation rate constant suggests that they 
also contribute to the structural stability of the receptor.
By contrast, C98A, C l78A and D99A lie above the 1:1 correlation line for NMS, while 
for QNB only D99A lies above the trend line. The removal of the disulphide bonded 
cysteine residues causes an acceleration of H-NMS dissociation, approximately a 3-5 
fold increase in the rate relative to WT receptors and a ~5-8-fold reduction in the 
calculated NMS association rate constant. However, the magnitude of the acceleration is 
much less than might be expected from the decreases in binding affinity. The same 
applies to D99A which also diminishes the calculated association rate constant for NMS 
about 10-fold. These observations might be consistent with the presence of an access 
channel and is also consistent with the calculated reduction in association rate constant 
derived for D99A. The strong effects of the cysteine mutations could suggest that the 
disulphide bond is also vital to the preservation of the entrance channel architecture. 
Smaller effects are seen for R171A and Y179A. These residues may also play a role in 
the structure of the entrance channel. Recent experiments by Avlani (Avlani, 2005) have 
shown slowing of the rate of dissociation of H-NMS by pinning down the E2 loop of 
the M2 mAChR by incorporating an additional disulphide bond between a Cys 
substituted for Val 171 of the E2 loop and Asp 419 of TM-7. By reducing this S-S bond 
with dithiothreitol the receptor recovers to wild type rates of ligand dissociation. These 
authors suggest that not only is the E2 loop important for the binding of allosteric 
modulators, it is also important for the natural entry and egress of ligands to and from 
the central binding cavity and that it is the dynamic nature of the E2 loop that allows for 
this.
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Figure 5.6. Plot of D issociation R ate  C onstan t vs Affinity C onstan t fo r
NM S B inding to A lanine Substitu tion  M utan ts
Y 17 9A
0.0 Q 17 7A
#  D 99A
C 178N R 171A E 17 0A
I180A
C 1 78 A-0 .5 C 9 8A
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F182A
" O  - 1.0
-1 .5
- 1.0-1 .5 -0 .5 0.0
d L o g  K
Correlation of the changes in dissociation rate constants and NMS binding affinity 
constants for mutants tested in this study. The positive correlation trend line represents 
the 1:1 ratio for change in dissociation and change in affinity. Mutants that lie above the 
trendline show smaller effects on the dissociation rate constant than would be expected 
from the change in affinity constant, whereas mutants below the trend line had greater 
effects on dissociation rate constants. Points close to the trend line are indicative of 
mutations where an increase in the dissociation rate constant can be accounted for by 
reduction in NMS affinity.
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F igure 5.7 Plot of Dissociation R ate C onstan t vs A ffinity C onstan t fo r 
QNB B inding to A lanine Substitu tion  M utan ts
0 .5
Q 1 7 7 A
0.0
D 99A  •
^  I180A 
•  Y 1 7 9 A-0 .5
•  R 1 71 A  F 182 A
- 1.0
F 197A
Y 4 0 8 A  Y 4 0 4 A
-1 .5
•  W 3 7 8 A
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-0 .5-2 .5 0.0 0.5
Correlation of the changes in dissociation rate constants and QNB binding affinity 
constants for mutants tested in this study. The positive correlation trend line represents 
the 1:1 ratio for change in dissociation and change in affinity. Mutants that lie above the 
trendline have smaller effects on the dissociation rate constant than would be expected 
from the change in affinity, whereas mutants below the trend line had greater effects on 
dissociation rate constants. Points close to the trend line are indicative of mutations 
where an increase in the dissociation rate constant can be accounted for by a reduction 
in QNB affinity. Values for QNB affinity: Y106A (Lu and Hulme, 1999a), N382A 
(Ward et al., 1999a)Y404A and Y408A (Lu et al., 2001).
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Does QNB access the receptor via the same entrance channel as ACh and NMS? A 
reduction in the association rate constant for QNB shown by the D99A mutation 
suggests that it may. The fact that QNB is a bulky and hydrophobic molecule may 
account for its slower association rate kinetics compared to NMS. However, since QNB 
is a tertiary amine it can become de-protonated and is therefore able to move through 
the lipid membrane. This is in contrast to NMS which has a permanent positive charge 
due to it being a quaternary ammonium species and as a consequence it cannot move 
through the lipid bilayer. These facts may explain why structurally destabilising 
mutations such as the TM domain mutants increase both rates of QNB association and 
dissociation. By disturbing the structural stability of the receptor these mutations may 
produce an alternative access route to the transmembrane binding site for QNB via the 
transmembrane helices. The increases in QNB association rates seen for the cysteine 
mutations may also suggest that these mutations disrupt or collapse the aqueous 
entrance channel. This too may result in the destabilising of the helix-bundle and 
facilitate the entry of a lipophilic molecule such as QNB via the transmembrane helices. 
Two mutations R171A and F182A both increased the association rate constants of QNB 
~6-fold to that of the WT receptor, approaching values close to the diffusion limited 
rate. Although these two mutations do not significantly reduce the affinity constant of 
QNB, it is possible that they perturb the structure of the E2 loop sufficiently to allow 
enhanced random movement of the TM helices. This ‘breathing’ motion, induced by the 
mutations in the E2 loop, may allow QNB to enter the binding site at a quicker rate than 
for the WT receptor, entering more readily through the gaps in the helices caused by a 
relaxation in the E2 loop structure.
In general the dissociation of antagonists from mutant WT and Mi receptors was found 
to be monophasic. The major exception was that of the C98A mutant. The dissociation 
data for this mutant better fitted the double exponential model (see figure 5.4). There
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was a rapid phase of dissociation where approximately 50% of 3H-QNB had dissociated 
within 2-5 minutes and a slow phase of dissociation whereby 50% of the remaining 
bound ligand took a further 98 minutes to dissociate. This finding may be explained by 
the possibility that the creation of the C98A mutation generated two separate 
populations of receptor. One population with a fast dissociation rate constant and 
another with a slow dissociation rate constant for 3H-QNB could exist simultaneously. It 
seems plausible that the putative populations might correspond to the high and low 
affinity ACh binding sites described in Chapter 4. Equilibrium 3H-QNB binding assays 
do not differentiate between the two sites. Further experimentation is required to 
discover which of the two populations of ACh binding sites seen for the C98A mutant 
receptor may be responsible for the rapid and slow QNB dissociation kinetics. This 
could be achieved by protecting the sites with a high affinity for ACh with a sufficient 
concentration of ACh. An ACh concentration of 10‘ M would be sufficient to block the 
high affinity site but allow 3H-QNB to bind to the unoccupied low affinity sites. 
Measuring the rate of QNB dissociation from the ACh unoccupied sites would provide 
an indication whether or not the low affinity site was responsible for the fast or slow 
QNB dissociation kinetics.
The C98A receptor effectively has a highly reactive free cysteine residue at C l78. This 
reactive free cysteine 178 could potentially form a disulphide bond with another free 
reactive cysteine elsewhere in the receptor. There are two free cysteine residues within 
the E3 loop of the Mi receptor at positions 391 and 394 respectively. It is possible that 
the formation of a disulphide bond with either of these residues could create a structure 
similar to that imparted by the natural S-S bond between C98 and C l78 in the wild type 
receptor, thus negating rapid dissociation of the antagonist. Again it is evidence 
provided by Avlani (Avlani, 2005) that may support this proposition. Avlani showed 
that it was indeed possible to create a non-native disulphide bond between the E2 and
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E3 loops. Therefore it may not be unreasonable to think that a free C l78 residue could 
form a similar intramolecular disulphide bond. Alternatively the free cysteine may form 
an intermolecular disulphide bond with an adjacent receptor, effectively forming a 
dimer with a high and low affinity antagonist binding site. The same observation is not 
seen for the C178A mutant, since the free reactive cysteine 98 residue is located at the 
top of TM3 and is probably out of range of the free cysteine in the E3 loop. However 
the presence of two populations of binding sites cannot be excluded for the C l78A 
mutant.
In all dissociation experiments conducted with NMS (but not QNB) in this study pre­
incubation times were of intermediate length (20-25 minutes) and no evidence of 
biphasic dissociation was witnessed. Jakubik et al (Jakubik et al., 2000) presented data 
where longer periods of pre-incubation (60-90min) with 3H-NMS followed by 
dissociation with varying concentrations of unlabelled NMS led to the observation that 
the dissociation of NMS from Mi receptors was significantly slowed. During the short 
pre-incubations (2-5min) faster rates of dissociation were observed the conclusion being 
that both 3H-NMS and unlabelled NMS can bind to the receptor simultaneously a 
finding also noted by Walbroeck using other muscarinic antagonists (Waelbroeck, 
1994). Jakubik proposed that his observations were indicative of there being a high and 
a low affinity site for NMS. Fast dissociation during the short pre-incubations is 
consistent with a low affinity site and conversely slow dissociation from a high affinity 
site as seen during longer pre-incubations. This led to the theory that there is an initial 
binding of antagonist to the receptor via an access channel before the ligand is 
translocated to the central binding pocket. In the case of Mi mAChR, D99 is the residue 
postulated to be involved in the initial binding of antagonist. As has been explained 
above there is some corroborative evidence that D99 is indeed part of an access channel.
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There is a well described access channel or ‘gorge’ lined with 14 conserved 
hydrophobic residues in the acetylcholinesterase (AChE) enzyme (Sussman et al. 1991). 
This hydrophobic gorge is believed to be in part responsible for the fast catalytic 
activity of this enzyme because it reduces the free energy required for the ACh molecule 
to reach the active site, effectively forming a slippery channel through which the ACh 
molecule reaches the catalytically active site deeper in the enzyme The quaternary head 
group of ACh interacts with AChE via cation - tt interactions with two highly conserved 
tryptophan residues in the anionic site while de-acylation occurs at the esteratic locus 
(Quinn, 1987), (Silman and Sussman, 2005) It is reasonable to imagine that there is a 
similar hydrophobic access channel in the muscarinic receptors that also allows rapid 
association of ACh with the binding site and that D99 and W157 (both fully conserved 
in the mAChR family) are the two residues situated at the entrance to that channel. 
These two residues are analogous to the negatively charged glutamate residue, Glu 292 
and an aromatic Tryptophan, Trp 286 which, among other aromatic residues, are located 
at the entrance to the gorge in AChE (Bourne et al., 1995).
Rhodopsin, which does not bind Ach, does not contain analogous residues at these 
positions. During the evolutionary process acetylcholine binding receptors and 
acetylcholinesterase may have developed similar strategies for the translocation of ACh 
from the hydrophilic milieu to the hydrophobic core of the functioning molecule.The 
findings of the present study would seem to suggest that the E2 loop of the Mi receptor 
fulfils an analogous role to that of the M2 receptor as described by Avlani et al (Avlani, 
2005). Furthermore, the role, structure and flexibility of the E2 loop of the muscarinic 
receptors probably differ from that of rhodopsin. In rhodopsin the ligand, retinal is 
covalently bound to the TM domains of the receptor and is not required to diffuse into 
the transmembrane binding site before activating. It seems reasonable therefore to 
suggest that the E2 loop of rhodopsin is required to be less dynamic than that of the
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muscarinic receptors but that it is more important for the protection of the ligand and 
providing the environment of the retinylidene Schiff base in the active conformation 
(Yan et al., 2002). This and other studies (Savarese et al., 1992; Ward et al., 2002; Zeng 
et al.1999) have shown that once properly folded and at the cell surface the maintenance 
of the disulphide bond is less critical to the binding of antagonists than the TM domain 
residues have proved to be so. Nevertheless the E2 loop maintains the conformation of 
the ligand binding pocket and probably the entrance channel and thus helps to minimise 
the change in free energy required to surmount the activation barrier necessary to favour 
ligand interaction with the receptor The cysteine mutations and D99A must increase the 
activation energy of the association step more than the dissociation step of NMS 
binding since the reduction in the association rate constants were more pronounced than 
the dissociation rate constants for these mutants. The~20-fold increase in QNB 
dissociation rate and 3-5-fold increase in NMS dissociation rates support the idea the 
removal of the important S-S bonded cysteines do indeed perturb the binding energies 
of ligands in the transmembrane binding pocket.
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Chapter 6 
Binding of Other Ligands.
6.1. Introduction-
Extensive residue substitution experiments have been reviewed (Hulme et al., 2003; Lu 
et al., 2001; Heitz et al., 1999; Vogel et al., 1997; Wess et al., 1991) These authors have 
identified the important amino acid side chains that form the central binding cavity of 
the muscarinic acetylcholine receptors. There is a large degree of overlap of key 
residues and interactions involved in the binding of the endogenous agonist, 
acetylcholine and the high affinity classical antagonist N-methylscopolamine, although 
differences do occur. A critical interaction for both ligands is the stabilizing ionic 
interaction of the positively charged tetramethylammonium head group of ACh and the 
quatemery amine head group of NMS with the negatively charged and highly conserved 
side chain of aspartate 105. The substitution of this residue with alanine reduces both 
ACh and NMS affinity 100-fold and completely abolishes any ACh induced signalling 
(Lu and Hulme, 1999b) There is a negatively charged residue at the analogous position 
in all cationic amine receptors, and this underlines the essential role of this residue for 
the binding of agonists with positively charged head groups such as ACh (Shi and 
Javitch, 2002).
The predominant transmembrane binding site residues, Tyr 106, Tyr 381, Tyr 404, and 
Tyr 408 form a charge-stabilized aromatic cage into which the quartemary ammonium 
head group of the active S(-) enantiomer of NMS and the gauche conformer of ACh can 
be docked in the ground state of the Mi mAChR homology model (Hulme et al., 2003) 
(see figure 6.1.) Interactions with the docked ligands are further stabilized by a 
hydrogen bonding network involving residues Ser 109, Thr 182, Thr 192, Asn 382 and 
Cys 407. The presence of an anionic group and of hydrogen bond donors within the
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muscarinic binding site had long been predicted by pharmacophore modelling 
(Schulman JM. Michael L. Sabio, 1983; Schwarz et al., 1995; Vogel et al., 1999) 
suggesting that there must be a negative charge in the binding site and that a full 
muscarinic agonist must have the equivalent of five atoms in its side chain, the classic
5-atoms rule. The specificity of muscarinic agonist binding is comprehensively 
reviewed by Ringdahl (Ringdahl, 1989a). The interaction of the quaternary ammonium 
head groups of NMS and ACh is with D105 and the carbonyl or ester oxygens of both 
NMS and ACh may be hydrogen bonded to the hydroxyl group of the Y381 residue. 
The side chain oxygens of both ligands may also hydrogen bond to the hydroxyl group 
of Y106, the mutation of which induces a comparable loss of affinity and function to 
that of the D105A mutant (Lu and Hulme, 1999a) and the hydroxymethyl group of 
NMS may hydrogen bond with Asn 382. NMS and ACh bind in a similar manner 
except that the side chain of NMS possibly binds deeper within the binding cavity than 
ACh. Confirmatory evidence for this has been provided in this thesis (see Chapter 3), 
whereby the mutation to alanine of Phe 197 (TM5) and Trp 378 (TM6) at the predicted 
base of the binding cavity, led to a ~ 100-fold and ~400-fold reduction in NMS affinity 
respectively and Trp 378 but not Phe 197 showed a -10-fold loss of affinity for ACh. 
Thus it is likely that these two residues also participate in the binding of NMS, but only 
Trp 378 in the binding of ACh. The binding modality of QNB, which contains a tertiary 
amine head group, probably differs to that of the quaternary ammonium-containing 
NMS molecule. Ward et al (Ward et al., 1999a) showed that the mutation of Tyr 381, a 
critical contact residue for NMS had virtually no effect on the affinity of QNB. A 
similar observation was made in results Chapter 3 of the present study, where mutation 
to alanine of Phe 197 severely reduced (-100-fold) the affinity of NMS but reduced the 
affinity of QNB less than 3-fold. This indicates that different residues may be important 
contact residues for one ligand but not another and revealing their identity has 
implications for pharmaceutical design.
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Other peripheral residues providing stabilizing polar and Wan der Waals interactions 
also discriminate between NMS and ACh binding modalities in the Mi mAChR. For 
example, the phenyl ring of NMS resembles the P-ionone ring of retinal (the covalently 
bound agonist of rhodopsin) and is predicted in the homology model to be in close 
proximity to residues Asn 110, Val 113 (TM3) and Phe 374 (TM6), where it is expected 
to support the contacts in TM3, TM5 and TM6 required for the preservation of the 
inactive conformer of the receptor. Additional residues surrounding D105 such as Trp 
101, Leu 102 (TM3), and Leu 386 may provide a second shell of interactions that help 
to position the primary binding site residues and residues Thr 189, Thr 192 and Ala 196 
may contribute to a hydrogen bonding network probably including water molecules that 
complete the muscarinic pharmacophore. The role of the E2 loop in the primary binding 
site has now been evaluated in this study and it appears that E2 loop residues may also 
provide a second tier of residues that stabilise the primary binding site without making 
any critical ligand contact.
The existence of a ligand docking site has been supported by work done in the present 
study (results Chapter 5), other kinetic studies (Jakubik et al., 2000) and radioligand 
binding studies where mutation of Trp 157 (W157) to alanine, significantly reduced 
ACh (~100-fold) and NMS (123-fold) affinity and signalling efficacy (160-fold) (Lu et 
al., 2001). However, in the homology model of the Mi mAChR this residue lies too far 
from the ligand binding site to participate in ligand contact without a conformational 
change. The other residue postulated to be part of the ligand docking site is Asp 99, a 
residue under investigation in this thesis. The D99A mutant has shown similar patterns 
of reduced ACh affinity but in contrast to W157 no significant reductions in efficacy. 
Although the reduction in ACh affinity is not as large as that seen for Trp 157, D99 also 
lies too distant from the central binding core to be directly involved in the binding site, 
according to the homology model (Hulme and Lu, 1998). Ligands need to enter and
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leave the central binding core rapidly, unlike the covalently bound retinal of rhodopsin 
and the idea of an entrance channel, based on this study and others (Heitz et al., 1999) 
seems highly plausible and may be synonymous with the peripheral ionic site at the 
entrance channel to the acetylcholinesterase enzyme (Silman and Sussman, 2005).
A previous study in this laboratory (Page et al., 1995) examining the effect of mutating 
the critical binding site residue Asp 105 to glutamate (preserving the negative charge) 
on agonist binding affinities showed that although the mutation reduced the affinity of 
ACh ~20-fold the effect on oxo-M, pilocarpine and McN-A-343 affinity was minimal, 
although oxo-M-induced signalling was severely disabled by the D105E mutant. This 
suggests that there are likely to be different modes of binding for different ligands that 
may or may not involve the critical binding site residues necessary for the binding of the 
endogenous agonist acetylcholine. However, there is an argument as to whether or not 
evolution of the cationic amine receptors binding site has allowed for the binding of 
non-endogenous or non- productive ligands. Have evolutionary forces positioned the 
side chains of the amino acids so as to minimise the possibility that the receptor can be 
activated by ligands structurally and chemically heterologous to the endogenous 
agonist?
The atypical muscarinic agonist 4-(chlorophenyl-carbamoyloxy)-2-butynyl 
trimethylammonium (McN-A-343) was first shown to stimulate mAChRs in 
sympathetic ganglia by Roszkowski (Roszkowski, 1961). McN-A-343 is unusual 
because it has a potent and selective muscarinic receptor mediated effect on sympathetic 
ganglia but a weaker muscarinic effect on non ganglionic tissues (Ringdahl, 1989b). It 
was proposed that McN-A-343 mediates these effects through Mi mAChRs and this 
was studied in more detail by Birdsall et al (Birdsall et al. 1983) on membrane 
preparations of the cerebral cortex (Mi) and myocardium (M2). The conclusion of their
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study stated that McN-A-343 “binds to a site distinct from that occupied by NMS” and 
that McN-A-343 “does not behave as a simple competitive ligand”. A study by 
Hardouin et al. (Hardouin et al., 2002) explains this earlier observation. They showed 
that although Mi is not expressed in cardiac tissue, it was the activation of 
postganglionic cells by McN-A-343 that results in the release of catecholamines that in 
turn affect cardiac stimulation. Hence the treatment of WT mice with ACh leads to 
arrhythmia. The residues responsible for the binding of McN-A-343 are still to be 
identified. It was shown that the primary binding site residue Asp 105 may not be 
involved. The mutation of Asp 105 to a negatively charged glutamate (D105E) reduced 
the binding of McN-A-343 less than 3-fold in the Mi receptor and less than 4-fold in the 
analogous D103E mutation in M2 receptors (Page et al., 1995). The mutation of D 103 to 
another negatively charged amino acid may not be the best mutation to make to analyse 
the contribution of D103 to the binding site, since maintenance of the charge may 
confer a similar phenotype to the WT receptor. Schwarz et al. (Schwarz et al., 1995) 
produced a more imfomative mutant in the M2 mAChR, D103N which also showed 
very little effect on McN-A-343 binding. This again suggests that mcN-A-343 does not 
bind in the transmembrane binding site. Therefore, the work presented in this chapter 
hopes to clarify whether or not McN-A-343 binds to an allosteric site distinct from that 
of the orthosteric site.
There are many ligands that have been shown to bind to sites other than the principal 
orthosteric site. Strychnine and brucine are just two examples of many ligands that bind 
at sites unique from the central or orthosteric binding site. The existence of allosteric 
sites first came to light during whole tissue studies on muscarinic agonist interactions 
with hexamethonium analogues on ileum and with gallamine in the heart (Birdsall and 
Lazereno, 2005). The existence of a second allosteric site was discovered by Lazareno 
et al., using equilibrium and non-equilibrium radioligand binding studies who showed
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that both sites can affect the binding of ACh in a co-operative manner (Lazareno et al., 
2000). It is has recently been proposed that there are three distinct binding sites on the 
Mi receptor in addition to the central orthosteric site. There are two extracellular 
allosteric binding sites and another cytoplasmic binding site which have been shown to 
bind the allosteric modulator staurosporine and chemical derivatives thereof (Espinoza- 
Fonseca and Trujillo-Ferrara, 2005).
AC-42 is a novel functionally selective Mi agonist developed by the USA-based 
company Accadia (Spalding et al., 2002). They discovered the compound using a live 
cell-based screening assay, receptor selection and amplification technology (R-SAT) 
(Brauner-Osbome H, 1996) whereby the binding of a selective agonist to cells 
expressing receptor induces (3-galactosidase that can be visualised by a change in colour 
of receptor transfected cells. The study by Spalding et al (Spalding et al., 2002) has 
suggested that the Mi receptor is selectively activated by AC-42 via a binding site 
different from the orthosteric site, since chimeric mutants of the central binding site 
domains did not affect the binding affinity of AC-42, whereas extracellular domain 
mutants did. The specific residues that bind this ligand have yet to be identified, but it is 
likely that AC-42 binds to an allosteric site, perhaps overlapping with the residues 
responsible for gallamine or perhaps with the analogous residues involved in the 
binding of alcuronium-like compounds to the M2 receptor (Ellis and Seidenberg, 2000). 
One of the aims of this section of work is to test whether or not mutations of the central 
binding site affect the binding affinity of AC-42 at Mi mAChRs or if residues of the E2 
loop are involved in the interaction of this ligand.
The questions for consideration in this chapter are: - (i) Do the ligand contact residues 
of the central binding pocket in the Mi mAChR, that participate in ACh and NMS 
binding, also participate in the binding of other agonists and antagonists? (ii) How do
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mutations of the E2 loop affect the binding of other ligands, in particular, do they 
participate in primary ligand contacts with other agonists? (iii) is the proposed ligand 
docking residue D99 also important for the initial binding of other ligands before their 
entry into the binding site? (iv) Do residues of the E2 loop provide binding contacts for 
the novel agonist AC-42 and the partial agonists pilocarpine and McNA-343?
Competitive radioligand binding assays on COS-7 cell membranes using a selection of 
competing ligands (described below) against either 3H-NMS or 3H-QNB were 
performed to provide insight in to these questions. A selection of the major binding site 
residues, mutated to alanine in previous studies, along with the E2 loop and TM domain 
mutants from this study, were analysed. Differences in affinity compared to wild type, 
were assessed for a small selection of typical and atypical agonists and antagonists. In 
addition to the classical antagonists NMS and QNB the NMS analogue scopolamine 
was analysed along with the acetylcholine homologues, oxotremorine-M (oxo-M), a 
potent agonist and oxotremorine. The classical partial agonist pilocarpine, the 
functionally selective Mi agonist McN-A-343 and the atypical and the novel AC-42 
compound were also investigated. Their structures are presented in figure 6.2 and a 
description is provided in the figure legend
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Figure 6.1. SM -N -M ethylscopolam ine and Acetylcholine Docked Into  
the Mi  m A C hR  T ransm em brane  B inding Pocket
Y408 W378
Y404
Docking of ligands into the central transmembrane binding pocket of the Mi mAChR.
a.) The S(-)-NMS enantiomer docked into the homology model of Mi. In addition to 
Asp 105 residues highlighted in yellow indicate amino acid side chains that, when 
mutated to alanine, reduce NMS affinity >30-fold (Tyr 105, Tyr 106, Tyr 381, Asn 382, 
Tyr 404 and Tyr 408 [aromatic cage residues]). Residues highlighted dark green, 
Vail 13 and Phe 374 reduced NMS affinity (but not ACh) ~10-fold. b.) Acetylcholine in 
the gauche conformer (as predicted by Furukawa et al. (Furukawa et al., 2002) is 
positioned with the tetramethylammonium head group anchored to Asp 105 and the 
acetoxy side chain stabilised by Tyr 381. Mutation of these and other residues 
highlighted in yellow reduce ACh affinity >30-fold (Tyr 106, Tyr 404 and Tyr 408).
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Figure 6.2. S truc tu res of M uscarinic L igands used in This Study
Chemical structure of ligands used in this study. In order from top left to bottom right: 
N-methylscopolamine (NMS) has a quaternary head group and a bulky scopine side 
chain with a benzene ring . Scopolamine is the tertiary amine analogue of NMS with 
reduced potency. Quinuclidinylbenzilate (QNB), a potent antagonist, has a tertiary 
amine and a two phenyl rings. Acetylcholine (ACh), the endogenous agonist, has a 
positively charged tetramethylammonium head group and an acetoxy side chain. 
Oxotremorine-M, a potent agonist with full efficacy is an acetylcholine analogue but 
contains a pyrrolidone ring. Oxotremorine is a tertiary amine analogue of ACh distinct 
from oxo-M by the presence of a pyrrolidine head group. Pilocarpine is a partial agonist 
with an N-methyl imidizole ring. McN-A343, a functionally selective M \  agonist, is 
also an ACh analogue but contains a chlorinated benzene ring. AC-42 a novel and 
functionally selective tertiary amine agonist is distinguished by a benzene and a 
piperidene ring structure.
N -m eth y lsco p o lam in e Scopolam ine 3-Q u in u clid yn yl B enzila te
O xo trem o rin e  -MA cety lcho line O x o tre m o rin e
n h c o o c h 2- c =c - c h 2—n — c h 3
P ilocarpine
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6.2. Results of Competitive Binding Assays for Other Ligands.
All competition curves were analysed using a 1-site model of binding assuming a Hill 
coefficient of 1. None of the data presented varied significantly from this model. Mean 
wild type Mi mAChR pKa values for the agonists Oxotremorine-M, McNA-343 and 
Pilocarpine at 4.56±0.11, 5.06±0.14 and 5.15±0.041 are slightly lower than values 
previously reported by this laboratory (Page et al., 1995), which were 5.1±0.04, 
5.53±0.02 and 5.69±0.03 respectively. The WT affinity constant for AC-42, 6.10±0.15, 
determined here, is in good agreement with Spalding et al (Spalding et al., 2002) and 
Baig (unpublished data). Similarly, the Mi mAChR WT mean pK value for scopolamine 
9.23±0.15 determined in this study is in close agreement with Ward et al (Ward et al., 
1999b) who recorded a value of 9.51±0.04. No previous data has been reported for the 
binding affinity of oxotremorine at WT Mi mAChRs expressed in COS-7 cells. In this 
study pK at WT Mi mAChRs for oxotremorine was found to be 5.6±0.1. All 
competition binding data generated in this section of work is summarised in tables 6.1, 
6.2 and 6.3 shown below.
6.2.1. £2 Loop Mutants
In general, the E2 loop mutants made no significant difference to the binding affinity 
constants of the agonists pilocarpine, McN-A-343 and AC-42. The exceptions were 
Q177A and I180A. Q177A reduced the affinity of both pilocarpine and McN-A-343 
(figure 6.6) by ~4-5-fold (p<0.05) compared to the WT pK value. I180A also slightly 
reduced the affinity of pilocarpine 3-fold (p<0.05) and more significantly reduced the 
affinity of McN-A-343 by 6-fold (p<0.01). Reductions in pilocarpine and McN-A-343 
affinity for I180A reflect similar reductions recorded for ACh at this mutant. The 1180A 
mutant also had the effect of increasing the binding affinity of the novel functionally 
selective AC-42 compound by 6-7-fold compared to wild type. I180A did not
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significantly change the affinity of either oxotremorine or oxo-M. Table 6.1 below
summarises the binding data for the E2 loop mutants.
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Table 6.1 Summary of Data for E2 L o o p  Mutants
L ig an d WT E170A R171A Q177A Y179A 11804L F182^
pKd pKd fold pKd fold pKd fold PKd fold pKd fold pKd fold
Scopolamine 9.2±0.2 ND ND ND ND ND 8.43* 8.7±0.1 3 ND ND
Pilocarpine 5.2±0.1 5.2±0.1 nsd 4.8±0.2 nsd 4.5±0.1D 5 4.7* 4.6±0.2 3 5.0±0.1 nsd
McN-A-343 5.1±0.1 4.8±0.2 nsd 5.0±0.2 nsd 4.5±0.2a 4.0 4.5* 4.3±0.3a 6 4.9±0.1 nsd
AC-42 6.1 ±0.2 6.0±0.1 nsd 6.4±0.2 nsd 6.0±0.3 nsd 5.9* 6.9±0.3° 7t 6.3±0.3 nsd
Oxotremorine-M 4.6±0.1 ND ND ND ND ND ND 4.0* 4.85±0.2 nsd ND ND
Oxotremorine 5.6±0.1 ND ND ND ND ND ND 5.3* 6.0±0.1 nsd ND ND
ap<0.05, bp<0.01 wrt corresponding WT (1 way anova / 2-tailed t-test)
nsd = no significant difference to WT value i.e. fold difference in pKd<3-fold. (f Indicates fold Increase) 
Values shown are pKd ±S.E.M to 1 significant figures where;
ND = No Data N=>3 except *
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6.2.2. Cysteine Mutants
Mutation of the cysteine residues produced more dramatic effects on affinity for 
oxotremorine, oxo-M pilocarpine and McN-A-343 than individual mutations of the E2 
loop. Comparable losses of affinity were seen for the antagonist scopolamine to those 
seen for NMS. C98A and C l78A reduced both oxotremorine and oxo-M affinities by 
between 7-13-fold (p<0.05). C98A, C l78A and C98A/C178A reduced the affinity of 
pilocarpine by —15, 6 (p<0.05) and ~20-fold (p<0.01) respectively. Insufficient data for 
the double cysteine mutant for these two agonists negates further comparison, although 
initial data suggests there may be a negative cumulative effect on the affinity of oxo-M 
for the double cysteine mutant. Interestingly, C l78A made no significant difference to 
the binding affinity of McN-A-343, despite C98A and C98A/C178A reducing the 
affinity of McN-A-343 by a modest~4-6-fold (p<0.05) from the wild type pK value. All 
three cysteine mutants consistently raised the binding affinity constant of AC-42 from 
the WT value of pK 6.1±0.1 to a mean pK6.9±0.1 for C178A and a mean pK6.6±0.1 for 
the C98A mutant. The double mutant also consistently increased the affinity binding 
constant although the increases were <3-fold in most cases (see table 6.2. below). The 
interesting difference between the reduced affinity of pilocarpine compared to the 
increased affinity for AC-42 at the cysteine mutants is highlighted in figure 6.3 below. 
The reduction in affinity of pilocarpine reflects the losses of affinity observed for ACh 
at the cysteine mutants, although perhaps because pilocarpine is a larger molecule than 
ACh and a partial agonist, the reductions in pilocarpine affinity are relatively smaller 
than those seen for ACh in results Chapter 1 of this thesis.
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Chapter 6
L ig an d WT C98A C178A C98A/C178A
pKd pKd fold pKd fold pKd fold
Scopolamine 9.2±0.2 7.83±0.2a 25.1 7.9±0.2D 22.0 7.78*
Pilocarpine 5.1±0.1 4.0±0.1b 14.5 4.3±0.3° 6.3 3.9±0.1b 19.5
McN-A-343 5.1±0.1 4.5±0.2a 3.8 4.7±0.2 nsd 4.3±0.1b 5.8
AC-42 6.1 ±0.2 6.6±0.1 3.0f 6.9±0.1b 6.3f 6.4±0.2 nsd
Oxotremorine-M 4.6±0.1 3.68±0.1t> 7.6 3.7±0.1a 7.9 2.76*
Oxotremorine 5.6±0.1 4.5±0.3a 12.9 4.8±0.1b 7.8 4.5*
Values shown are pKd ±S.E.M to 1 significant figures where;
N>3 except * where N=1 
ND = No Data
ap<0.05, bp<0.01 wrt corresponding WT (1 way anova / 2-tailed t-test) 
nsd = no significant difference to WT value i.e. fold difference in pKd<3-fold. 
(t Indicates fold Increase)
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Figure 6.3 C om parison of Changes in Affinity for P ilocarpine and AC- 
42 a t the Cysteine M utan ts .
•  Wild Type
•  C98A
•  C178A
•  C98A/C178A
140
•io n  _
•  Wild Type
•  C98A/C178A
•  C98A 
A C178A
log[Pilocarpine] (M) log [AC-42] (M)
Pilocarpine and AC-42 competition assays were performed on transfected COS-7 cell 
membranes incubated at 30°C for 2 hours with [3H-NMS] at 10‘9M (mutants) or 10'10M 
(WT) respectively. Plocarpine concentration range = log -8.52 to log -3.00, AC-42 
concentration range = log -10.52 to log 4.52. N.S.B was determined using 10'6 M 
atropine (K values are the mean ±S.E.M of at least 3 independent experiments) Data 
was fitted to a 1-site model of binding and corrected using the Cheng-Prusoff equation.
a. Representative pilocarpine competition curves for; WT pK = 5.25±0.04, C98A pK = 
4.18±0.05, C178A pK = 4.92±0.10, C98A/C178A pK = 4.24±0.06
b. Representative AC-42 competition curves for; WT pK = 6.02±0.04, C98A pK =
6.29±0.06, C178A pK = 6.69±0.05, C98A/C178A pK = 6.56±0.06.
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6.2.3. Transmembrane Mutants
As expected, the loss of affinity for the antagonist scopolamine (-125-fold) at the 
Y381A mutant pK= 7.1±0.1 (p<0.01) compared to pK = 9.2±0.1 for WT was in 
accordance with the huge losses of NMS affinity (630-fold) seen in a previous study in 
this lab (Ward et al., 1999a), where the tertiary amine analogue (scopolamine) also had 
an affinity for this particular mutant -5  times that of the quaternary amine containing 
NMS molecule. A similar 5-fold difference in the reduction in affinity was seen at the 
Y106A mutant where a 10-fold reduction in scopolamine affinity is compared to a 50- 
fold loss of affinity for NMS at the Y106A mutant (Lu and Hulme, 1999a). These 
observations add further evidence to support the premise that Y106 and Y381 are 
crucial central binding site residues.
The affinity of oxotremorine-M was reduced by 10-16-fold at the Y106A and Y381A 
mutants, a change in pK from 4.6±0.1 (WT) to 3.6±0.1 (p<0.05) and 3.4±0.1 (p<0.05) 
respectively. The transmembrane binding domain mutants Y106A and Y381A both 
gave pK values for pilocarpine of 3.91 ±0.1 (p<0.05) a 16-fold reduction in affinity 
compared to the WT value. However, these two mutations had virtually no effect on the 
binding affinity constant of McN-A-343 compared to WT (pK= 5.1 ±0.1, giving pK 
values = 5.0±0.1 and 4.6±0.5 respectively. Consistent with the majority of the mutants 
tested in this study the Y381A mutant generated a small but reproducible and significant 
(p<0.01) increase in the affinity of AC-42, giving a mean pK = 6.9±0.1 representing a
6-fold increase over the WT binding affinity constant (see figure 6.4). The Y106A 
mutant had a substantial and significant effect on the binding affinity of oxotremorine, 
reducing its affinity 20-fold (p<0.01) from the mean WT value to a mean pK = 4.3±0.1 
(see figure 6.5). The Y381A mutant reduced oxotremorine affinity less significantly 
(p<0.05), producing a 6-fold loss of binding affinity compared to WT.
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The proposed central binding site residues F I97 and W378, overall, had minimal effects 
on the binding of muscarinic agonists. The exception was the ~13-fold loss of affinity 
seen at the W378A mutant pK = 4.1±0.1(p<0.05) compared to WT (pK = 5.1±0.1) for 
pilocarpine. This reflects a similar reduction in affinity (14-fold) seen for acetylcholine 
at the W378A mutant. The binding site mutants Y404A and Y408A both reduced the 
affinity of pilocarpine between 5-10-fold (p<0.05 and p<0.01 respectively) and the 
antagonist scopolamine by ~8-fold, but had little effect on the other ligands for which a 
full data set was collected.
In general, none of the TM domain mutations reduced the affinity of McN-A-343 and if 
they did, it was to reduce affinity between 3-6-fold. Two interesting exceptions were 
F I97A and N382A, where the mutation slightly, but significantly, increased McN-A- 
343 affinity by 3 and 5 fold respectively (p<0.01). Mutation of the proposed access 
channel residue D99 to alanine did consistently reduce the affinity of all the agonists 
tested and with the exception of AC-42 and oxotremorine-M, the reductions in affinity 
although relatively small were significantly different to WT values.
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Table 6.3 Summary of Binding Data for Transmembrane Domain Mutants.
Ligand W T D99A Y 106A F197A Y381A W 378A N382A Y404A Y408A
pKd pKd fold pKd fold pKd fold pKd fold pKd fold pKd fold pKd fold pKd fold
Scopolamine 9.2±0.2 8.7±0.3 3 8.3±0.4a 10 8.2±0.4 10. 7.4±0.4b 63 8.5* 7.3* 8.3±0.3 8 8.4*
Pilocarpine 5.2±0.1 4.5±0.1a 4 3.9±0.1b 16 4.8±0.1 nsd 3.9±0.1b 16 4.1±0.1b 13 4.8±0.2 nsd 4.3±0.1b 6 4.2±0.1a 9
McN-A-343 5.1±0.1 4.5±0.1b 4 5.0±0.1 nsd 5.6±0.1a 3T 4.6±0.5 nsd 5.2±0.1 nsd 5.8±0.3a 5T 4.7±0.3 nsd 4.5±0.1 4
AC-42 "1 6.1±0.2 5.8±0.1 nsd 6.3±0.1 nsd 6.5±0.3 nsd 6.9±0.1a 6 ! 6.2±0.3 nsd 6.4±0.3 nsd 6.6±0.3a 3 t 6.4±0.3 nsd
Oxo-M 4.6± 0 .1 4.4±0.2 nsd 3.6±0.1b 10 4 .9± 0 .1 nsd 3.4±0.1b 16 4.0* 4.1* 4 .6± 0 .1 nsd 4.0*
Oxo 5.6±0.1 5.2±0.1a nsd 4.3±0.1a 20 5.2±0.1 nsd 4.8±0.1b 6 4.7* 4.8* 5.6±0.1 nsd 4.7*
Values shown are pKd ±S.E.M to 1 significant figures where;
N>3 except *
ND = No Data
ap<0.05, bp<0.01 wrt corresponding WT (1 way anova / 2-tailed t-test)
nsd = no significant difference to WT value i.e. fold difference in pKd<3-fold. ( t Indicates fold Increase)
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Figure 6.4 Effect of Y381A M utation on AC-42 Affinity.
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AC-42 Competition assays were performed in quadruplicate on transfected COS-7 cell 
membranes incubated at 30°C for 2-4 hours with [3H-QNB] at 10‘9M (mutant) or 1010M 
(WT) respectively. AC-42 concentration range = log -10.52 to log -5.00. N.S.B was 
measured using 10'6M atropine. Data were fitted to a 1-site model of binding and corrected 
using the Cheng-Prusoff equation pK values are the mean ±S.E.M of at least 3 independent 
experiments. WT pK = 6.17±0.06, Y381A pK = 7.00±0.03.
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Figure 6.5 Reduction in O xotrem orine Affinity Caused by the Y106A 
M utation
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Oxotremorine competition assays were performed on transfected COS-7 cell membranes 
incubated at 30°C for 2-4 hours with [3H-QNB] at 10‘10M Oxotremorine concentration 
range = log -8.00 to log -3.00. N.S.B was measured using 10'6 M atropine.. Data were fitted 
to a 1-site model of binding and corrected using the Cheng-Prusoff equation. pK values are 
the mean ±S.E.M of at least 3 independent experiments. Representative oxotremorine 
competition curve: W T  pK = 4.73±0.07; Y106A pK = 3.63±0.05.
228
Chapter 6
6.3 Discussion and Conclusions
In 2000 the 2.8 A resolution of rhodopsin, reported by Palczewski et al (Palczewski et al., 
2000), indicated that a key feature of the E2 loop was an anti-parallel p-sheet (P3-P4) that 
formed a lid or a plug over the central binding pocket. In 2004 Li et al (Li et al., 2004) 
refined the X-ray crystallographic structure of rhodopsin to 2.65 A. With a higher definition 
3D map they revealed the hydrogen bonding network between the pl-p2 sheet in the El 
loop and the p3-p4 sheet in the E2 loop that helped stabilise not just the loop structures 
themselves, but the receptor as a whole. The two P-hairpins are crossed-linked by water- 
mediated H-bonds between the main chain atoms of Tyr 10 in p-2 and Pro 180 in P3. There 
are three water molecules involved in this network and they also form additional H-bonds 
with Gly 182 and Gin 184 in the p3-p4 hairpin and to Tyr 192 near to P4. This network 
serves to anchor the pl-p2 hairpin to the transmembrane regions and consequently, secures 
the plug over the central binding pocket. In rhodopsin the E2 loop residues provide 
hydrophobic contacts that maintain the covalently bound chromophore 11 cis-retinal in the 
inactive dark state. In particular Ser 186, Cys 187, Gly 188, lie 189 and Tyr 191 lie mostly 
in the p4 sheet within 4 A of the chromophore and are participating residues of the 
rhodopsin binding site. The rhodopsin residues are analogous to Q177, C l78, Y179, 1180 
and FI82 in the Mi mAChR.
6.3.1 E2 Loop Mutants
A summary of the binding data for McN-A-343, AC-42 and pilocarpine at E2 loop mutant 
receptors is shown below in figure 6.6. It has been predicted, using homology modelling 
that the Mi mAChR E2 loop residues may also participate in the binding of ligands in the 
central orthosteric binding pocket and that the [3-hairpin and plug-like structures are also
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features common to both rhodopsin and the Mi mAChR. Evidence collected in this study 
seems to highlight the fact that mutations of the E2 loop in Mi, apart from the highly 
conserved cysteine residue at position 178, do not have an overtly dramatic effect on the 
affinity of various ligands. It is likely that residues beyond the conserved cysteine at 
position 178 do extend towards the orthosteric binding site, where they contribute to a 
second shell of ligand interaction, stabilising the predominant and critical orthosteric 
binding site residues. The inference from the reduction of affinity for ACh shown by the 
1180A mutant is that it may be analogous to ligand contact residues in both rhodopsin (Yan 
et al., 2002) and the D2 dopamine receptor (Shi and Javitch, 2004) and similarities between 
the structure of the E2 loop of rhodopsin and the predicted structure in the Mi receptor may 
be made. Menon and colleagues (Menon et al., 2001) argued that the buried nature of the 
E2 loop in the central binding site was a feature unique to rhodopsin, but the present study 
and that of Javitch suggest that in the biogenic amine class of receptors at least, this 
structural feature may be the norm rather than the exception.
Although it appears that residues in the E2 loop of the muscarinic receptors do not 
participate directly in ligand binding, although they do probably face towards the binding 
site, evidence exists from several studies that residues in the E2 loop of other aminergic 
receptors in the rhodopsin family of GPCRs do in fact make important ligand contacts. For 
example, Javitch et al (Shi and Javitch, 2004) using a substituted cysteine accessibility 
method (SCAM) highlighted two residues, 1184 and N186 in the E2 loop of the dopamine 
D2 receptor that were very likely to make contact with the antagonist N-methylspiperone. 
These residues are analogous to 1180 and FI82 in the Mi mAChR. Perez and colleagues 
(Zhao et al., 1996) also identified three consecutive residues (G196, VI97 and T198) in the 
E2 loop, that when substituted changed the ligand specificity profile of the aib adrenergic
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receptor to that of the <xia adrenergic receptor and vica versa. Furthermore, Olah et al. (Olah 
et al., 1994) identified several important glutamate residues in the E2 loop, using a chimeric 
substitution approach, that were critical for the binding of the antagonist l,3-dipropyl-8- 
cyclopentylxanthine to adenosine receptors.
Considering this evidence it may be a little surprising that mutations in the Mi mAChR E2 
loop did not have more profound effects on the binding of either endogenous or synthetic 
ligands. Although mutations to Q177, Y179,1180 and FI 82 which are part of the predicted 
p3-(34 strand lid structure, did cause minor reductions in ligand affinity, the effects were not 
significant enough to suggest that they make any critical or direct contact with ligands 
bound to the central binding pocket. The mutation that most consistently reduced the 
binding affinity of the majority of ligands was 1180A. Interestingly of all the mutations, 
including the cysteine and the TM domain mutants, 1180A caused the biggest reduction 
(~7-fold) in McN-A-343 affinity. McN-A-343 was originally proposed as an allosteric 
modulator of M2 mAChRs (Birdsall et al., 1983.) but a later study (Christopoulos and 
Mitchelson, 1997) could not distinguish whether this compound interacted with the 
receptor allosterically with high negative co-operativity or via simple competition with the 
orthosteric binding site, when tested against carbachol. Contact residues for McN-A-343 
have yet to be identified and the loss of affinity effected by 1180 (see figure 6.6 below) may 
provide a clue as to the mode of binding for this mysterious ligand. Mutation of 1180 also 
significantly increased the affinity of AC-42 (~7-fold), probably because this mutation 
allows better access of AC-42 to its binding epitope.
The 1180 residue (apart from C l78) is the only E2 loop candidate that one might tentatively 
suggest makes a contribution to the ligand binding environment other than to provide a
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structural role. Possibly 1180 contributes to the hydrophobic nature of the central binding 
cavity as indeed may Q177, Y179 and FI82, but 1180 being in closer proximity (as 
suggested by the homology model in figure 6.7) to a bound ligand (ACh for example) may 
exert a more influential effect. Loss of these residues could be easily compensated for by 
the other non-polar residues if their role was simply to maintain a hydrophobic environment 
in the core binding site. This would be consistent with our findings that single point 
mutations of the E2 loop residues do not perturb the structure or the ligand binding 
capabilities of the Mi mAChR enough to warrant their inclusion in a list of binding site 
residues. Nevertheless, the small reductions in affinity seen for these mutants for various 
agonists supports the idea that agonists bind closer to the extracellular surface of the central 
binding pocket and may therefore have a role in stabilizing or restraining agonists in the 
central binding cavity. This is concordant with the idea of the E2 loop, and in particular the 
residues C-terminal to the conserved cysteine C l78, acting as a “lid” covering the central 
binding site. Thus, the function of the E2 loop maybe to maintain the structural stability of 
the central binding cavity without making any direct contact with bound ligands by 
providing second shell stabilizing interactions. Figure 6.7 below shows the possible 
orientation of a bound ACh molecule in relation to the E2 loop and 1180 in particular and 
supports the idea that the p4 strand dives down into the central binding pocket.
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Figure 6.6 Sum m ary of Differences in the Binding Affinities of Ligands to 
E2 Loop M utants Com pared to WT.
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Bars represent the mean log difference of in pK values for E2 loop mutants compared to 
wild type receptors for the partial agonist pilocarpine and the atypical agonists McN-A-343 
and AC-42 and error bars show the S.E.M. N=>2 unless stated and statistical significance 
analysed by a 2 tailed T-test where * = p<0.05 and **=p,<0.01 with respect to wild type 
values.
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Figure 6.7 Homology Model of the Mi m AChR Showing Acetylcholine 
Docked Into the T ransm em brane binding Site In Relation to 1180
The figure highlights the proximity of the 1180 residues (red) of the E2 loop (white) of the 
Mi mAChR to a docked acetylcholine molecule (default colour) in the Mi mAChR 
homology model. This simple model suggests that acetylcholine is in close enough 
proximity (4.3A) to allow second shell interactions with 1180 and that analogous to 
rhodopsin the P4 strand dives down into the transmembrane binding pocket.
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6.3.2 Cysteine Mutants
The substitution of the cysteine residues with alanine exerts more pronounced effects on the 
binding of ligands. There is now a substantial weight of evidence (Davidson et al., 1994; 
Savarese et al., 1992; Zeng et al., 1999a; Zeng et al., 1999b) stating that the disulphide 
bond between the two conserved cysteine residues is of major importance to the structural 
stability of nearly all GPCRs, both in terms of correct folding and expression but also in 
terms of ligand binding affinity and the stabilization of the central binding site. Without 
rescuing the expression of the cysteine mutants with an atropine chaperone there would be 
no cysteine mutants to examine, underlining their importance in the correct folding and 
compartmentalization of the receptors in the cell membrane. Nevertheless, once cysteine 
mutants are coerced into correctly expressing and locating their importance in the binding 
of ligands is secondary to those residues of the TM domains that are critical for ligand 
binding. There is a modest but significant losses of affinity (p<0.01) seen for NMS and 
QNB. There is a larger effect on ACh affinity and a reduction in ACh signalling efficacy 
(15 -  20-fold), but this is probably not as large as the loss in efficacy incurred by the 
mutation of binding site residues D105 or Y3 81 for example.
Data gathered from analysis of the cysteine mutants C98A, Cl 78A and the double cysteine 
mutant C98A/C178A suggests a more complex role for these particular residues than just 
the maintenance of structural stability. The C l78A and the C98A/C178A mutants reduced 
ACh affinity by 66-fold and 79-fold respectively but reduced pilocarpine affinity by only 6- 
fold and 20-fold respectively (p<0.01). Pilocarpine being a partial agonist and a larger 
molecule than ACh has the potential to make more interactions with the receptor and the 
loss of one or two contacts may not affect pilocarpine binding as dramatically as ACh, 
which has fewer possible interactions. The discrepancy between the reductions in affinity
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seen between ACh and pilocarpine may reflect this fact. In general the C98A mutant 
reduced the binding affinity of acetylcholine, (although the presence of 2 populations of 
binding sites as shown in results Chapter 3 is a complicating factor), pilocarpine, 
oxotremorine and oxotremorine-M by ~10-15-fold, and there is no conclusive evidence 
therefore that C l78 itself participates directly in the binding of these ligands or ACh. This 
is because the reduction in affinity of these ligands at the C l78A receptor is more 
consistent with a general perturbation of the binding site rather than removal of a critical 
contact residue, where reductions in affinity would likely to be > 100-fold. Also, there was 
no evidence that C98A produced two populations of binding sites for the other ligands, as 
all C98A data fitted a 1-site model of binding for both the partial, full and atypical agonists. 
The phenomenon seems to be limited just to ACh as far as the evidence provided in this 
thesis can discern.
The cysteine mutants all had similar effects (~7-13-fold reductions in affinity) on the
binding of oxotremorine and oxotremorine-M, probably due to global structural changes
rather than any direct disruption of binding contacts. The more interesting results for the
cysteine mutants concerned the binding of AC-42 which consistently bound with a higher
affinity to the cysteine mutants than to the wild type receptors. In particular AC-42 bound,
consistently, with a 6-fold higher affinity to C178A than to WT receptors. A very recent
paper by Langmead and colleagues (Langmead et al., 2006) has provided direct
pharmacological evidence that AC-42 is in fact an Mi selective allosteric agonist, but these
authors did not identify the regions or residues of the Mi receptor that impart the selective
properties of this ligand. The results presented here concur with the findings of both
Langmead and Spalding (Spalding et al., 2002) in that they suggest that AC-42 does not
bind within the central binding pocket. The fact that the C l78A increases the affinity of
AC-42, may indicate the uncovering of a high affinity epitope on the receptors extracellular
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surface. Removal of the disulphide bond may increase the dynamic nature of the E2 loop 
creating a more “relaxed” receptor, allowing AC-42 better access to its high affinity 
binding epitope. Spalding (Spalding et al., 2002) implied from their study that the binding 
epitope for AC-42 may actually be located at the N-terminal region and incorporating 
residues of the E3 loop. As has already been stated only 1180 of the E2 loop residues 
increased the affinity of AC-42, the rest having no effect at all. Thus it seems unlikely that 
the AC-42 binding epitope resides in the E2 loop, although perturbation of the E2 loop may 
allow better access of the AC-42 ligand to its binding epitope, elsewhere on the 
extracellular surface of the receptor. Further mutagenesis based investigations of the N- 
terminal and E3 loop domains are required to identify a binding epitope for AC-42. A 
summary of the differences in affinity from WT receptors for the binding of ligands to 
cysteine mutant receptors is shown below in figure 6.8.
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Figure 6.8 Sum m ary of Differences in Binding Affinity of Ligands to 
Cysteine M utants Com pared to WT.
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Bars represent the mean log difference of in pK values for cysteine mutants compared to 
wild type receptors for the partial agonists pilocarpine and oxotremorine and the atypical 
agonists McN-A-343 and AC-42 and error bars show the S.E.M. N=>3 except # where N 
<3 and statistical significance was analysed by a 2 tailed T-test. * = p<0.05 ** = p<0.01 
and *** = p«0.01 with respect to wild type values.
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6.3.3 Transmembrane Mutants
A summary of ligand binding to TM domain mutants is presented below in figure 6.9. The 
transmembrane domain binding site mutants, Y106A, FI97A and Y381A as might have 
been expected reduced the ground state affinity of the tertiary amine NMS analogue 
scopolamine by 10, 10 and 63-fold respectively. It is the removal of a methyl group from 
NMS (quaternary ammonium) head group to form the tertiary amine of scopolamine that 
resulted in a ~5-fold decrease in binding affinity for the WT receptor. In general the 
magnitude of the reduction in affinity seen for Y106A, F197A and Y381A was less for 
scopolamine than was seen for NMS. The results obtained here for Y381A are in good 
agreement with previous binding data for NMS and scopolamine (Ward et al., 1999a) and 
confirm the premise that Y381 is a primary contact residue for this ligand. It is the aromatic 
nature of Y381 that is responsible for the binding of NMS and scopolamine compounds. In 
this study the mutation of FI 97 and W378 to alanine reduced the affinity of NMS 100- and 
~500-fold, respectively. There was also a significant reduction seen for scopolamine. It has 
been proposed in this lab that the benzene ring of the NMS and scopolamine ligands may 
form a pi-pi stacking bond with the aromatic rings of FI97 and W378. This interaction 
would be possible if a slight re-orientation of the torsion angles in the homology model 
were made (see figure 6.10). It may also be possible that the loss of NMS and scopolamine 
binding affinity caused by W378A is due to a disruption of the aromatic cage environment. 
FI97 is too far away from the NMS or scopolamine head group to be a part of the aromatic 
cage environment of the head group but W378 is close enough. FI97, it has been proposed 
in the present study (Chapters 3 & 5), may make a pi-pi stacking bond with the benzene 
ring of NMS. This would explain the differences seen in the reductions in affinity for these 
two mutants. Thus, making critical contact with the head group of NMS or scopolamine
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and potentially with ACh, W378 can probably be considered as a key binding site residue,
whereas FI97 may only be critical to the binding of atropine-like antagonists.
The mutants Y106A and Y381A caused significant losses of affinity for both oxotremorine 
(20 and 6-fold respectively), oxotremorine-M (10 and 16-fold respectively) and pilocarpine 
(both 16-fold). This reflects the loss of ground state ACh affinity seen previously for these 
mutants (Lu and Hulme, 1999b; Ward et al., 1999a). In general, losses of pilocarpine 
affinity for the majority of TM binding site mutants were similar to losses of ACh affinity. 
This may suggest that there is an overlap of residues that bind both ACh and pilocarpine 
despite significant differences in structure. It is likely that the positively charged N-methyl- 
imidizole head group of pilocarpine forms an ionic bond with the key binding site residue 
Asp 105 and a hydrogen bond may be formed between Y381 and the internal ester of the y- 
lactone ring in a manner analogous to the binding of ACh as described by Ward et al. 
(Ward et al., 1999a). The fact that the W378A mutation also reduces pilocarpine affinity by 
~ 15-fold as it does ACh, might suggest that W378 contributes significantly to the aromatic 
cage environment. It was suggested earlier in this work that ACh and probably pilocarpine, 
bind more towards the extracellular surface of the receptor than the antagonists NMS and 
scopolamine and the data shown in this chapter seems to corroborate this.
As part of the proposed ligand access channel (Lu et al., 2001) the D99A mutant did
significantly reduce the affinity of the agonists pilocarpine and McN-A-343 by 4-fold and
the antagonist scopolamine by 3-fold. This loss of affinity was not as pronounced as seen
previously for ACh (23-fold reduction) or NMS (11-fold). However, since it can be
assumed that the D99A (and W157) residues are positioned extracellular to the central
binding core, just above the lipid bilayer, these small but significant losses in agonist and
antagonist affinity are consistent with a two step binding process. This is such that a ligand
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binds initially to the outer surface of the receptor, perhaps binding to D99 and W157 (TM4) 
before translocation to the core binding site. Mutation of the analogous residues D97N 
(Vogel et al., 1999) and W155A (Heitz et al., 1999) in the M2 mAChR also significantly 
reduced agonist affinity and agonist mediated signaling responses. It is interesting to note 
that, affinity constants for oxotremorine and oxotremorine-M were not significantly 
reduced from WT values when bound to the D99A mutant in the present study. What this 
implies however may have to be left as an open question.
Thus the results presented here on D99 are in accord with previous analysis and support the
theory that D99 and W157 (Mi) may be initial contact residues for only some agonists at
the opening of a ligand access channel, leading to the central binding pocket. It would have
been interesting to include the W157A mutant in this study on the binding of other atypical
agonists to provide further evidence of its involvement in an access channel. However, this
oversight means that further investigation into this mutant is still outstanding. Nevertheless,
mutation of the W157 to alanine has a much larger effect (100-fold reduction) on both ACh
affinity and signaling efficacy (>1000-fold) (Lu et al., 2001), than the D99A mutation,
which although it reduces agonist binding and expression, does not severely affect efficacy
as seen in Chapter 4 of this thesis. This is consistent with the fact that affinity and efficacy
are not related, i.e. the ability of the agonist receptor complex to couple to G-protein is
independent of the binding of the ligand to the receptor. So, although the mutation of D99
to alanine may reduce the ability of ACh to bind to the receptor, once bound the receptor
can be activated in the usual way since the mutation does not influence the change to the
active conformation. Thus, it can be concluded that D99 is not a residue important for
receptor activation. It can be imagined, however that an agonist with a positively charged
head group can be stabilized at the entrance to the channel via the negative charge of the
D99 but that it is the maintenance of the non-polar environment of the channel and the
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binding pocket that is the key for ligand access. The non-polar W157 residue may be 
crucial in this respect and may be analogous to the residue found at the entrance gorge of 
the acetylcholinesterase enzyme, where ligands bind to the peripheral site by the indole ring 
of the Trp 279 (Silman and Sussman, 2005). Further investigations are required to elucidate 
fully the role of W157 and D99 in a possible two-step system of agonist binding in the Mi 
mAChR.
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Figure 6.9 Sum m ary of the Differences in Binding Affinity of Ligands to 
TM  Domain m utants Com pared to WT.
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Bars represent the mean log difference of in pK values for transmembrane mutants 
compared to wild type receptors for the antagonist scopolamine, the partial agonists 
pilocarpine and oxotremorine and the atypical agonists McN-A-343 and AC-42 and error 
bars show the S.E.M. N=>3 except # where N=<3 and statistical significance analysed by a 
2 tailed T-test where * = p<0.05 and ** = p<0.01 and *** = p«0.01 with respect to wild 
type values.
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Figure 6.10 Possible pi-pi-Stacking Bond Between Benzene Ring of NMS 
o r Scopolamine and Phe 197 and T rp  378.
NMS
W378A
F197A
Consistent with binding data collected Phe 197 and Trp 378 are key residues for the 
binding of both NMS and scopolamine, but not QNB. A slight change in the torsion angles 
in the homology model may allow for a pi-pi stacking bond between the benzene ring of 
NMS/scopolamine and the aromatic rings of Phe 197 (red) and Trp 378 (blue). The loss of 
such a strong bond would severely reduce binding affinity as has been borne out by the 
data. Alternatively the significant losses of affinity may be due to the disruption of the 
aromatic cage environment. Relative distances between ligand and residues are indicated in 
yellow dotted lines and are marked in angstoms.
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6.4 Summary
The main findings of the section of work on the effects of mutations on ligand binding are 
as follows.
1) The classical antagonists, NMS & scopolamine, the agonists ACh and oxo-M, and the 
partial agonists oxotremorine and pilocarpine showed similar responses to the mutations 
studied. This is consistent with their binding within the primary ACh binding pocket
2) The E2 loop is likely to function as a stabilising element, constraining the binding site 
environment, maintaining a conformation conducive to correct ligand orientation in the 
central binding pocket, without making direct contact with bound ligands
3) The C178A mutation consistently enhanced affinity for AC-42. Relaxation of the 
receptor due to disruption of the disulphide bond may allow better access of AC-42 to its 
binding epitope.
4) McN-A-343 and AC-42 showed weak or no interaction with the primary ligand binding 
residues. There was evidence that Asp 99 participates in the initial binding of some but not 
all agonists or antagonists
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Chapter 7 
Final Discussion
7.1 E2 Loop Residues
One of the features of the E2 loop seen in the rhodopsin structure is that residues Ser 186 
and Asp 190 of the 04 sheet dive down into the transmembrane region and sit on top of the 
ligand binding crevice, Glu 181 is positioned ~4 A from C\2 of retinal and is part of the 
linking sequence between the 03 and 04 sheets (Yan et al., 2002). E2 loop residues Glu 181 
and Ser 186 also provide important H-bonds with Glu 113 of TM3 via a water molecule 
and are directly linked to the process of photoisomeration of the ligand from 11-cis retinal 
to all-trans retinal and subsequent receptor activation. These residues are part of a proton 
transfer mechanism for switching the protonated Schiff base counterion and are believed to 
be essential for the photon induced activation of rhodopsin (Yan et al., 2003). Considering 
the importance of these residues and the E2 loop in rhodopsin function, it is logical to 
suppose that the functional importance of the E2 loop in other GPCRs is analogous to 
rhodopsin. The main difference, and it is not a minor difference, is that rhodopsin and its 
natural retinal ligand are covalently bound and that isomerization of other GPCR ligands 
may not be an issue. Nevertheless, this study set out to examine the possibility that the E2 
loop of the muscarinic receptor family also provided important elements for the efficient 
functioning of the receptor. Specifically, an attempt was made at identifying residues that 
may provide a role in ligand binding, structural stability and activation.
The data presented here does not support the idea that any of the E2 loop residues make 
direct critical contact with NMS, QNB or the endogenous agonist ACh. Mutation of 
important binding site residues generally leads to very large reductions in binding affinity 
constants. For example, the mutation to alanine of the highly conserved Arg 3.50 reduces
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both agonist and antagonist affinity ~ 100-fold. Reductions in binding affinity constants of 
that magnitude were not observed for any of the E2 loop residues. In general however, 
reductions in ACh affinity were observed, leading to the conclusion that ACh binds more 
superficially in the binding pocket than NMS. The E l70 residue in the Mi mAChR is 
analogous to the important El 81 in rhodopsin, but its mutation to alanine had very little 
effect on expression, agonist or antagonist binding or agonist induced activation of the Mi 
receptor. It should be noted that E l70 is not conserved in M2 , M3 , M4 or M5 mAChRs and 
so it may not be surprising that its mutation produced null effects. More interesting is the 
1180 residue which is completely conserved in the muscarinic sub family of aminergic 
receptors. Mutation to alanine of 1180 significantly reduced both NMS and ACh affinity. 
As part of the p4 sheet 1180 may be in close proximity to the bound ACh molecule and may 
provide a second shell of electron density that helps to stabilise the ACh molecule with the 
transmembrane binding site. Small reductions in affinity were also seen for McN-A-343 
and pilocarpine at the I180A mutant. These observation may be in line with the suggestion 
by Shi & Javitch (Shi and Javitch, 2004) that the conserved analogous residue 1184 in the 
dopamine D2 receptor lines the binding site crevice and contributes in some way to the 
binding site environment. This may also be true for R171 (conserved) and Y179 (not 
conserved) which also reduced NMS and ACh binding. In the homology model of the E2 
loop (figure 1.12 in the main introduction) R171 is positioned pointing away from the 
transmembrane binding site. The significant reductions in both ACh and NMS binding 
affinity constants seen for the alanine mutant may imply that in fact R171 is orientated into 
the binding site where its positively charged side chain may provide an important ionic 
interaction, which again may stabilise the ligand in the binding pocket. However, it is more 
likely that R171 forms part of a stabilising microdomain since a positively charged residue 
would negate a possible interaction with the positively charged ACh head group.
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The involvement of certain E2 loop residues in the activation of the Mi mAChR seems to 
be more important than ligand binding. In particular residues W164, Q177, Q181 and SI84 
seem to provide important H-bond interactions important for the activated state of the 
receptor. Using a modelling program (Deep view) the analogous residues in rhodopsin, all 
appear to make H-bond interactions. So, by comparison it is possible that the Mi residues 
may also be involved in a similar set of H-bond interactions. Except for Q177 these 
residues are conserved in the mAChR family and in particular the W175 residue of 
rhodopsin receptor is analogous to W164. H-bonds of the highly conserved tryptophan in 
rhodopsin (W175) are formed with a proline at PI90 and a serine at S202. Figure 7.1 shows 
the analogous residues and the potential H-bond interactions of W164 of the Mi mAChR. 
W164 and W175 (rhodopsin) both lie at the N-terminus of the E2 loop just a few residues 
beyond the top of TM4. A space filling model (figure 7.2) also suggests that W164 and 
PI59 are close enough to form a Van der Waals interaction. The striking feature is that in 
both models the conserved tryptophan forms a H-bond, via the backbone nitrogen atom to 
the backbone carbonyl oxygen of a highly conserved proline residue PI59 (PI70 in 
rhodopsin) which sits at the top of the fourth transmembrane helix. In the rhodopsin model 
however there is a H-bond formed between the nitrogen of the pyrrole ring of the 
tryptophan and a protonated serine (S202), an analogous H-bond does not appear to be 
possible in the Mi receptor as the 9.27A distance between the backbone of the nearest 
serine residue in the Mi receptor (SI84) is too great. Mutation of the of PI59 (Lu et al 
2001) to alanine had a somewhat larger effects on ACh affinity (100-fold) and potency 
(~1000-fold) than W164A. this may be explained by the proximity of PI 59 to the important 
W157 residue which is critical for ACh binding and potency. The P159A mutant did 
however show a similar loss of efficacy (~ 10-fold) to that of W164A, which may support 
the claim that the maintenance of W164 is important for receptor activation. Mutation to
alanine of W164 reduced ACh potency ~30-fold and signalling efficacy by ~7-fold.
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Furthermore, basal signalling was practically abolished compared to wild type basal 
signalling levels. It is suggested therefore that W164 is an important residue providing 
interactions necessary for the structural stability of the E2 loop which is required for the 
conformational rearrangement of the TM helices upon ACh induced activation of the Mi 
mAChR receptor.
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Figure 7.1 H-Bond Interactions for the Conserved T ryptophan Residue at 
the N-Term inus of the E2 loop in Mi mAChR
The figure represents the W164 residue at the N-terminal of the E2 loop that potentially 
may make important hydrogen bonds important for the structural stability of the E2 loop. 
Dose response data shows that mutation of W164 to alanine significantly reduces the 
receptors ACh potency and reduces the ability of the receptor to couple effectively with G- 
protein. The disruption of these bonds may be important for the receptor to attain the active 
conformation. The figure was adapted from the Mi mAChR homology model and H-bonds 
were set a detection threshold with a minimum distance of 2.2 A and a maximum distance 
of 3.27 A using the webviewer lite modelling programme. Nitrogen atoms are shown in 
blue, hydrogen atoms are shown in red and carbonyl backbones are shown in white.
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Figure 7.2 Space Filling Model to Show Possible Interaction Between 
W164 and P159
W164
A
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The figure highlights the relative proximity of W164 and PI59 at the top of TM4 and the 
N-terminal of the E2 loop. Both residues appear to be important for signalling of the Mi 
mAChR. The approximate distance between these residues is 3.9 A, close enough to make 
a Van der Waals intertaction. The mutation of W164 to alanine significantly reduced both 
ACh potency and efficacy, suggesting that there may be an interaction between W164 and 
PI59 after a conformational change in the E2 loop upon ACh induced receptor activation. 
This model was adapted from an in-house Mi mAChR model using the Webviewer Lite 
modelling programme.
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A recent paper by Kota et al. (Kota et al., 2006) has provided good evidence using FRET 
and cysteine substitution cross-linkig studies that W175 is a key residue in the formation of 
the rhodopsin dimer. Their study did not address the role of dimerisation and in particular 
W175 in opsin function. Nevertheless, the rearrangement of the H-bonds between W164 
and PI59 may be necessary for the conformational change of the Mi receptor upon ACh 
induced activation. In light of the Kota et al. (Kota et al., 2006) study W164 may be 
important for a functional Mi dimer, although further study is required to explore this 
possibility. In terms of maintaining the structural stability of the E2 loop, W164 may 
provide the first of three anchor points, the second being the disulphide bond between C98 
and C l78 and the third at the C-terminus of the E2 loop via a H-bond interaction between 
SI84 and PI86. The conservation of both the tryptophan and the proline in the mAChR 
family is a good indication of that these residues have been maintained during evolution of 
the receptor because of their importance in efficient receptor function. It is interesting to 
note that, although the tryptophan analogous to W164 is not conserved in the dopamine D2 
receptor the proline residue analogous to PI 59 is.
At the C-terminal end of the E2 loop where the loop meets the top of TM5, the SI84 
residue also appears to make an important H-bond interaction. In an interaction similar to 
W164 at the N-terminus of the E2 loop SI84 potentially also makes a H-bond interaction 
with a proline residue (PI86) at the top of TM5, and potentially provides a third anchor 
point for the E2 loop. Figure 7.3 shows the potential H-bond interaction between the side 
chain oxygen of the SI84 and the carbonyl oxygen in the backbone of PI 86. The fact that 
mutation to alanine of the SI 84 residue does not significantly reduce ACh affinity (Matsui 
et al., 1995) but reduces ACh potency and efficacy more than 15-fold strongly implicates 
this residue as being important for the active state of the receptor. Again the S184A mutant
abolished WT levels of basal activity but had no effect on receptor expression levels.
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Furthermore, the SI84 residue may make two H-bond contacts with Q181 that are required
for the ground state of the receptor since the Q181A may have genuinely raised basal
activity compared to wild type.
A serine at the analogous position to SI84 is conserved in all 5 mAChR sub types and in 
rhodopsin there is a similar uncharged polar threonine side chain. The proline at position 
159 in the Mi sub type is conserved in M3 M4 and M5 but not in M2 which contains an 
alanine at the analogous position, but a similar H-bond with the protonated backbone of the 
M2 alanine residue may also be possible. To use an analogy, W164 and SI84 may act like 
the two ends of a skipping rope, the other end in each case is S-S bond in the approximate 
centre of the loop. If the person at one end of the skipping rope lets go the entire structure 
of the rope changes, particular if the rope is required to be activated (rotating). Similarly by 
removing these important residues the overall conformation of the E2 loop is affected and 
in turn restricts the proper conformational changes required for the receptor to assume the 
active conformation.
In the rhodopsin homology model the inner strand of the (3-hairpin of the E2 loop forms a 
“lid” on the retinal binding site (Palczewski et al., 2000). If the E2 loop of the Mi mAChR 
functions in an analogous manner, it is easy to imagine that mutations in the E2 loop 
structure especially in the P-hairpin region would cause the acceleration of 3H-NMS 
dissociation. The E2 loop mutants that increased 3H-NMS dissociation rate constants, 
R171A, 1180 A and FI 82 A are all proximal to or indeed part of the P-hairpin structure. This 
evidence may support the idea that the E2 loop of the Mi receptor serves to prevent the 
premature release of ligand from the central binding pocket. In Chapter 3, evidence was 
provided to show that NMS binds deep in the central binding pocket and that it is unlikely
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that residues of the E2 loop are critical for NMS binding. The dissociation rate constant 
data supports this since loss of critical binding residues might be expected to accelerate the 
dissociation of 3H-NMS more than is actually observed. Removal of critical binding site 
residues would decrease the activation energy of the reverse reaction RL—>R+L. The 
increases in dissociation rates for NMS seen for the E2 loop mutants R171A, 1180A and 
F182A are not of the order to suggest that they are ligand contact residues. However this 
data may support the idea that these residues are involved as second shell residues helping 
to stabilise the ligand in the transmembrane binding pocket. Nevertheless this data provides 
corroborating evidence that E2 loop residues do not make contacts essential for NMS 
binding. However, perturbing the structure of the E2 loop proximal to the p-hairpin 
structure does appear to have a deleterious effect on the stability of the ligand in the binding 
pocket. There were no significant changes in the association rate constants for the E2 loop 
mutants. Only R171A and Y179A reduced the association rate by a factor of 2-3 relative to 
the WT and the diffusion limited association rate constant. This may be due to slight 
changes in the conformation of the region above the TM binding site creating small 
perturbations in the alignment of specific contact residues, thus slightly increasing the 
activation energy barrier for the bound ligand.
The wild type residues of the E2 loop probably fulfil the role which has been proposed, that
is, they form a plug or lid like structure that helps retain the ligand in the binding cavity.
There is the question of whether or not the conformation of the E2 loop is altered along
with other structural changes that occur on the binding of ligand. If the E2 loop is a
dynamic structure, being able to move into and away from the central binding pocket, it is
possible that the binding of ligand invokes movement of the E2 loop in towards the binding
cavity to create a conformational change favourable to the retention of ligand. This closing
in effect may be a result of movement of the TM-domain helices. Potentially, the effect of
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the proximity of the re-aligned E2 loop residues could be to sterically hinder any movement
of the ligand as it dissociates from the receptor
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Figure 7.3 H-Bond Interactions for the Conserved Serine Residue a t the 
C-Term inus of the E2 loop in mAChR
Analagous to the the W164 residue at the N-terminus o f the E2 loop, SI 84 also appears to 
provide important H-bonds with a proline residue (P I86) at the top o f TM5. Mutation o f 
S I 84 also significantly reduced ACh potency and receptor efficacy. The implication is that 
SI 84 provides another point o f contact with the TM helices that help maintain the structural 
integrity o f the E2 loop which is important for allowing the correct movement o f the TM 
helices upon receptor activation. The figure was adapted from the Mi mAChR homology 
model and H-bonds were set a detection threshold with a minimum distance o f 2.2 A and a 
maximum distance o f 3.27 A using the W Ebviewer Lite modelling programme. Nitrogen 
atoms are shown in blue, hydrogen atoms are shown in red and the carbon backbone is 
shown in white.
256
Chapter 7
7.2. Cysteine Residues
There now seems little doubt that the most highly conserved pair of cysteine residues in the 
whole family of GPCRs form a disulphide bond, stabilising the inactive ground state and 
are important for allowing the correct re-alignment of the helices during activation of the 
receptor. Evidence provided by this study supports the existence of an S-S bond and show 
that the bond is important for both expression of the receptor and agonist induced 
activation. In addition the maintenance of the disulphide bond would appear to also 
stabilise the transmembrane binding site, especially for the binding of the endogenous 
agonist acetylcholine. It still remains to be determined however whether or not the C l78 
residue itself provides a specific contact residue. The model of C l78 in relation to ACh in 
the binding site shown in figure 7.4, implies that the electron fields of the atoms in C l78 
are too far distant at 6.3 A from the bound ACh molecule to make direct and specific 
contact. However, it must be stressed that the model is just a homology model and the real 
distances may be shorter, allowing for contact. What is clear is that mutating the conserved 
cysteine residues reduces ACh affinity by ~ 100-fold. The conclusion of this report, 
therefore, is that it is the general perturbation of the central binding site cavity caused by 
the disruption of the stabilising E2 loop structure that decreases the free energy resulting 
from the binding of ACh to the receptor. As a result of the cysteine mutations ACh potency 
and signalling efficacy are also dramatically and significantly affected and this highlights 
the importance of the overall structure of the E2 loop to receptor activity and ground state 
stability.
One of the most interesting observations during this study was the apparent formation of 
two populations of receptors caused by the mutation of C98 to alanine, one with a high 
affinity for ACh and the other with a low affinity. Evidence for this was seen in both the
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ACh competition binding experiments and in the QNB dissociation kinetics and it appears 
to be a real phenomenon. It has been suggested that the two populations may exist as 
dimers with one population having an inter-molecular S-S bond formed between the two 
free C l78 residues and the other population existing as a monomer with the C l78 residue 
unconnected. Alternatively, the C l78 residue could form a S-S bond with one of the free 
cysteine residues of the E3 loop leaving the second population with no alternative S-S 
bonds. The relative distance between C l78 and the C394 in the E3 loop is 18.3 A (see 
figure 7.3) as determined by the homology model and is sufficiently close to propose that 
an interaction is possible. In the homology model the E2 loop actually crosses double over 
itself (see main introduction figure 1.5). Removing the anchoring S-S bond would make the 
loop more dynamic and with a total length of ~50 A it could be imagined that the free C l78 
could reach the free C394 in the E3 loop. Obviously a conformational rearrangement of the 
structure would result from this. It was shown that the high affinity site could not have been 
responsible for ACh induced signalling since the potency of ACh was less than its affinity 
for the high affinity site. Certainly this requires further investigation, not least to ascertain 
which population of binding sites is responsible for the fast dissociation rate constant of 
QNB and which site is responsible for the slow rate of dissociation. In general the cysteine 
mutants increased the rates of dissociation for both NMS and more significantly for QNB. 
The general disruption of the central binding site may reduce the amount of free energy 
required for NMS and QNB to surmount the activation barrier for the reverse binding 
reaction and so dissociate more readily from the cysteine mutated receptor than from the 
wild type receptor.
Another surprising result was the significant increases in AC-42 affinity seen particularly
for the C178A mutant. This mutation may uncover an epitope on the exo-facial surface of
the receptor that allows AC-42 to bind with higher affinity. In fact, the increase in AC-42
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affinity was a feature of the cysteine mutants. Reductions in the affinity of other agonists 
and antagonists seen for the cysteine mutants was in keeping with a general perturbation of 
the central binding site caused by disruption of the S-S bond. Since there was an equal 
effect seen for the double cysteine mutant it could concluded that neither C98 nor C l78 
makes specific contact with the other ligands tested.
259
Chapter 7
Figure 7.4 Relative Distance Between C l78 and ACh and Cysteine 394 of 
the E3 Loop
rS  2365
ACH 2
The figure serves to show the relative distance of the disulphide bonded cysteine pair to 
both the bound ACh molecule and the free cysteine in the E3 loop, shown here as Cys 265 
since the image was designed from a homology model of the Mi mAChR that omitted the 
large intracellular loop 3 region, hence the unusal numbering.. In fact the this cysteine is at 
position C394 in the wild type receptor. There is the possibility that the C98A mutant may 
allow the free C l78 to make an alternative S-S bond with C394 in the E3 loop. The 
homology model also predicts that C l78 at 6.33 A is too far distant to make direct contact 
with ACh. However, the model may require refinement and radioligand binding studies in 
this report have shown that the C178A significantly and severely reduces ACh affinity.
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7.3. TM Domain Residues
The residues F197 (TM5)and W378 (TM6) were also mutated to alanine in this study to 
help complete the identification of binding site residues. The potential ligand docking 
residue D99 was also mutated to further investigate the possibility of there being a ligand 
access channel in the Mi mAChR. Evidence from ligand binding studies suggest that both 
FI97 and W378 make critical contacts with the antagonist NMS, as their mutation reduced 
the affinity constant for NMS greater than 90 and 400-fold respectively. It is possible that 
the benzene ring of NMS can form pi-pi stacking bond with FI 97 and the indole ring of the 
tryptophan may contribute to the aromatic cage environment of the transmembrane binding 
site by making contact with the head group of the NMS molecule. Interestingly, there was 
further evidence for a different mode of binding of QNB compared to NMS. This was 
highlighted by the fact that W378A reduced QNB affinity by ~ 10-fold whereas F197A did 
not significantly reduce QNB affinity at all. Also, only W378A significantly reduced ACh 
affinity by ~13-fold. Thus, W378 which is highly conserved in rhodopsin like and 
aminergic receptors seems to be another critical transmembrane binding site residue. The 
mutation D99A severely reduced expression of the receptor and significantly reduced the 
affinity of NMS 11-fold and ACh 22-fold, but had little effect on the binding of QNB. This 
may be the best evidence we have that QNB actually enters the central binding cavity via a 
different route than either NMS or ACh. That is QNB being a hydrophobic molecule may 
access the central binding cavity through gaps in the TM helices via the lipid membrane. 
The fact that D99A reduces ACh affinity but not the signalling efficacy of the receptor is 
circumstantial evidence that D99 potentially in partnership with W157, does indeed act as a 
docking residue in a two step process of binding analogous to the model described by 
Jakubik et al (Jakubik et al., 2000). That is, once ACh has found its way to the
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transmembrane binding site, the D99A mutation does not affect the activation of the
receptor induced by ACh binding.
Both F197A and W378 affected the potency of ACh and both reduced the efficacy of the 
receptor by 10-fold. It is likely that W378 is part of a H-bond network that is rearranged 
upon activation of the receptor. Consistent with the conserved nature of this residue, its 
importance to both, the binding of ligands and to the activation of the receptor have been 
confirmed by these studies. For example the W378A also reduced the affinity of 
pilocarpine by more than 10-fold. It may be of little surprise therefore that the mutation of 
W378 also substantially increased the dissociation rate constant of QNB. This was also true 
for the other proven binding site residues. Mutation of these residues may disrupt helix- 
helix interactions, allowing a less impeded egress of QNB from the receptor, reducing the 
amount of free energy required for the ligand to proceed in both the forward and reverse 
binding reaction.
Interestingly, the major binding site mutant residues Y106A, Y381A and N382A had little 
or no effect on the affinity of McN-A-343 or AC-42, the strongest evidence provided by 
this study that these two atypical agonists bind to a site distinctly different from the 
transmembrane binding site. In fact N382A significantly (p<0.05) increased the affinity of 
McN-A-343 by 5-fold. It is likely therefore McN-A-343 and AC-42 bind to an allosteric 
site on the exofacial surface of the receptor and may bind to a site analogous to the 
gallamine allosteric site. Evidence shown in this study suggests that the E2 loop is not part 
of this ectopic site for these ligands since the selected mutant E2 loop residues did not 
significantly reduce affinity.
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Chapter 8 
Future Work
The following list highlights interesting points that have arisen during this study and 
require further investigation to provide a more comprehensive understanding of the 
molecular basis of ligand binding to muscarinic acetylcholine receptors.
1. The Cysteine mutants, in particular, require further study. In particular, more evidence is 
required that there exist two populations of receptor for the C98A mutant. A more detailed 
analysis of the dissociation kinetics is needed for this particular mutant. Since the initial off 
rate is so fast, an experiment needs to be conducted that has more time points to provide 
data on the initial slope in the rapid phase of QNB dissociation. Furthermore, an experiment 
needs to be conducted whereby the high affinity binding site is blocked with a single high 
concentration of unlabelled acetylcholine at ~10‘3M concentration. Then a detailed 
dissociation assay should be performed in the usual way. This experiment would tell us 
whether or not it was the high or low affinity site that was responsible for the fast rate 
dissociation kinetics of QNB at the C98A receptor.
2. To ascertain whether or not there is an alternative S-S bond formed between the free
C l78 residue in the C98A mutant, a reduction experiment using DTT could be performed
on purified C98A mutant receptors followed by a gel analysis. The existence of dimers
would be evident by comparison of DTT treated receptors with non treated receptors and
examining the relative molecular weights of the different bands on a Western blot. The fact
that C98A severely reduces receptor expression might be a problem however. Another
approach would be to make a double mutant C98A and C394A and analyse the differences
in acetylcholine competition assays between the double mutant and the single C98A
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mutant. A two site model of binding would not fit the double mutant data if indeed the free
C l78 residue were forming an alternative S-S bond or a dimer with C394.
This study was unable to confirm or refute whether C l78 itself makes direct contact with 
the bound ACh molecule. One approach to further investigate this question is to try to 
chemically reduce the S-S with DTT or Tributyl phosphine and then perform standard ACh 
competition binding assays. An initial attempt at this approach was made during the course 
of this investigation but an effect was not seen. The buried nature of the conserved S-S 
bond may render it difficult to access with DTT. A more systematic and comprehensive 
approach is recommended. In particular, reduced S-S bonds would require treatment with 
iodoacetamide for example; to prevent re-oxidisation of reduced SH groups. This was not 
done in the initial attempt.
3. There was tantalising evidence that the Q181A mutant imparted significantly raised basal 
activity to the receptor. Should this be true it may have important implications for the 
further study of receptor activation. Unfortunately in one of three experiments the Q181A 
mutant showed basal levels of activity similar to wild type. It may have been the case that 
in that particular assay there was a problem with the transfection of plasmid. Therefore, it is 
necessary to conduct more PI assays on this particular mutant to confirm or deny that this 
mutant significantly raises basal activity and whether the wild type residue is crucial for the 
ground state conformation of the receptor.
4. In order to test the theory that W164 and SI84 provide important H-bonds and act as
anchor points at either end of the E2 loop it would be interesting to see if certain mutations
could restore receptor activity. For example, by mutating SI84 to another uncharged polar
side chain, such as threonine, it may be possible to reinstate H-bonds lost by the mutation
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of SI84 to alanine. Comparing the S184T mutant to the S184A and WT receptors may 
provide more insight into the function of this strategically placed residue. Also mutation of 
the corresponding proline residues would be necessary to gain a full insight as to whether 
or not the E2 loop is anchored to the TM helices by the H-bond interaction described 
above. The analogous mutation for W164 would be changing it to a histidine residue and 
conducting a similar analysis to the SI84 mutants.
5. Some evidence was provided in this study that D99 is part of an entrance channel and 
participates in a two-step binding process. Another approach may be to mutate D99 to a 
bulkier residue, one that effectively blocks the access channel, leucine or valine or perhaps. 
Performing NMS binding and dissociation experiments would show whether or not the 
bulkier residue restricted NMS access and egress to and from the central binding site. It 
would also be interesting to see the effect of changing the negative charge of D99 for a 
positively charged lysine residue to assess the importance of the negative charge of D99 in 
the native receptor. An oversight of this study was not to further characterise W157, for 
which our laboratory has the alanine mutant. Assessing the binding of other ligands to the 
W157A mutantwould further our understanding of the role played by W157 and D99 in the 
initial binding of ligands.
6. From this study it was apparent that single point mutations of the E2 loop, apart from a
couple of exceptions, did not drastically perturb ligand binding or receptor activity. Also
some residues in the E2 loop were not mutated and analysed at all. It may be prudent,
before definitive statements about the function of the Mi mAChR E2 loop can be made, to
mutate and examine not only the residues overlooked by this and Leppiks (Leppik et al.,
1994) study, but also to perform multiple substitutions on E2 loop residues. Amino acids do
not exist in isolation and it is likely that there are several specific interactions between the
265
Chapter 8
E2 loop residues that need to be disrupted before they affect the properties of a functioning 
receptor. Therefore there is the scope for many more E2 loop mutations to be made, both 
multiple substitutions and mutating residues to residues other than alanine to alter the 
physico-chemical properties of the E2 loop. In particular it would be informative to replace 
the cysteine residues at C98 and C l78 with other residues to see if any function could be 
gained.
7. As a general point, association assays need to be performed on all the mutants tested in 
this study to compare with the calculated association constants derived from dissociation 
assays. Also data needs to be acquired for all mutants to fill in the missing affinity 
constants of the other agonists and antagonists used in this study to better understand the 
nature of non-endogenous ligand binding.
8. There is a need for a more comprehensive analysis of the residues responsible for the 
binding of McN-A-343 and AC-42. Evidence indicates that these selective agonists bind to 
an allosteric site distinct from the orthosteric site. It is proposed that systematic mutations 
of the N-terminal region, the El loop and the E3 loop would reveal the ligand contact 
residues responsible for the binding of these two unusual agonists.
9. Based on the results of this thesis it is envisaged that further manipulation of the Mi 
homology model may be required. The current homology model suggests that the E2 loop 
is in closer proximity to the central binding site than the data in this thesis may suggest. 
Molecular dynamic modelling may help to resolve these issues.
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